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Abstract 
The human malaria parasite, P. falciparum, replicates within a membrane-bound 
intraerythrocytic parasitophorous vacuole (PV). The resulting daughter merozoites 
actively escape from the host cell in a process called egress. There is convincing 
evidence that proteases are key players in this step. These proteases could serve as 
excellent targets for the development of new antimalarial drugs. P. falciparum Serine 
Repeat Antigens (SERAs) form a family of 9 proteins all containing a central papain-
like domain that identifies them as putative cysteine proteases. They are highly 
conserved throughout all Plasmodium species, and there is strong genetic evidence 
that they may play a role in egress. P. falciparum SERA6 is one of the most highly-
expressed SERAs in asexual erythrocyte stages. In this study biochemical fractionation 
and indirect immunofluorescence analysis were used to confirm localisation of SERA6 
to the PV. It was shown that SERA6 is a substrate for PfSUB1, a subtilisin-like 
protease which is crucial for egress and which is released into the PV just prior to 
egress. SERA6 is cleaved by PfSUB1 at 3 positions, releasing the papain-like domain. 
Processing of SERA6 by PfSUB1 is partially indispensable in in vitro P. falciparum 
parasites, as some mutations in SERA6 that block cleavage are not tolerated in the 
parasite. In addition, the putative catalytic Cys of SERA6 cannot be replaced with a 
non-catalytic Ala residue in the parasite, indicating SERA6 is an indispensable cysteine 
protease. Finally it was demonstrated that PfSUB1-mediated processing of the P. 
berghei orthologue of SERA6 converts it to an active cysteine protease. It can be 
proposed that SERA6 is a key player in a proteolytic cascade that leads to egress of 
the blood-stage malaria parasite. 
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1 Introduction 
1.1 Malaria: The disease in all its aspects 
1.1.1 A history of bad air 
Malaria has been affecting humanity as a scourge for several thousand years 
and is thought to have killed more people than any other known human disease. It is 
one of the most devastating diseases of humankind, behind only tuberculosis (TB) and 
HIV. Despite one million deaths annually, its high profile cases of humans suffering 
from the disease known as “black fever” ranges from ancient Egyptian pharaohs, such 
as Tutankhamun (Hawass et al., 2010;Timmann et al., 2010) to modern world football 
players (Didier Drogba) or even pop stars (Cheryl Cole) and actors (George Clooney), 
keeping malaria in the news of non-endemic countries (other famous fatalities of 
malaria include Oliver Cromwell, Dante and Lord Byron). Even Christopher Columbus 
suffered from malaria on at least one occasion, indicating strongly that the disease has 
been affecting humans of all social classes throughout history and in recent days. 
Malaria has received many names throughout history, mainly derived from the 
symptoms sufferers were able to observe. The word malaria however derives from the 
Italian “mala (bad) aria (air)” as the disease was mainly associated with the fact that 
humans fell ill with malarial symptoms after sojourning in areas with strong odour of 
swamps or stagnant water. It was not before 1740 that the word “mal’aria” was 
introduced into the English culture by Horace Walpole. In the meantime it was 
portrayed as jungle fever, marsh fever, paludal fever or swamp fever. One name, black 
fever, was based on the colour of the urine passed by severely infected individuals. 
Regardless of the attention malaria has received in more recent years, the 
origin of the malaria parasite, Plasmodium spp., can be dated back much further. It is 
now generally thought that the human malaria parasite first occurred in our primate 
ancestors in Africa and evolved with human migration. A series of studies have 
attempted to date the origin of a variety of worldwide parasite strains by analysing 
mitochondrial DNA polymorphisms (Conway et al., 2000;Joy et al., 2003). It is 
suggested that recent parasite strains originate back as far as 50,000 years and that 
the common ancestors originated millions of years ago (Escalante et al., 1994) with the 
most virulent human parasite, Plasmodium falciparum, diverging from its closest 
ancestor around 8 million years ago (Escalante et al., 1995). However, contradictory 
reports suggest a rather younger history for the malaria parasite with a common 
ancestor being dated only around 5,000 to 60,000 years ago (Rich et al., 
1998;Volkman et al., 2001;Conway et al., 2002;Rich et al., 2009). First descriptions of 
humans suffering malarial symptoms emerged in ancient Chinese medical reports 
around 2,700 BC, describing re-occurring tertian or quartan fevers (fever after 48 or 72 
hours) with spleen enlargement and other symptoms (Ni, 1995). Hippocrates, however, 
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was the first consistent and epidemiologically detailed source to describe malarial 
symptoms in humans in early Greece (approximately 400 BC). In his medical diary “Of 
the Epidemics” Hippocrates describes symptoms as a “paroxysm” falling on “even days 
or odd days” and subsequently only re-occurring on even and odd days respectively. 
He also noticed “that if crises fall on days other than those mentioned above, there will 
be a relapse, and this may be deadly” and describes possible improvement “but it is 
essential to pay attention and know at which times the crises will lead to death and in 
which to recovery, or during which is there tendency to fair better or worse“ 
(Hippocrates, 2004). Before Hippocrates’s detailed first rendition of malarial symptoms, 
many more mentions of the human plague were found. Writings by Aristophanes, 
Aristotle, Sophocles and Plato (all around 400 BC) seem to describe what are now 
known to be malarial symptoms (Sherman, 1998). Even Homer (approximately 750 
BC) poetically portrayed “Sirius, harbinger of fevers” caused by what he calls an “evil 
star which dominates the night sky at harvest time” most likely describing mosquitoes 
as the source of the fever which soldiers suffered from during the Trojan war (Homer et 
al., 2007). Malaria of course was not only restricted to Europe and Africa, and reports 
of the disease were found globally with many fatalities. There is also experimental 
evidence for humans suffering from malaria in the ancient world. A first indication of the 
presence of malarial antigens in ancient mummies was found with a series of 
immunological tests (Miller et al., 1994). To further confirm previous studies, mummy 
bone tissue samples were tested for the pfcrt region of P. falciparum in an elegant PCR 
based approach. Two out of 91 mummies from two different originating tombs in Egypt 
were identified to have suffered from malaria between 1,500 and 500 BC (Nerlich et al., 
2008). Of course there can be discussions about stability and longevity of such DNA 
samples; however there is no doubt that malaria has been playing a major role in the 
lives of many humans for thousands of years (Brier, 2004). 
In 1882 Charles Louis Alphonse Laveran, a French military medical doctor, was 
the first person to unravel the connection between blood parasites and malaria. 
Laveran detected the parasites in the blood of Algerian soldiers. The disease had a 
colossal impact on the health of the French army and Laveran tirelessly attempted to 
uncover the secret cause of the disease. His observations published and distributed in 
scientific literature were at first dismissed by his medical colleagues. In 1884 he 
published his “Treatise on marsh fevers” but was only acknowledged with awards for 
his discovery in 1889. Laveran could not have established his findings and theories 
without previous work by Louis Pasteur. He undoubtedly prepared the ground for 
Laveran’s investigations by stating that most infectious diseases are caused by 
microbial germs in his “germ theory” in which microorganisms were proposed as the 
cause of many diseases (Pasteur, 1881). One of the major questions however still 
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remained unanswered until the year 1897 when Ronald Ross was the first investigator 
to uncover through the infections of birds that the malaria parasite was transmitted via 
the saliva of Anopheles mosquitoes (Ross, 1897).  
Malaria has a very long history as scourge of humanity affecting people from all 
backgrounds and from all continents. However, it has not lost its relevance rather it has 
gained in importance as it causes devastation in the poorest of the poor countries, and 
affecting individuals that have no alternative but to live with the disease in silence. 
 
1.1.2 Malaria: a socio-economic burden of the developing world 
Malaria has not always been restricted to the developing world as up until the 
early 20th century it was widespread throughout the northern hemisphere, reaching its 
peak in the 19th century (Carter et al., 2002). Mosquitoes and their breeding sites were 
long thought to be connected with the disease even before the first scientific evidence 
that an insect is in fact the transmission vector. Those breeding sites, which are mainly 
any areas with standing water and a temperature above a mean of 18°C, are found 
globally (Craig et al., 1999). However, changing macro- and microclimates has caused 
eradication of the vector and the parasite in many countries and areas. Although the 
vector can still be found in some areas the parasite simply cannot survive in colder 
climates (Paaijmans et al., 2009). Only a few non fatal autochthonous malaria cases 
have been located within those areas since eradication (Santa-Olalla Peralta et al., 
2010), although some of these cases are thought to be related to travel (Doby et al., 
1981). Malaria is currently thought to be responsible for around one million deaths 
annually worldwide with an incidence rate of clinical cases of approximately 300-500 
million (Snow et al., 2005;Guerra et al., 2008). Due to the climate conditions required 
for malaria transmission the vast majority of these fatalities (80-90%), occur in sub-
Saharan Africa where the incidence rate is as high as 212 million (see Figure 1), with 
98% of all cases being caused by P. falciparum (WHO, 2009). Approximately 3.2 billion 
people live in 109 malaria-endemic countries, representing nearly half of the world´s 
population thus making malaria one of the most devastating diseases of our time, third 
only to HIV and TB (WHO, 2010). In recent years the impact of urbanisation on malaria 
mobility and morbidity in sub-Saharan Africa has been highlighted. It is suggested that 
the annual entomologic inoculation rates for malaria are reduced in urban settings 
compared to rural sub-Saharan Africa (Robert et al., 2003); nevertheless, the estimated 
area covered by urban settings in Africa is only 1.6% of the total African surface (Keiser 
et al., 2004). As few as 35 countries (30 in sub-Saharan Africa and five in Asia) 
account for around 95% of the global malaria death toll with children under the age of 
five and pregnant women being predominantly amongst those affected (WHO, 
2003;Snow et al., 2005;WHO, 2008;WHO, 2010). Of all the deaths due to malaria as 
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many as 85% occur in children under the age of five with every fifth childhood death 
being caused by malaria (Snow et al., 2004). Those children living in endemic countries 
can expect to experience between one to six episodes of malarial infection before the 
age of five.  
 
1.1.2.1 The economic impact of malaria  
The countries with the highest malaria death toll are Nigeria, Democratic 
Republic of the Congo, Uganda, Ethiopia and the Democratic Republic of Tanzania. 
According to their per-capita gross domestic product (GDP) some of these countries 
are amongst the poorest in the world. Additionally they suffer from poor infrastructure, 
civil wars and/or political corruption resulting in financial deficits and a lack of 
investment from the private sector (Gallup et al., 2001). The countries with the highest 
malaria prevalence and poverty are distributed identically over the world suggesting 
that malaria and poverty go hand in hand (Sachs et al., 2002). Malaria accounts for a 
growth reduction of 1.3% in holo-endemic areas with up to 40% of public expenditure in 
these countries being spent on maintenance of health facilities and their staff, vector 
control and education and research required for managing the disease (WHO, 2009). 
The correlation between malaria prevalence and poor economic growth cannot be 
denied. Low GDP is an indicator for people being unable to afford necessary 
antimalarial treatment and prevention. These individuals will suffer from malaria and 
are incapable of attending work which in turn leads to growth reduction. Malaria has its 
most devastating impact on children, with prolonged and repeated periods of illness 
along with the many fatalities. In Kenya a child may miss approximately 15% of annual 
school days (Brooker et al., 2000). In countries where full school education is the 
exception malaria has a devastating impact. Young children suffering from malaria 
need to be taken care of and carers will be unable to attend work, or if hospitalisation is 
required parents need to spend their little money on medication and care. 
 
1.1.3 Apicomplexa 
Malaria is caused by the obligate intracellular parasite Plasmodium spp. and is 
taxonomically ranked within the phylum Apicomplexa. To date over 5000 species can 
be found within the Apicomplexa and all are eukaryotic, protozoan, obligate, 
intracellular parasites of invertebrate and vertebrate hosts. The disease-causing 
parasites are not only a nuisance but also have a dramatic impact on human health, 
animal health and on the worldwide economy (Hung et al., 2011). Some of the world’s 
most devastating diseases are caused by members of the Apicomplexa. Antony van 
Leeuwenhoek was the first person to observe an apicomplexan parasite in 1674, 
identifying oocysts of Eimeria stiedae in the gall bladder of a rabbit. The first extensive 
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classification, however, was not attempted until 1987. Levine and colleagues (Levine, 
1988) summarised all taxonomic knowledge about Apicomplexa which had a major 
impact on the understanding of the organisms. Plasmodium (malaria), Toxoplasma 
(toxoplasmosis), Babesia (babesiosis), Cryptosporidium (cryptosporidiosis), Isospora 
(isosporiasis), Cyclospora (cyclosporiasis) and Sarcocystis (sarcosporidiosis) are the 
seven genera which also infect and cause symptoms and disease in humans. An 
additional genus, Theileria, is an apicomplexan parasite with major impact on cattle 
livestock (Heussler et al., 1999). Plasmodium and Toxoplasma however are of the 
utmost clinical and economic impact for humans, causing millions of deaths and huge 
financial losses each year (Jones et al., 2001;WHO, 2010). Toxoplasma infects a third 
of the world’s human population and although infection is generally asymptomatic, it 
can be fatal in immunosuppressed individuals, causing symptoms with co-infections 
such as HIV/AIDS (Kim et al., 2008). Babesia, Theileria (both infecting cattle) and 
Eimeria (poultry) are major livestock pathogens and their impact on worldwide 
economies is a major challenge (Morrison et al., 2006;Shirley et al., 2007). 
All apicomplexan protozoa share certain common features, whereas other 
features are only maintained by some of the genera. An apical complex, from whence 
the name Apicomplexa is derived, is composed of a group of organelles thought to be 
involved in penetrating or invading the host cell, and forms the most distinctive feature 
of the phylum. The apical complex is located at the apical end of the parasites and is 
comprised of a set of spirally arranged microtubules, the conoid, a cone-shaped 
cytoskeletal structure at the very apical end, a secretory body (the most prominent of 
which are the club-shaped rhoptries), polar rings and smaller electron dense secretory 
organelles (micronemes). The conoid is not essential for invasion across all the 
parasites, as it can only be found in the coccidian Apicomplexa, Toxoplasma, Eimeria 
and Sarcocystis. Coccidia have in common that at least one of the life stages requires 
to penetrate the intestinal epithelium, therefore a role for the conoid in that step has 
been suggested (Nichols et al., 1987;Hu et al., 2002);(Morrissette et al., 2002). One 
additional essential structural feature is a chloroplast-like organelle, called the 
apicoplast, which is conserved throughout most of the Apicomplexa (Waller et al., 
2005). The apicoplast is a vestigial plastid of red algal origin (Janouskovec et al., 2010) 
and was first found in malarial parasites of ducks (Kilejian, 1975). Its function has yet to 
be conclusively determined but many hypotheses, including plastid-like metabolic 
pathways, have been proposed (McFadden, 2010). All species across the Apicomplexa 
not only share common intracellular features but also have complex but similar life-
cycles with sexual and asexual reproduction. A motile and infectious stage, the “zoite”, 
which undertakes host cell invasion, is a common feature of the apicomplexan life-
cycle. The host cell gliding form of the parasite injected by the mosquito vector 
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(Menard, 2001), named the sporozoite, actively invades the host cell by attachment 
and subsequent penetration. During schizogony it multiplies asexually and generates 
progeny within the invaded cell. Motile daughter cells are then released into the host 
and subsequently infect new cells. A few daughter cells will eventually further develop 
to form male and female gametes through gametogony. These combine to then 
produce new invasive forms during sporogony, the only sexual reproduction step in the 
life-cycle, allowing genetic recombination within species. Apicomplexan parasites carry 
a haploid genome, with one exception during sexual reproduction with the formation of 
a zygote (Morrissette et al., 2002).  
Toxoplasma gondii is the best understood member of the Apicomplexa and 
serves as a model organism for many other members including human pathogens, e.g. 
Plasmodium spp. or other pathogens of veterinary importance e.g. Theilaria spp.. The 
genome of T. gondii is amenable to manipulation in parasite cultures and allows for 
efficient stable and transient transfections of the parasite (Soldati et al., 1993). 
Additionally, the phrase “size matters” can be applied literally to the understanding of 
the parasite’s biology. Most apicomplexan life stages are very small and test the limits 
of modern day microscopy. A P. falciparum infected red blood cell (iRBC) only 
measures 5 µM in diameter whereas T. gondii’s ability to infect a wide variety of cells 
can lead to infected host cells with diameters which are several fold higher than iRBCs.  
 
1.1.4 Plasmodium: an introduction  
Plasmodium spp. is a genus of obligate intracellular parasites with more than 
200 species described to date. Reptiles (reptilia), birds (avis) and mammals 
(mammalia) are the main hosts for the disease (Cox, 2010). Morbidity and mortality 
caused in humans was the first impetus to investigate the origin of the disease. 
Interestingly the initial malaria parasites identified were not of human origin but 
Plasmodium cynomolgi, Plasmodium inui, and Plasmodium pitheci extracted from 
monkey blood samples (Garnham, 1966). Throughout the longest period of the 20th 
and the beginning of the 21st century four Plasmodium species were considered to 
widely infect humans: Plasmodium ovale, Plasmodium vivax, Plasmodium malariae 
and P. falciparum (Escalante et al., 1995). In 2004 a fifth naturally acquired species, 
Plasmodium knowlesi, was shown to be responsible for fatalities in humans (Singh et 
al., 2004) confirming Garnham’s hypothesis from 1957 that P. knowlesi might be 
another species causing human malaria (Garnham et al., 1957). P. knowlesi was 
originally considered to only infect long-tailed macaques and human cases were 
thought to be occurring rarely until the realisation that it had potentially been 
misdiagnosed as P. malariae for many years based on their morphological similarities 
(Singh et al., 2004;Cox-Singh et al., 2008a;Cox-Singh et al., 2008b;Lee et al., 2009). 
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1.1.5 Plasmodium distribution and mortality 
P. falciparum is the most virulent human malaria pathogen and is responsible 
for the vast majority of human deaths from malaria, especially in sub-Saharan Africa. It 
is transmitted by the female Anopheles mosquito. The intra-erythrocytic life-cycles, 
which cause most of the symptoms, between the five human malaria pathogens are 
surprisingly dissimilar. P. knowlesi undergoes its full intra-erythrocytic development 
within 24 hours, whereas P. falciparum, P. vivax and P. ovale require 48 hours for their 
full development. P. malariae however undergoes the longest intra-erythrocytic 
development, lasting 72 hours, and is known to establish an asymptomatic blood stage 
infection which can persist for decades. Although P. vivax and P. ovale are the only 
species known to develop dormant stages, called hypnozoites, within the human liver, 
which occasionally cause relapses months post-infection (Collins et al., 2005;Coldren 
et al., 2007;Imwong et al., 2007). Not all of the five species are prevalent in all malaria 
endemic countries. P. vivax is widespread mainly in Asia and central and South 
America, affecting over 75 million people annually (Mendis et al., 2001) and therefore 
coming second only to P. falciparum based on its epidemiology. The greater part of P. 
ovale derived infections can be seen in sub-Saharan Africa, mainly the western and 
eastern part, and some islands in the western pacific (Collins et al., 2005). P. malariae 
distribution has been described as “patchy” but it is prevalent in most malaria endemic 
countries (Mueller et al., 2007). P. knowlesi is almost exclusively spread around 
Southeast Asia (Lee et al., 2011). The most virulent species P. falciparum is mainly 
found in sub-Saharan Africa where it accounts for more than 75% of the malaria cases 
(WHO, 2010). Therefore work in this study will focus on P. falciparum. 
 
1.1.6 Experimental understanding of P. falciparum 
P. falciparum has a haploid genome of 23 megabases distributed over 14 
chromosomes and encoding approximately 5,300 genes. The genome is the most 
adenine and thymine-rich sequenced to date making P. falciparum relatively difficult to 
examine and explore with molecular genetic techniques (Menard, 2001;Gardner et al., 
2002). In 1975 Trager and Jansen were successful in culturing the pathogen in human 
blood in vitro, opening completely unexploited pathways in malarial research towards 
the understanding of the biology of the organism (Trager et al., 1976). Despite the 
ability to explore P. falciparum’s biology in vitro, analysis of the entire life-cycle in vitro 
is a major challenge, since no in vitro model for mosquito-human interchange, or for the 
human immune response to malaria infections, has been established. Thus the search 
for an ideal system mimicking the human malaria pathogen keeps the research 
community on its toes. One goal was reached with the findings that Plasmodium 
berghei, a rodent parasite, can be used as a model for transmission from vector to the 
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mammalian host and for the first in-host stage with the sporozoite transit from the skin 
to the liver (Cao et al., 2009b). Additionally, its close ancestry to P. falciparum makes it 
an intriguing model organism for further approaches. 
 
1.1.7 Pathology: The disease in different aspects 
P. falciparum is responsible for the most severe form of malaria and the intra-
erythrocytic stages are causative of the associated pathology. Different severities of 
symptoms are associated with many factors and can range from mild and 
uncomplicated to severe malaria to cerebral malaria with a mortality rate of 19% 
(Newton et al., 1998a). The clinical outcome of severe malaria is associated with many 
factors driving severe and fatal symptoms. Severe malaria in high transmission areas 
mainly affects young children between the age of six months and four years. Children 
up to the age of six months benefit from passive immunity transferred horizontally by 
maternal antibodies. After the first six months of their lives children need to rely on the 
establishment of their own immunity (see below) and mostly suffer from one to several 
malarial episodes until the age of four. By the time they reach the age of four, 
pathogenesis is rarely seen and generally has a mild outcome (Reyburn et al., 2005). 
Adult sufferers can mainly be found in meso-endemic areas as they lack constant re-
infection to maintain immunity against malaria. Clinical pathophysiological features of 
severe malaria are mainly characterised by metabolic acidosis, lactic acidosis 
(predominantly in infants), hypoglycaemia, severe anaemia, multi organ failure, 
respiratory distress, renal failure, hepatic dysfunction, microvascular obstruction and 
cerebral malaria. Uncomplicated malaria ranges from asymptomatic to flu-like 
symptoms, especially in immune individuals (Newton et al., 1998b;Clark et al., 
2003;Francischetti et al., 2008). High fever occurs every 48 hours coinciding with the 
rupture of infected red blood cells (iRBCs) and release of P. falciparum into the blood 
stream.  
Cerebral malaria is caused by the adhesion of iRBCs to the microvasculature in 
the brain. This is possible due to parasite-induced RBC surface alterations. Adhesion 
of iRBCs in the vascular endothelium also leads to reduced tissue perfusion (Aikawa, 
1988;Chakravorty et al., 2008). By attachment of iRBCs to the lining of the vascular 
endothelium the parasite avoids clearance by the spleen, called sequestration. 
Sequestered parasites have been observed within various organs, for instance heart, 
lung, placenta and brain causing enlargement of the microvasculature. The key 
molecule involved in sequestration and in evading the host immune system is thought 
to be P. falciparum erythrocyte membrane protein 1(PfEMP1). PfEMP1 is parasite 
induced and highly expressed on the surface of iRBCs and interacts mainly with 
surface receptors of the microvasculature (Kyes et al., 2001). PfEMP1 is encoded by 
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around 60 different gene copies in the parasite. Expressing one variant at a time 
enables the parasite to bind to tissue receptors and by switching approximately 2% per 
generation ensures evasion of the host’s immune response (Roberts et al., 1992;Bull et 
al., 2005). Additionally P. falciparum causes rosetting, a process in which iRBCs 
adhere to non-infected RBCs. This leads to reduced deformability of non-infected 
RBCs, RBC lysis and obstruction to microvasculature causing additional pathology 
(Aikawa, 1988;Miller et al., 2002a). 
Although parasite factors, for instance cytoadherence, antigenic polymorphisms 
and variation are important, the role of host factors such as previous parasite exposure 
hence state of immunity or the host genetic background (sickle cell trait, thalassaemia), 
cannot be neglected.  
  
1.1.8 Immunity and vaccination 
Very little is known about immunity to P. falciparum derived malaria. It is 
understood however that different pathology in humans is influenced by both parasite 
and host factors. The differences between severe malaria, mild malaria and the 
establishment of asymptomatic infections are thought to occur based on previous 
exposure to the pathogen. Two types of immunity can be described: anti-disease, 
which mainly alleviates the symptoms but does not affect the parasite, and anti-
parasite, which is involved in reducing parasitaemia. Humans living in holo-endemic 
areas with constant re-infections have a level of anti-disease immunity but not sterile 
immunity (Kyes et al., 2007). It was shown that constant re-exposure to P. falciparum is 
required to achieve a state of premunition. People from holo-endemic areas that moved 
to non-endemic countries suffer from malaria if being infected again after living away 
for a certain amount of time.  
As previously mentioned newborn children up to six months of age obtain low 
level immunity through maternal antibodies. However, between the age of six months 
and approximately four years children need to establish their own protective immunity. 
They will acquire some immunity only if exposed to the parasite, but at the same time 
they might suffer from severe malaria, cerebral malaria or possibly leading to death 
(Snow et al., 2001). Acquiring immunity to malaria is very effectively challenged by the 
complex life-cycle of the parasite. The parasite is exposed directly to the human 
immune system for only a brief amount of time during its life-cycle - first, as pre-
erythrocytic infective sporozoites before invading hepatocytes and second as 
merozoites are released into the host’s blood stream before invasion. Immunity is 
mainly established against parasite-derived antigens which are expressed on the host 
cell surface. Even though immunity to a repertoire of these variant surface proteins 
may be slowly acquired, variant erythrocytic surface antigen expression (antigenic 
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variation) attenuates the possibilities of inducing a naturally acquired immune response 
against these variants, and, more importantly, affects host immune memory (Bull et al., 
2005). The host’s genetic pre-disposition also contributes to pathology and some RBC 
polymorphisms are understood to lead to milder pathology (Wellems et al., 2009). 
Individuals heterozygous for sickle cell anaemia, named sickle cell trait (HbAS), suffer 
milder malaria pathophysiology and lower parasitaemia compared to healthy 
individuals (Allison, 1954). The exact mechanisms are unknown. It is believed that 
parasites are less capable of invading the crescent shaped erythrocytes and infected 
erythrocytes undergo reduced sequestration limiting parasite survival hence restricting 
pathology. Additionally it has been suggested that HbAS causes the infection to persist 
longer in the body, therefore a better immune response can be established (other 
theories for the HbAS effect have been proposed; Williams. A third of all sub-Saharan 
Africans are heterozygous for sickle cell anaemia which increases fitness of affected 
individuals towards malaria, suggesting selection for sickle trait sufferers has taken 
place in endemic areas. Other genetic alterations that improve fitness against malaria, 
are α-thalassaemia, causing a reduction in severe malaria and adhesion of infected 
and non-infected RBCs and glucose-6-phosphate dehydrogenase (G6PD) deficiency, 
leading to increased phagocytosis of early stage parasitised RBCs (Cappadoro et al., 
1998;Lopez et al., 2010).  
Although the P. falciparum induced immune response still raises many 
questions, attempts to develop effective and protective vaccines to induce anti-disease 
immunity are continuously on their way (Crompton et al., 2010). However, these efforts 
are hindered by the complex life-cycle of the parasite, antigenic variation and the above 
mentioned lack of understanding of the pathogen-host interaction in the immune 
response. PfEMP1 plays a central role in host-parasite immune development and is 
exclusively expressed by transcription of var genes (Gardner et al., 2002), making it a 
rather less interesting target for the development of vaccines because of antigenic 
variation. A few non-antigenic variation encoded transcripts provide targets for the 
immune response and are considered vaccine candidates (Riley et al., 2006). The 
circumsporozoite protein (CSP) on the surface of infective sporozoites can be targeted 
by the immune response after the inoculation of irradiated or genetically attenuated 
sporozoites (Kumar et al., 2006). Protection is believed to be most efficient if 
sporozoites invade hepatocytes but cannot develop completely. Additionally a vaccine 
carrying a part of CSP in fusion with a surface coat protein of Hepatitis B virus, called 
RTS,S, has succeeded as far as clinical Phase III trials, with conferring protection with 
efficacies of between 40% and 50% in Phase II (Alonso et al., 2005;Casares et al., 
2010). The above mentioned vaccination approaches target pre-erythrocytic stages, 
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preventing the establishment of blood stage infections by diminishing intra-hepatocytic 
development.  
Antibodies produced against blood stage molecules, e.g. the merozoite surface 
protein (MSP1) expressed on erythrocytic stage merozoites, reduce parasite growth by 
inhibiting RBC invasion. Development of vaccines based on recombinant MSP1 is 
ongoing (Christian Epp, unpublished; Ramasamy. Vaccines against blood stage 
molecules however suffer widely from low-level efficacy.  
 
1.1.9 Malaria control 
Attempting to control malaria has been a challenging battle for the last few 
centuries. Many approaches were taken to eradicate the parasite and the vector, or if 
not to eliminate then to invent strategies for coping with the disease. Although mortality 
appears to be declining (WHO, 2008;WHO, 2010), malaria still is as prominent as it has 
been for many centuries. The struggle to understand all the key parts in the parasite’s 
life-cycle, the host-parasite interaction, and the resulting immune response have 
prepared the ground for new approaches in the antimalarial battle. Efforts were 
additionally turned towards vector elimination, especially with the new availability of 
chemicals attacking Anopheles mosquitoes.  
Over the past decades both organisms have evolved high levels of resistance 
to insecticides (Ranson et al., 2000;Catteruccia, 2007) or antimalarial drugs (Takebe et 
al., 2007). Therefore numerous obstacles still have to be overcome in controlling the 
disease. However, malaria control has not always appeared that way. In the 1950’s 
malaria eradication was believed to be imminent (Russell, 1955;Hay et al., 2004). In 
recent times the targets have been re-evaluated and the short term main objectives are 
malaria control independently from eradication (Moonen et al., 2010). Improving 
malaria control means improving monitoring malaria morbidity as misdiagnosis leads to 
unnecessary treatment causing parasite resistance against antimalarial drugs. 
The fight against malaria can be addressed from diverse angles; reducing 
transmission and infection and administering disease management.  
 
1.1.9.1 Parasite control: Antimalarial drugs  
Drugs with antimalarial capacity are currently the best therapy for decreasing 
morbidity and mortality. Nearly all antimalarials are developed to target the most severe 
form of malaria caused by P. falciparum by attempting to kill the parasite within infected 
erythrocytes. The search for effective and suitable medication has been ongoing.  
Ever since malaria has been affecting humans people relied on naturally 
derived compounds primarily from plants or extracts thereof. The anti-fever properties 
of a natural compound qinghao, Artemisia annua (sweet wormwood), were first 
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described in China in 168 BC. It was frequently used to treat fever and is considered to 
have been in use widely long before that time (Klayman, 1985). The most effective 
recent antimalarials are semi-synthetic artemisinin derivatives and their analogues and 
these are now the recommended first-line treatment. They target the intra-erythrocytic 
stages of the parasite, reducing parasitaemia and disease symptoms. They are used in 
severe malaria mainly in combination therapy to avoid recrudescence and parasite 
resistance (Maude et al., 2010). Two of the most widely used applied semi-synthetic 
artemisinin analogues are artemether and artesunate. Unfortunately, the first resistant 
parasite strains have now been reported (Saralamba et al., 2011). Despite its long 
history, it took until the early 1970’s for researchers to gain interest into artemisinin, 
coinciding with the first severe cases of P. falciparum resistance to another group of 
antimalarials. Chloroquine was discovered in 1934 as a methylene blue derivative and 
first administered in the 1940’s (Coatney, 1963). The mode of action is conferred by 
chloroquine being passively taken up into the food vacuole of the parasite (residing 
within an erythrocyte) where chloroquine undergoes protonation, accumulates within 
the food vacuole and inhibits the sequestration of hem in the form of haemozoin. This 
causes the parasites to become slowly intoxicated and die. Combined with vector 
control, chloroquine was one key tool in the WHO malaria eradication programme 
launched in 1955 (WHO, 1999). Unfortunately, resistance emerged quickly, mostly 
associated with mutations within the P. falciparum chloroquine transport channel 
(PfCRT) in the food vacuole (FV) membrane. These mutations are thought to allow the 
protonated chloroquine to exit, leaving a resistant P. falciparum (Payne, 1987;Fidock et 
al., 2000;Wellems et al., 2001). Chloroquine resistance had a disastrous effect on 
morbidity and mortality caused by P. falciparum and P. vivax and led to termination of 
the WHO malaria eradication programme in 1972. Resistance emerged as a severe 
effect of over usage and large scale administration without effective control strategies 
in place (all individuals suffering from malaria-like symptoms were treated without 
confirmed diagnosis). Resistance is wide-spread, and additionally it can be detected in 
travellers returning from holo-endemic countries to the UK; see Figure 2). Because of 
its cost-effectiveness chloroquine is still used in many places as a first-line treatment. 
Other antimalarials are for instance administered as a combined therapy between 
atovaquone and proguanil inhibiting the parasite’s dehydrofolate reductase (DHFR), 
e.g. Malarone™. Mefloquine, a quinine analogue is also used, but with resistances 
emerging as quickly as one year after administration (Wongsrichanalai et al., 
2002;Price et al., 2004;Sutherland et al., 2008). 
Many effective antimalarials mimic natural compounds or are in fact derived 
from direct plant extracts. Intelligent drug design has only come into place within the 
last decades and understanding the parasite’s biology is of utmost importance. Until 
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then re-design of old drugs, rediscovery of old molecules, drug combinations and the 
application of natural compounds are required to not elevate the malaria death toll. 
 
1.1.9.2 Vector control and disease prevention 
In efforts to reduce malaria prevalence all possible steps must be taken. 
Therefore vector control can play as important a role as parasite control. Vector 
management can be approached from diverse angles as the mosquito undergoes two 
morphologically distinct phases, a larval and adult stage. Prevention of breeding or 
killing the larval and the adult forms would interfere with transmission as would the 
prevention of the blood meal by adult female mosquitoes. Different vector control 
measures include the distribution of insecticide-treated bed nets (ITNs) to reduce bite 
count, varying methods of insecticide spraying to attack either the adult mosquito or 
breeding sites, and finally the latest approaches to establish transgenic mosquitoes. 
Attacking adult mosquitoes has many advantages over larvae control. Larval breeding 
sites are not only extremely widespread but also inaccessible. Aquatic breeding sites 
require frequent treatment with insecticides whereas ITNs or solid indoor wall spraying 
persist for up to six months. Additionally the maturation of the eggs within the female 
mosquito takes up to 12 days during which time it can return up to three times for a 
blood meal, increasing the likelihood of elimination. In the past the main focus was 
indoor residual spraying (IRS) or the large scale outdoor spraying of insecticides with 
dichlorodiphenyltrichloroethane (DDT). In combination with chloroquine treatment of 
infected individuals excessive DDT spraying was used for the malaria eradication 
programme in the 1950’s. In some low transmission areas the programme had a 
colossal impact on the reduction of malaria prevalence (WHO, 1999). However, little 
impact was achieved in high transmission areas where health concerns about the 
extremely widespread and extensive application of DDT were raised as quickly as 
reports of resistant mosquitoes, which lead to abortion of insecticide application and to 
the arrest of the entire eradication programme (Wellems et al., 2009). The focus has 
now returned to IRS with pyrethroids as the chemical of choice as the vectors are 
known to feed and rest indoors making walls covered in insecticides an applicable and 
controllable approach. Furthermore bed nets have been useful in controlling malaria 
transmission since ancient times. Even Cleopatra was thought to have used bed nets 
to keep the biting nuisances away at night. Distribution of ITNs is easier to monitor than 
the use of chemicals and they are cost-effective. A considerable amount of effort has 
been combined between several non-profit organisations and profit based companies 
operating in some African countries. For example lorries which are required for the 
transport of coffee beans from place of cultivation to distribution centres can also serve 
to transport ITNs (personal communication, All Party Parliamentary Meeting for Malaria 
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and Neglected Tropical Diseases 2010). 40-60 million ITNs were distributed in 2008 
and in some African countries the household ITN ownership was up to 80% (WHO, 
2009). However, the data can be misleading as some countries, e.g. Nigeria, have less 
than 10% household ITN ownership. 
Although there has been a relative long history in the application of sterile 
mosquitoes (Knipling, 1959) it was not before the completion of the A. gambiae 
genome project in the past decade that practical advances were made (Holt et al., 
2002). Progress has been made towards the establishment of genetically driven 
systems as a basis of transgenic vector control. Population replacement and population 
eradication are considered as two main strategies in vector control. An alternative 
approach has been taken with the development of sterile mosquitoes to reduce or 
eliminate Plasmodium transmission (Thailayil et al., 2011). Methods like the use of 
symbionts for instance Wolbachia and the direct offensive against Plasmodium in the 
host´s midgut and salivary glands to prevent transmission are now in use 
(Christophides, 2005;Hughes et al., 2011;Isaacs et al., 2011). 
 
1.2 The P. falciparum life-cycle  
P. falciparum is transmitted by mosquitoes of the genus Anopheles and exhibits 
a complicated life-cycle of asexual multiplication in the human host and sexual 
reproduction in the dipteran vector (see Figure 3). Of the 400 Anopheles species 
distributed worldwide, only 30 are considered to be of major importance in malaria 
transmission (Tuteja, 2007), with Anopheles gambiae being the most important in 
transmission of human malaria in Africa (Holt et al., 2002). Even though the parasite 
causes sequelae and morbidity mostly in the human host (Dawes et al., 2009), man 
acts merely as an intermediate stage, and the parasite´s sexual reproduction is 
completed exclusively in the insect vector. Only female mosquitoes transmit malaria as 
male do not feed on human blood, as the blood meal is required for the full 
development of the eggs within the female mosquito. 
Throughout its life-cycle P. falciparum varies between motile, invasive, encysted 
and intracellular sexual and asexual stages. Other Plasmodium species additionally 
form dormant forms. Infective sporozoites are inoculated from the female mosquito`s 
salivary glands into the subcutaneous tissue (and, less frequently, directly into the 
blood stream) via injection by the proboscis of the female mosquito during the blood 
meal (Daily, 2006). Sporozoites breach the blood vessels of the skin, migrate via the 
blood stream to the liver and actively invade hepatocytes. For reasons that are poorly 
understood sporozoites traverse several hepatocytes before the final invasion of a cell 
where they undergo exo-erythrocytic mitotic division (exo-erythrocytic schizogony 
(Prudencio et al., 2007;Sturm et al., 2007). Eight to ten days after invasion, hepatic 
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schizonts rupture, each releasing several thousand merozoites into the host circulation 
in membrane-surrounded vesicles called merosomes (Sherman et al., 2004;Sturm et 
al., 2006). Once in the blood stream, infective merozoites actively invade RBCs, 
beginning the blood stage cycle (intra-erythrocytic cycle). Post-invasion, the parasite, 
which resides in a parasitophorous vacuole (PV) with its own parasitophorous vacuolar 
membrane (PVM) develops into the ring stage (0-24 h post invasion), followed by the 
trophozoite stage (24-36 h post invasion) and finally the schizont stage (36-48 h post 
invasion). Throughout the intra-erythrocytic the parasite acquires its nutrients in a very 
sophisticated way by the breakdown of the host cell haemoglobin and by the uptake of 
nutrients from its surroundings (Tilley et al., 2007;Polonais et al., 2010). Erythrocytic 
schizogony coincides with multiple rounds of nuclear division of the trophozoite to 
produce mature schizonts that then undergo cytokinesis to finalise asexual 
reproduction and produce numerous daughter cells (merozoites). The host cell finally 
ruptures in an active process called egress and 16 to 32 merozoites (in the case of P. 
falciparum) are released into the blood stream to infect fresh RBCs. Not all released 
merozoites undergo another erythrocytic cycle. Some will differentiate, may be 
triggered by the level of parasitaemia and the availability of nutrients (Nacher et al., 
2002), into sexual stages called macrogametocytes and microgametocytes that mature 
but are incapable of reproduction in the human host. Their ingestion by a feeding 
Anopheles activates further maturation, such as exflagellation of microgametocytes 
(Billker et al., 2004). Altered pH and temperature conditions, xanthurenic acid and 
calcium signalling via a cGMP-dependent protein kinase are some of the known factors 
that facilitate DNA replication and cell division and induce differentiation of the male 
and female gametocytes to gametes (Vlachou et al., 2006;McRobert et al., 2008). Soon 
after the gametes fuse, the resulting elongated ookinete penetrates the mosquito´s 
midgut epithelium and matures to an oocyst while embedded in the midgut epithelium. 
Finally, sporozoites which develop in the oocyst breach the oocyst wall and migrate to 
the salivary glands of the dipteran host (Ghosh et al., 2009) ready to be injected into a 
new human host. 
Although P. falciparum survives within a rather multifaceted life-cycle with 
varying developmental stages and a range of host cells it is important to mention that 
despite all complexity conservation within various life-cycle steps can be found. Active 
invasion and active escape are a common theme for P. falciparum and can be found in 
all hosts throughout all life stages. 
 
1.3 Intra-erythrocytic stage 
The complexity of the P. falciparum life-cycle is a major obstacle that can only 
be overcome by completely understanding all the individual events. Despite involving 
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various different developmental stages, one in particular is the most problematic for 
humans. The intra-erythrocytic (see Figure 4) stage starts after the release of several 
thousand merozoites from hepatocytes via merosomes into the host’s blood stream.  
 
1.3.1 Getting in: Invasion 
Invasion by Plasmodium spp. is a rapid and tightly regulated process that was 
first characterised and is best understood in P. knowlesi although it is now believed that 
P. falciparum undergoes a very similar process (Bannister et al., 1975;Dvorak et al., 
1975;Aikawa et al., 1978;Bannister et al., 1990). Merozoite invasion of RBCs is a 
necessity to ensure survival of the parasite and it is the step initiating pathology in the 
human host. Successful invasion begins after the initial weak and reversible 
attachment between the merozoite surface and the virgin erythrocyte (Bannister et al., 
1990). This step is required for recognition and identification of the host cell as only 
RBCs can be invaded at this stage. Subsequent re-orientation wherein the apical part 
of the merozoite is in contact with the RBC surface is required before the parasite can 
invade the RBC. Re-orientation coincides with the specific formation of a tight junction 
orchestrated by the release of proteins from parasitic secretory organelles onto the 
RBC surface whereupon the former weak attachment becomes irreversible (Bannister 
et al., 2003). To now enter the cell the tight junction moves towards the posterior end of 
the merozoite driven by a parasite actin-myosin motor (Keeley et al., 2004;Baum et al., 
2006).  
Understanding the molecular basis of invasion requires some knowledge of the 
merozoite’s ultrastructure and its organelles (see Figure 5). Merozoites are membrane 
bound invasive stages that assemble after several asexual nuclear divisions of a parent 
very late in the parasite’s intra-erythrocytic life-cycle. The surface of the merozoite is 
coated with glycosylphosphatidylinositol (GPI) anchored, peripheral and 
transmembrane domain containing proteins that are discharged from merozoite 
secretory organelles before or during and after egress and invasion. They are generally 
called merozoite surface proteins (MSPs) and the most prominent member covering 
the majority of the surface is MSP1 and is the most studied MSP. It is essential for 
parasite survival, is a major vaccine candidate (see 1.1.8) and is thought to initiate the 
first weak attachment between merozoite and the RBC surface (Holder et al., 
1982;Holder et al., 1992;O'Donnell et al., 2000). Band 3 and heparin-like molecules are 
considered possible RBC surface ligands to interact with MSP1 (Goel et al., 
2003;Boyle et al., 2010a). Antibodies against MSP1 abolish parasite invasion in vitro 
and protect against blood stage challenge in vivo (Holder, 2009;Woehlbier et al., 2010). 
MSP1 forms a merozoite surface complex with the peripherally associated family 
members MSP6/7 (Stafford et al., 1994;Stafford et al., 1996) and regulated extensive 
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maturation of the complex prior and throughout invasion is thought to be required for 
parasite survival (Pachebat et al., 2007;Child et al., 2010). Different MSPs are believed 
to hold different roles in invasion as they are unevenly distributed across the merozoite 
surface (Sanders et al., 2005). Further GPI-anchored surface proteins are Pf12, Pf38, 
Pf92 and the putative Pf113 with some of them being refractory to genetic disruption in 
the parasite suggesting an important role (Cowman et al., 2006).  
 
1.3.1.1 Irreversible attachment and tight junction formation 
After the initial weak attachment (see Figure 6A) with the RBC ligands the 
merozoite re-orientates for an irreversible contact between the apical end and the host 
cell surface, positioning the secretory organelles juxtaposed to the RBC surface (see 
Figure 6B). This process is thought to be triggered by the accumulation of proteins 
towards the apical end of the merozoite possibly coinciding with discharge from 
micronemes of proteins that then translocate across the merozoite surface (Lew et al., 
2007). Apical membrane antigen 1 (AMA1) is believed to be translocated from 
micronemes across the merozoite surface prior to invasion but probably does not 
display any role during the initial weak attachment (Mitchell et al., 2004). AMA1 is 
highly conserved throughout Apicomplexa and is essential for parasite invasion in P. 
falciparum and T. gondii (Triglia et al., 2000;Silvie et al., 2004;Mital et al., 2005).  
Now being correctly positioned the merozoite apical organelles continue to 
secret a subset of proteins to promote invasion and to form an irreversible tight junction 
between the merozoite and the host cell (see Figure 6C/D). The discharge from 
organelles is strongly believed to be tightly regulated by calcium efflux through signal 
transduction cascades, as intracellular calcium chelators inhibit secretion, but secretion 
can be induced with calcium ionophores in T. gondii (Carruthers et al., 
1999a;Carruthers et al., 1999b). Additionally, specific inhibition of T. gondii calmodulin-
like domain protein kinase 1 (CDPK1) prevent attachment and micronemal secretion 
(Kieschnick et al., 2001).  
Candidates for the establishment of the irreversible interaction (tight junction) 
between the RBC and the apical end of the merozoite are proteins of the Duffy binding 
ligand (DBL) family and P. falciparum reticulocyte binding homologues (PfRh). DBLs, 
which are characterised by a cysteine-rich domain towards the N-terminus, were first 
identified in P. vivax and have been shown to interact with the Duffy antigen on the 
surface of RBCs (Wertheimer et al., 1989;Fang et al., 1991). Prominent members of 
the DBL family in P. falciparum are erythrocyte binding proteins EBA-140, EBA-175 
and EBA-181. EBA-175 and EBA-140 bind to the RBC surface proteins glycophorin A 
and C respectively. The interaction partner of EBA-181 however has yet to be 
determined. DBL mediated surface binding is neuraminidase sensitive suggesting a 
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sialic-acid dependent interaction. PfRh homologues were first identified in Plasmodium 
yoelii and P. vivax and are believed to be involved in determining host-cell specificity 
(Galinski et al., 1992;Preiser et al., 2002). It appears that merozoites possibly invade 
with alternating receptors as transcription of P. yoelii reticulocyte binding homologues 
can vary within one single schizont and different variants can be expressed in different 
stages of the life-cycle (Preiser et al., 2002). P. falciparum reticulocyte binding 
homologues are PfRh1, which binds to glycosylated RBC receptors and PfRh 2a/b and 
PfRh4 (Rayner et al., 2001;Duraisingh et al., 2003;Stubbs et al., 2005). A novel RBC 
surface ligand for PfRh4 has recently been identified. Complement receptor 1 (CR1) 
interacts with PfRh4 in a sialic-acid independent invasion pathway (Tham et al., 2010). 
Additionally, PfRh2b plays a role in invasion though its interaction partner has yet to be 
identified. EBA family members are thought to be released from micronemes whereas 
PfRhs are discharged from the rhoptry bulb prior to the irreversible attachment between 
merozoite and RBC.  
The formation of the tight junction per se is poorly understood. AMA1 is 
translocated to the merozoite surface before it is shed, while some rhoptry neck 
proteins (RONs) are inserted into the host cell membrane. In T. gondii, AMA1 and the 
RON2/4/5/8 complex interact in an electron dense contact point of the moving junction 
which appears to surround the invading merozoite in a ring like structure (Alexander et 
al., 2005;Lebrun et al., 2005;Besteiro et al., 2009;Besteiro et al., 2011). This interaction 
between AMA1 and RON2/4 has recently been confirmed in P. falciparum (Cao et al., 
2009a;Collins et al., 2009).  
 
1.3.1.2 Invasion and PV formation 
Upon the formation of a surface complex between AMA1 and RON2/4/5/8 T. 
gondii releases proteins and lipids into the host cell in order to establish the PV 
(Hakansson et al., 2001). Similar cascades with discharge from rhoptries and dense 
granules have been suggested for Plasmodium (Aikawa et al., 1983). The merozoite is 
ready and set to now push its way into the host cell under the calcium–dependent 
function of an actin-myosin motor. The motor is located just below the merozoite 
plasma membrane and is believed to interact with proteins of the surface complex 
(Green et al., 2008). Shedding of merozoite surface adhesins that interact with RBC 
surface receptors from the anterior to posterior end is thought to help internalisation of 
the merozoite (Blackman, 2000;Harris et al., 2005;O'Donnell et al., 2005;O'Donnell et 
al., 2006;Baum et al., 2008); see Figure 6E). MSP1 and AMA1 are both shed by 
PfSUB2, a serine protease. A second family of serine proteases, the rhomboids which 
cleave in intra-membrane domains, are also involved in shedding of surface proteins. 
Rhomboids are believed to process surface adhesins like EBA-175, at the intra-
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membrane and juxtamembrane domain in order to release the merozoite from its 
attachment to the host cell surface (O'Donnell et al., 2005;Baker et al., 2006;O'Donnell 
et al., 2006). Although some understanding of how Apicomplexa enter new host cells 
has been collected, many questions remain, including the contribution made by 
proteolytic cascades in this complex process. 
While invading the red blood cell the parasite creates the PV, a sack like 
compartment wherein the parasites resides and multiplies throughout its life-cycle. The 
PV is separated from the RBC cytosol by a porous PVM. The origin and assembly of 
the PVM is not clear. It is thought to contain both parasite and RBC components and its 
formation coincides with the release of the contents from the parasite’s secretory 
organelles, such as dense granules and club-shaped rhoptries (Baum et al., 2008) at 
the apical end into the host cytosol (Lingelbach et al., 1998;Preiser et al., 2000). While 
residing within the PV passive bidirectional transport across the PVM takes place to 
supply the growing parasite with nutrients (Nyalwidhe et al., 2002). The exact purpose 
of the PV is yet to be established, although it has been shown that proteases and 
chaperones are the most abundant proteins in the PV lumen suggesting an 
involvement in protein sorting and nutrient uptake (Nyalwidhe et al., 2006). The PV is a 
compartment of special interest particularly throughout the later parasite life stages. It 
plays a key part in the release of parasites into the blood stream as it is believed that 
proteases required for that step are discharged into the PV lumen just prior to egress 
(see above). Most Apicomplexan parasites establish a PV within the host cell; 
however, the timing of its persistence varies. Toxoplasma and Plasmodium reside 
within the vacuole throughout their entire intracellular stages whereas other 
Apicomplexa, for example Theileria and Babesia escape their PV shortly after invasion 
(Potgieter et al., 1977;Shaw, 1997). 
 
1.3.2 Getting out: Egress 
At the end of asexual division the newly established daughter cells are required 
to escape from the host cell in order to continue the parasite life-cycle. This step is 
called egress (see Figure 7). The merozoites appear to become viable just prior to 
egress (Gilson et al., 2009). Egress is essential in the asexual and sexual stages of the 
parasite’s life-cycle. P. falciparum has to escape from hepatocytes, RBCs in the human 
host, RBCs after the uptake from the mosquito vector and the oocyst in the mosquito’s 
midgut. The exact mechanism of egress is poorly understood and the proteins possibly 
involved have been under thorough investigation for two decades. An important role of 
proteolytic activity in disintegration of both membranes has been proposed (Deguercy 
et al., 1990). Involvement of proteases was first shown by treating in vitro parasite 
cultures with a combination of several protease inhibitors. Parasite cultures treated with 
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the cysteine/serine protease inhibitor leupeptin, the broad spectrum protease inhibitor 
chymostatin, an aspartic protease inhibitor pepstatin and the cysteine/serine protease 
inhibitor antipain failed to rupture the host cell. Instead highly segmented and trapped 
schizonts could be observed (Lyon et al., 1986). 
To exit the infected host cell P. falciparum blood stage merozoites are required 
to breakdown two membranes, the PVM and the erythrocyte plasma membrane (EPM). 
Breaching the PVM might appear as the easier task as only one bi-layer has to be 
overcome (structural complexes have yet to be identified within the PV lumen). 
Overcoming the EPM might be considered more challenging with an intact cytoskeleton 
still in place. Early insights into egress were gained with the ambitious approach of 
recording the moment of egress of a duck malaria parasite (Plasmodium iophurae) with 
real-time live light microscopy (Trager, 1956), followed by recordings of P. knowlesi 
release from RBCs (Dvorak et al., 1975). In the latter study an increase in intra-
erythrocytic pressure was observed indicating that osmotic swelling might instigate 
egress in a mechanical way. Recordings of P. falciparum egress only emerged in 1999 
(Winograd et al., 1999;Wickham et al., 2003;Glushakova et al., 2005).  
 
1.3.2.1 Current models of asexual blood-stage merozoite egress 
Currently there are four major models describing egress of Plasmodium 
parasites (see Figure 8). Winograd et al. reported in 1999 (Winograd et al., 1999) a 
non-explosive event which leads to parasite egress via localised fusion of the PVM and 
EPM (see Figure 8A). Merozoites were then slowly discharged into culture supernatant. 
This model is based on the observation that a membranous structure or RBC ghosts 
persists for a certain time period after the merozoites are released into the blood 
circulation. Densitometric measurement suggests that the RBC cytosol only slowly 
diffuses into the culture medium several seconds after the merozoites and residual 
body have left the host cell. A duct-like structure can be observed on the surface of the 
RBCs from which one or two merozoites escape at one time (Clavijo et al., 1998).  
A second model illustrates the hypothesis that the EPM undergoes degradation 
before PVM rupture (see Figure 8B). In a protease inhibitor study the membrane 
surrounding released merozoites was derived from the PVM (Salmon et al., 2001). The 
resulting structures were referred to as so-called PVM-enclosed merozoite structures 
(PEMS). Parasites were cultured in the presence of N-[N-(L-3-transcarboxyirane-2-
carbonyl)-L-Leucyl]-agmatine (E64) a covalent cysteine protease inhibitor, followed by 
colocalisation of merozoite PVM proteins and EPM proteins. According to the authors, 
this together with data from electron micrography of inhibited parasite cultures supports 
the hypothesis for an “outside-in” release of merozoites from erythrocytes. 
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A more recent study supports the idea that the PVM might remain intact around 
clusters of merozoites after the disintegration of the EPM (Soni et al., 2005). The latter 
study took previous hypotheses further. Using IFAs and 3D reconstruction with 
antibodies specific to PVM or EPM proteins, the authors proposed that the PVM 
surrounds merozoites during late mitotic division hence inducing the formation of 
PEMS. At egress PEMS escape the RBC and only then the PVM ruptures under the 
control of cysteine proteases releasing invasive merozoites outside of the RBC. 
Notably both studies observe PEMS in untreated control P. falciparum cultures 
suggesting that they may represent egress intermediates rather than final egress 
structures, which contain merozoites and PVM residues. Additionally the reliability of 
information gained from IFAs can be questioned as the PVM was implicated to be of 
parasite and RBC origin. Therefore antibodies raised against RBC markers might not 
exclusively bind to the EPM but also recognise the PVM. 
A third model suggests the breakdown of the PVM before disintegration of the 
EPM and is therefore a two-step egress also called the “inside-out” model (see Figure 
8C). Wickham et al. investigated the mechanisms of egress by fluorescently tagging 
proteins which were exported either to the PV or the RBC cytosol of intra-erythrocytic 
P. falciparum. By differential temporal analysis with the help of protease inhibitors 
evidence was provided for a primary disintegration of the PVM before the EPM. In 
egress-inhibited parasites, both tagged proteins colocalise in the erythrocyte cytosol 
suggesting that PVM breakdown precedes EPM rupture. Additionally the authors 
proposed a role of distinct proteases being linked to distinct functions in egress as 
differential inhibition led to disintegration of either the PVM or EPM (Wickham et al., 
2003).  
In accordance with the previous model Glushakova et al. described an 
explosive egress event following a cascade of parasite-induced modifications to the 
iRBC (see Figure 8D). All membranes were labelled non-specifically and in addition the 
EPM was biotinylated and detected with streptavidin-quantum dots and the relative 
localisation determined by microscopy. This approach is advantageous as it does not 
involve specific antibodies with a bias for altered binding properties between antibody 
and antigen as some intra-membrane proteins might undergo structural changes during 
egress. Next they followed egress by differential interference contrast (DIC) real-time 
microscopy. They showed that schizonts adopt a so-called “flower” formation 
immediately before rupture of the RBC. This stage is marked by the spatial distribution 
of the merozoites where they occupy the entire RBC cytosol. The formation of free 
PEMS could not be observed at any point. Glushakova et al. additionally attempted to 
investigate the membrane-fusion hypothesis (see above). By incubating iRBCs with 
positive-curvature inner leaflet amphiphiles an increase in parasitaemia should be 
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observed (if membrane breakdown during egress is facilitated by amphiphiles). Their 
results rule out the possibility of PVM and EPM fusion during egress. They suggest that 
modifications of the RBC cytoskeleton (possibly by proteases) and the increase in 
intracellular volume result in EPM rupture. The authors suggested that the breakdown 
of the PVM occurs immediately prior to or simultaneously with the breakdown of the 
EPM (Glushakova et al., 2005). Recently, the same group very intriguingly showed the 
rupture of the PVM preceding the disintegration of the EPM, followed by an explosive 
release of merozoites (shown using confocal microscopy of living cells; Glushakova et 
al., 2008;Glushakova et al., 2010). In addition Glushakova et al. showed that the highly 
selective cysteine protease inhibitor E64 has an irreversible effect on the release of 
merozoites by affecting rupture of the EPM and not the PVM.  
An additional approach to understand the order of egress was undertaken by 
analysing the sequential movement of the EPM during merozoite release. A succession 
of rapid movements by the EPM was described, beginning with curling of the EPM 
towards the outside and followed by buckling to retract the EPM even further. This 
eventually leads to eversion, the forceful release of merozoites and finally vesiculation 
of the remains of the EPM (Abkarian et al., 2011;Lew, 2011). Other theories about 
egress have been suggested including the role of pore-forming proteins. The recent 
identification of the function of perforin-like proteins, or perforins, in T. gondii egress 
has led to the suggestion that pore formation is required for egress (Kafsack et al., 
2008;Kafsack et al., 2010). Perforins contain a membrane attack complex (MAC) 
domain, which inserts into membranes forming pores, and are secreted by many cells 
for example natural killer cells and other immune cells (Horta, 1997). Perforin-like 
proteins were recently identified in Plasmodium (Kafsack et al., 2010). The first 
indication of the role of perforins in Plasmodium spp. was given recently. Two perforins 
of P. berghei were shown to be indispensable in the parasite sexual stages as 
ookinetes with a disrupted membrane attack protein lost their infectivity in the mosquito 
(Andrea Ecker, unpublished; Ecker et al., 2008)). The authors suggest that the 
ookinete lacks the ability to break down the midgut epithelium in order to complete the 
life-cycle (Kadota et al., 2004). Perforins are considered to be actively involved in 
membrane degradation prior to parasite egress. Although present evidence of the 
temporal succession of PVM and EPM breakdown leaves room for speculation the 
necessity of protease participation is clear.  
 
1.3.2.2 The role of proteases and calcium signaling in egress 
The first insights into the function of proteases into egress were gained by 
approaches from two different perspectives; 1. the analysis of parasite cultures in vitro 
after the addition of specific inhibitors; 2. by identifying the activity and substrates of 
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specific proteases. A model for P. falciparum egress involving a cascade of protease 
activation has now been established with a cysteine protease called dipeptidyl 
peptidase 3 (DPAP3) and a serine protease called subtilisin like protease 1 (PfSUB1) 
as key players (Yeoh et al., 2007;Arastu-Kapur et al., 2008). PfSUB1 is released from 
dense granule-like organelles, termed exonemes (see Figure 5), into the PV lumen 
prior to egress where it processes many of its substrates (Janse et al., 2007;Yeoh et 
al., 2007;Silmon de Monerri et al., 2011). The earlier mentioned MSP1 undergoes 
extensive primary processing by PfSUB1 prior to egress and invasion. In addition 
serine repeat antigen (SERA) family member SERA5, one of the most abundant 
proteins in the PV lumen, is processed by PfSUB1 just moments before egress at 
several identified processing sites (Yeoh et al., 2007). Other substrates for PfSUB1 
have recently been identified including proteins that are expressed late in the parasite 
life-cycle which suggests a role in egress and/or invasion (Silmon de Monerri et al., 
2011).  
Previously the role of the PV was thought to be restricted primarily to the 
parasite’s nutritional supply. However, recently its role in egress has been highlighted. 
The still intact or semi-intact PVM possibly ensures optimal temporal-spatial distribution 
of PV proteases and their substrates. This hints at the PV and PVM being involved in 
actively coordinating egress. Therefore putative proteases expressed late in the 
parasite life-cycle and secreted into the PV appear attractive targets for further 
investigation. In addition, certain parasite-derived proteases have been shown to be 
capable of processing RBC cytoskeleton components in vitro suggesting once again a 
role for proteases in egress (Deguercy et al., 1990). However, it can be argued that the 
role of the PV evolved individually in different apicomplexan parasites as some egress 
without the presence of a PV (Theileria and Babesia spp.). 
The exact mechanisms and the all important activators of egress however are 
mainly unknown. It remains unclear when and how fully developed merozoites receive 
the signal to breach the surrounding membranes in the hunt for fresh RBCs. Calcium-
dependent signal transduction has been considered to play a key role in regulating this 
transition in the parasite life-cycle. The importance of calcium-mediated signalling was 
first shown by culturing T. gondii infected macrophages in the presence of calcium 
ionophores (Endo et al., 1982) where protein kinases play a key role in invasion and 
possibly also egress. Recently, a plant like calcium-dependant protein kinase 
(PfCDPK5) has been identified in P. falciparum. The kinase is expressed in merozoites 
and is essential for parasite egress and survival, suggesting for the first time a direct 
involvement of calcium signalling in parasite escape from the erythrocyte (Dvorin et al., 
2010).  
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1.4 Proteases: a brief introduction 
Proteases can be defined as enzymes that hydrolyse peptide bonds. Those 
enzymes cleave peptide bonds for an immense variety of specific or unspecific bio-
chemical reactions to degrade, recycle or assemble peptide chains (Hooper, 2002). 
Proteases, also called peptidases or proteinases, are essential to the correct function 
of most organisms. Proteases represent about 2% of the total protein numbers of all 
organisms whose genomes have been sequenced to date (MEROPS database: 
http://merops.sanger.ac.uk). The human genome alone for example encodes ~500 
proteases.  
The catalytic process is mediated by the nucleophilic attack of either an 
essential active site residue or an activated water molecule on the carbonyl carbon 
atom of the scissile peptide bond. Hydrolytic enzymes are known to have two different 
types of active sites:  either a catalytic dyad or catalytic triad protease domain, with two 
or three amino acid residues directly involved in the catalytic activity respectively. 
Some amino acid residues located within reach of the catalytic site usually deliver 
additional stabilising support. Protease families are based on the homology of the 
protease domain and several families have been identified: these include serine 
proteases, threonine proteases, cysteine proteases, aspartic proteases, glutamic 
proteases and metallo proteases (Rawlings et al., 1993;Rawlings et al., 2010). Metallo 
proteases received their name from the fact that they need to incorporate zinc ions 
through the side chains of the catalytic residues, called a zinc motif (Tallant et al., 
2010). Serine and cysteine proteases form a covalent acyl-enzyme intermediate during 
the reaction with active site residues facilitating the nucleophilic attack. In an aspartic 
acid- and metallo protease- mediated reaction the water molecule attacks the substrate 
rather than an active site residue. Proteases can function as endopeptidases to 
catalyse the degradation of peptide bonds between internal amino acids or as 
exopeptidases. Two different types of exopeptidases can be described that attack the 
polypeptide chain on its carboxy- or amino-terminus, named carboxy- and 
aminopeptidases respectively.  
Proteases are categorised into clans, families and even more detailed groups 
depending on identity or similarity of the active side residues. Clans only have 
structural or sequence similarities due to evolutionary links whereas families are 
defined based on homologies. Serine proteases for example span many families and 
some of those have virtually identical structures or sequences establishing one clan 
(Rawlings et al., 1993). Despite the identical catalytic site residues, proteases from 
within one type, e.g. serine proteases, vary widely in their amino acid composition, fold 
and substrate specificity.  
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It is important to distinguish between varying protease substrate specificities. 
Some cleave their substrate with a very high specificity and accuracy, allowing only 
very specific amino acid residues within the catalytic trough. Others accept a variety of 
residues within the substrate binding site with lower specificity. The active site of 
proteases has two functions, to recognise and bind a specific substrate and to catalyse 
the proteolytic processing. Residues within the active site or “groove” are generally 
labelled according to the Schechter and Berger nomenclature (Schechter et al., 1967). 
Subsites (amino acids around the cleavage site within the substrate) upstream of the 
scissile bond are labelled P4-P1. Downstream residues are labelled P1′-P4′, where 
proteolytic processing occurs between P1 and P1′.  
The best studied examples of less stringent protease activities with essential 
roles in the protein turnover of the cell are two mammalian cytoplasmic proteolytic 
pathways involving the proteasome and the lysosome (Clague et al., 
2010;Ciechanover, 2011). The lysosome is defined as a vacuolar structure with an acid 
pH containing degrading proteases, lipases and nucleases. It has been described as a 
non-specific degradative system (Whitford, 2005) and is mainly involved in the turnover 
of plasma proteins such as membrane channels. Aspartic, cysteine or serine proteases 
are the major components of the lysosome. Some of the serine proteases are 
members of the chymotrypsin family (Rawlings et al., 1993). Chymotrypsin and trypsin 
are promiscuous serine proteases with major roles in many organisms ranging from 
viruses to vertebrates (Rawlings et al., 1994;Barrett et al., 1995). In vertebrates for 
example chymotrypsin is secreted into the digestive tract to process peptides so that 
they can be absorbed from the gut endothelium. 
A second pathway with importance in the cellular protein turnover is the 
proteasome. In contrast to the lysosome, the proteasome is comprised of ATP-
dependent endopeptidases with multicatalytic domains forming a barrel shaped 
complex of 2.1 mega Dalton (mDa). The proteasome degrades 90% of all cellular 
proteins (Whitford, 2005). The eukaryotic 26S is the best known proteasomal structure 
composed of two 19S cap regulatory units and one 20S core barrel shaped structure 
(Peters et al., 1994). The 20S proteasome is thought to act in a manner similar to 
threonine-proteases and in most cases proteolytically processes proteins that have 
been ubiquitinated (Voges et al., 1999;Rape et al., 2002). The above mentioned activity 
patterns highlight the complexity involved in proteolytic processing in a high number of 
different organisms.  
 
1.5 Plasmodium proteases in a wider context 
Proteases have been shown to play major roles in the intracellular development 
of apicomplexan parasites. Many proteolytic enzymes have been identified and 
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characterised in P. falciparum, T. gondii and other Apicomplexa. It has long been 
thought that P. falciparum requires protease activity in order to egress, invade or 
proliferate. A total of 92 proteases have been identified in the genome of P. falciparum, 
however the function of the majority of these is unknown (Wu et al., 2003). Vanguard 
studies using protease inhibitors proved to be milestones in understanding parasitic 
protozoan biology. They showed that broad spectrum protease inhibitors arrest both P. 
falciparum schizont egress (Lyon et al., 1986) and the invasion of rhesus monkey 
erythrocytes by P. knowlesi merozoites (Hadley et al., 1983). These approaches were 
the first opportunity to gain insights into protease regulated mechanisms of protozoan 
parasites. Shortly after, direct implications for the involvement of proteases in specific 
erythrocytic stages were made (Rosenthal et al., 1987). Several mechanistic classes of 
Plasmodium proteases have been identified. Since then many approaches with various 
serine, cysteine and other protease inhibitors showed the involvement of proteolytic 
activity in egress and invasion of P. falciparum merozoites and in other extra-
erythrocytic stages (Blackman, 2008). Their exact function however is poorly 
understood. With many proteins undergoing essential proteolytic processing throughout 
distinct life-cycle stages proteases are now one of the main targets for innovative 
antimalarial research. 
 
1.5.1 Metallo proteases 
P. falciparum metallo proteases are very poorly understood. In order to 
accomplish substrate recognition and catalytic activity metallo proteases require the 
binding of metal ion cofactors such as zinc to a specific binding motif. The imidazole 
side chains of two His residues within the motif confer the interaction with Zn++. Once 
bound to the imidazole ligands, zinc promotes the nucleophilic attack on the peptide 
bond. Metallo proteases are believed to be involved in parasite invasion as the 
treatment with metal chelators leads to egress but inhibits invasion (Kitjaroentham et 
al., 2006). In 2003 Wu et al. identified several previously unknown P. falciparum 
metallo proteases, preparing the ground for future work (Wu et al., 2003). Only one P. 
falciparum metallo protease has been described and its action investigated. Falcilysin, 
a member of the M16 metallo protease family is expressed in erythrocytic stages of P. 
falciparum parasites. It was first described to be involved in degradation of small 
haemoglobin derived peptides within the acidic food vacuole (Eggleson et al., 1999). 
However, it was noted that falcilysin alters substrate specificity depending of the 
surrounding pH. Additionally the metallo protease was not only distributed within the 
acidic food vacuole but also outside within other parasite organelles, suggesting a dual 
function (Murata et al., 2003). Falcilysin has been hypothesised to also be involved in 
degrading apicoplast transit peptides (Ponpuak et al., 2007).  
1 Introduction 
 
43 
 
1.5.2 Aspartic Proteases 
Aspartic proteases exist in an extensive host range from viruses to plants, and 
fungi to mammals. Humans are thought to have used the aspartic protease chymosin 
in the form of rennet for thousands of years in cheese production. They were the first to 
be described and are well understood in their function, e.g. porcine pepsin (Szecsi, 
1992). An acid/base catalytic activity is conferred by two aspartic acid residues, one 
functioning as a proton acceptor from a water molecule-derived hydrogen. A water 
molecule is activated by general acid-base catalysis, and then acts as the nucleophile 
(Coombs et al., 2001). It is important to mention that aspartic proteases do not form a 
covalent acyl-enzyme intermediate. Not only are aspartic proteases well characterised 
in humans but they are also the best studied proteases within the Apicomplexa. The 
function of at least five aspartic proteases has been identified and characterised in P. 
falciparum. The major group of aspartic proteases in P. falciparum is the plasmepsins. 
Ten of these can be found in the genome of the parasite and appear to have 
orthologues in most Plasmodium species (Gardner et al., 2002;Shea et al., 2007). 
Plasmepsin I and plasmepsin II were the first members of the aspartic protease family 
to undergo thorough functional analysis. Together with two plasmepsin I and II 
homologues, plasmepsin IV and hispo-aspartic protease (HAP), they are located within 
the food vacuole (FV) and synthesised as type II integral membrane proteins with the 
active site placed within the FV. Once inserted into the membrane, falcipains, members 
of the cysteine protease family (see 1.5.5.2), activate plasmepsins by cleaving off the 
inhibitory propeptide and releasing a now soluble and active protease into the FV 
lumen (Drew et al., 2008). This processing step is redundant as in transgenic parasites 
which lack falcipains, plasmepsins undergo autocatalytic processing (Drew et al., 
2008). HAP, which is also named plasmepsin III, is an interesting aspartic acid 
protease as it carries an active-site His residue substitution (Berry et al., 
1999;Humphreys et al., 1999). However, this replacement does not appear to cause 
any impairment in catalytic activity (Banerjee et al., 2002).  
It is essential for the parasite to digest RBC haemoglobin within the FV in order 
to gain amino acids that in return can be incorporated into protein synthesis (Sherman 
et al., 2004). The FV-located plasmepsins are responsible for haemoglobin degradation 
in what appears to be a regulated cascade involving first aspartic proteases followed by 
cysteine proteases, then metallo proteases, and finally aminopeptidases (Gluzman et 
al., 1994;Banerjee et al., 2002;Klemba et al., 2002). HAP and plasmepsin IV are 
believed to act downstream of plasmepsin I/II (Banerjee et al., 2002). Although not 
individually essential, the genetic disruption of each of plasmepsin I-IV individually in 
the parasite led to reduced growth rates of the transgenic lines. Simultaneous deletion 
of all four of these plasmepsins leads to deformation and malfunction of the FV (Bonilla 
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et al., 2007a;Bonilla et al., 2007b). Their roles are partially overlapping which suggests 
functional redundancy and might also indicate why P. falciparum maintained four 
copies in the genome (Omara-Opyene et al., 2004;Liu et al., 2005;Bonilla et al., 
2007a;Bonilla et al., 2007b). Interestingly genetic disruption of plasmepsin IV in the 
rodent parasite, P. berghei, confers reduced virulence and protective immunity against 
experimental malaria which is possibly due to lower fitness (Spaccapelo et al., 2010). A 
similar role for P. falciparum plasmepsins cannot be excluded. Additionally, in T. gondii 
aspartic protease 1 (a possible homologue of plasmepsin I) is suggested to have a role 
in cell division, indication further and yet unexplored roles for the P. falciparum 
plasmepsins (Shea et al., 2007). In a first instance it was unclear whether plasmepsins 
could serve as new antimalarial drug targets because of their similarity to cathepsin D 
and E, two major and very important human aspartic proteases. However, 
thermodynamic studies showed that in fact both proteases significantly differ in their 
activity, which opens doors for the design of specific plasmepsin inhibitors (Xie et al., 
1997). But the previous functional redundancy has to be considered in the attempt to 
design and screen for novel anti-plasmepsin drugs. 
The role of the other six aspartic proteases remains less well characterised. 
Plasmepsin V resides within the endoplasmatic reticulum (ER; Klemba et al., 2005). It 
has only very recently been characterised as an essential protease, which 
proteolytically processes cargo proteins downstream of a certain export signal called 
the PEXEL motif (Boddey et al., 2009;Russo et al., 2009a;Haase et al., 2010). 
Plasmepsin VI/VII/VIII are not expressed in asexual parasite stages and are yet to be 
characterised (Florens et al., 2002;Le Roch et al., 2004). Plasmepsin IX and X are both 
expressed late in asexual stages indicating a putative role in parasite egress or 
invasion. Plasmepsin X was found in a yeast two-hybrid system to interact with P. 
falciparum asparagine and aspartate rich protein 2 (PfAARP2) (LaCount et al., 2005). 
PfAARP2 is believed to localise to the RBC cytosol (Barale et al., 1997). This might be 
considered particularly interesting as plasmepsin II was shown to process the 
erythrocyte skeleton proteins actin, band 4.1 and spectrin in vitro (Le Bonniec et al., 
1999), suggesting that some plasmepsin substrates could be found in the RBC. 
 
1.5.3 Serine proteases: Subtilisins 
Serine proteases are endopeptidases that constitute the largest and most 
diverse group of proteolytically active enzymes. First insights into the understanding of 
the active site were gained by the analysis of chymotrypsin in the 1960s (Bender et al., 
1973). Chymotrypsin was also the first protease for which a three-dimensional structure 
was solved (Matthews et al., 1967;Matthews et al., 1977). Serine proteases are found 
in eukaryotes, prokaryotes, archaea and viruses where they are involved in processes 
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as diverse as digestion and immune responses (Polgar, 2005). According to their 
degree of homology serine proteases are classified into four major clans. They are then 
further categorised into families in agreement with their substrate specificity and activity 
spectrum. The two best understood and characterised clans are the chymotrypsin-like 
and subtilisin or subtilisin-like proteases. The chymotrypsin-like family includes 
promiscuous proteases such chymotrypsin, trypsin and elastase. In humans all three 
proteases are produced and secreted within and from the pancreas and play major 
roles in the digestive system. Although they all appear similar in structure the substrate 
specificity varies considerably. Chymotrypsin prefers to proteolytically cleave after a 
rather large and hydrophobic residue. Trypsin processes most successfully and 
specifically after a positively charged amino acid. Elastase on the other hand requires a 
small neutral residue in order to fully cleave a peptide bond. These three examples 
highlight the diversity within the serine proteases. The second, and, from the P. 
falciparum view, the most important clan are the subtilisins or subtilisin-like proteases. 
Subtilisins derived their name from the organism in which they were first discovered 
and from which they were first isolated, Bacillus subtilis. Under conditions of nutrient 
deprivation these bacteria express subtilisins in high amounts (Pierce et al., 1992). 
Interestingly subtilisins and the chymotrypsin-like proteases share the same catalytic 
mechanisms, even though sequence and structural identity between both is 
exceedingly low. Subtilisins are well-characterised and commercially applied in 
somewhat unusual methods such as additives in many cosmetics and cleaning 
detergents (Aaslyng et al., 1991). There are over 200 known subtilisins and based on 
their sequence identity they are divided into six families (Siezen et al., 1997). All 
subtilisins require Ca2+ for stability and activity. Activity is conferred by a classical 
catalytic triad which is comprised of a His-, a Ser- and an Asp residue. The active site 
Ser residue undergoes activation by the imidazole ring of the His residue. The 
imidazole accepts a hydrogen (proton) from the serine in order to enable the hydroxyl 
group to begin the nucleophilic attack on the carbonyl carbon of the scissile peptide 
bond to form a tetrahedral intermediate. The imidazole ring however can only accept a 
hydrogen proton if the Asp residue functions as electron donor to begin with. The 
incorporation of a water molecule then leads to the completion of the reaction and 
release of the substrate. Additional residues are required in order to stabilise the 
reaction. 
The essentiality of the catalytic Ser of serine proteases has been shown by site 
directed mutagenesis that only alters the Ser to an Ala residue. Mutations to the Ser 
residue inhibit the proteolytic processing of substrates (Carter et al., 1988). In the same 
study it was shown that the mutation has no impact on the actual protease fold and 
only very little impact on the substrate affinity. Therefore replacing the catalytically 
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essential residue with a “silent” Ala residue has since been used to study protease 
activity for many peptidases. Subtilisins are generally expressed as inactive protease 
precursors, called zymogens or proproteins, which carry an inhibitory prodomain. Upon 
autocatalytic processing subtilisins are separated from the prodomain and the active 
protease domain is released. One important and well characterised example of 
autocatalytic activation is furin a subtilisin-like serine protease which undergoes 
ordered, pH dependent and compartment specific auto-processing which leads to its 
activation (Anderson et al., 1997;Anderson et al., 2002). Folding of furin occurs in the 
ER where it also undergoes the first initial auto-cleavage. This step is not sufficient to 
separate the prodomain from the active protease and together they are trafficked to the 
trans-Golgi network. Now entering an acidic compartment a second autocatalytic step 
takes place to free the now fully active protease from its inhibitory prodomain 
(Anderson et al., 1997). Prodomains are considered to function in many ways. They 
are extremely specific inhibitors and intramolecular chaperones that ensure the correct 
fold and accurate trafficking of the inactive protease precursor (Anderson et al., 2002). 
The hypothesis of protease folding, directed inhibition and trafficking to the place of 
activity is now widely accepted as a general model for the activation of subtilisins and 
proteases of other clans (Yabuta et al., 2003;Subbian et al., 2005). 
 
1.5.3.1 P. falciparum subtilisins 
As mentioned above, broad spectrum protease inhibitor studies led to the 
conclusion that serine proteases are essential for parasite egress from and subsequent 
invasion of RBCs (Dluzewski et al., 1986;Blackman et al., 1993;Blackman, 2000). The 
P. falciparum genome encodes three subtilisin-like proteases or subtilisins, termed 
PfSUB1, 2 and 3 (Withers-Martinez et al., 2004). Therefore these proteases appeared 
as prospective candidates for fulfilling important functions within the above mentioned 
life-cycle stages. PfSUB1 was the first of these subtilisin-like proteases to be described 
(Blackman et al., 1998). The first characterisation of PfSUB2 followed shortly after, by 
approaches from two independent laboratories (Barale et al., 1999;Hackett et al., 
1999). Both PfSUB1 and PfSUB2 are active proteases, and PfSUB3 displays weak 
autocatalytic processing in recombinantly expressed material (Michael Shea, 
unpublished). All three subtilisin-like proteases only exist as a single copy within the 
genome. Expression of PfSUB1 and PfSUB2 peaks at very late schizont stages making 
those proteases even more intriguing as to whether they play important roles in egress 
and invasion (Blackman et al., 1998). PfSUB1 and PfSUB2 are refractory to deletion in 
the parasite indicating an essential function. Despite sharing a conserved subtilisin-like 
protease domain the protein composition and fold of PfSUB1 and PfSUB2 varies 
remarkably. PfSUB1 is a soluble protein with a rather small size of 688 amino acid 
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residues. PfSUB2 however is much larger comprising twice as many amino acids as 
PfSUB1 and contains at least one membrane spanning domain downstream of the 
catalytic groove. It is considered a type I integral membrane protein. 
Several subtilisin-like proteases have been identified in other apicomplexan 
species, e.g. Babesia divergens, T. gondii and Neospora caninum. All Plasmodium 
species have one copy of SUB1 and SUB2. Out of all these orthologues only SUB2 
has been studied in P. berghei, where it is expressed in merozoites (Han et al., 
2000;Uzureau et al., 2004).  
 
1.5.3.2 PfSUB1 
PfSUB1 is expressed as a proteolytically inactive zymogen. It requires auto-
processing in order to become active and hydrolyse its substrates. PfSUB1 activity was 
first shown by recombinant expression of the protease followed by autocatalytic 
processing (Sajid et al., 2000). Several approaches with fluorogenically labelled 
peptides based on the autocatalytic cleavage site then revealed further insight into 
PfSUB1 substrate specificity and protease activity (Sajid et al., 2000;Blackman et al., 
2002;Withers-Martinez et al., 2002;Jean et al., 2003). Based on broad spectrum 
protease inhibitor studies, PfSUB1 was first postulated to be responsible for shedding 
the merozoite surface proteins MSP1 and AMA1 prior to and during invasion. However, 
specific protease inhibitors of PfSUB1 do not interfere with the shedding of these 
proteins but do inhibit invasion (Blackman, 2004). These results excluded the theory 
that PfSUB1 might be displaying the previously predicted sheddase function. PfSUB1 
biological activity and function has since been investigated and understood in much 
more detail. It exhibits not only a role in invasion but also in egress. In order to gain 
insights into PfSUB1’s biological role, its location and native substrate had to be 
identified. IFA revealed that PfSUB1 does not colocalise with any markers of known P. 
falciparum compartments such as RhopH2 (rhoptry protein), AMA1 (microneme 
protein) or RESA (dense granule protein). Immunoelectron microscopy (EM) suggested 
that PfSUB1 localises to a dense granule like organelle which is however distinct from 
dense granules, as proteins such as RESA do not colocalise with PfSUB1 even in EM 
(Aikawa et al., 1990;Harris et al., 2005;Yeoh et al., 2007). These novel organelles have 
now been named exonemes (Janse et al., 2007). Additionally Yeoh et al. discovered 
that selective PfSUB1 inhibitors interfere with P. falciparum egress and block the 
proteolytic processing of the highly abundant putative papain-like protease SERA5. 
SERA5 was identified as the first physiological substrate of PfSUB1 and the mapping 
of the proteolytic processing sites established an improved picture of PfSUB1 substrate 
specificity and function. SERA5 is a well characterised protein which is located in the 
PV (see 1.6.2). Therefore PfSUB1 is believed to possibly induce a proteolytic cascade 
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facilitating schizont rupture and the release of merozoites from the host RBC. Exoneme 
discharge precedes egress with PfSUB1 translocating to the PV where it now meets its 
physiological substrates such as SERA5 (Yeoh et al., 2007).  
PfSUB1 possibly also exhibits a role in merozoite invasion by processing 
merozoite surface proteins in late schizogony, so as to prime them for invasion. Indeed, 
at lower concentrations, the specific inhibitor of PfSUB1 does not block egress but still 
inhibits invasion (Yeoh et al., 2007;Koussis et al., 2009). The complex between MSP1, 
MSP6 and MSP7 uniformly coats the surface of merozoites and is suggested to be 
involved in receptor mediated interactions that precede merozoite invasion (Goel et al., 
2003;Li et al., 2004;Kauth et al., 2006). This MSP complex is known to undergo several 
proteolytic cleavages in the parasite prior to invasion. Recombinant PfSUB1 cleaves 
parasite-derived MSP1/MSP6/MSP7 in vitro at the same sites that they are processed 
in the parasite (Kadekoppala et al., 2008;Kadekoppala et al., 2010). Additionally 
substrate peptides based on these sites are also correctly processed by recombinant 
PfSUB1. To confirm these results a specific and highly efficient inhibitor of PfSUB1 was 
required (the chemical inhibitor described above is from a relatively impure extract and 
shows activity only in the micromolar range). A characteristic of subtilisin-like proteases 
is that the prodomain generally forms a specific and high-affinity inhibitor of its cognate 
enzyme. The recombinant PfSUB1 prodomain indeed proved to be a specific 
nanomolar inhibitor of recombinant PfSUB1 (Jean et al., 2003) and allowed 
confirmation of the cleavage of MSP1/6/7 by recombinant PfSUB1 in vitro (Koussis et 
al., 2009). This processing step however displays priming properties rather than 
shedding as the complex remains associated with the surface of the merozoite. A 
recent global proteomic analysis identified additional PfSUB1 substrates and a 
significantly improved model for PfSUB1 substrate specificity was compiled (Silmon de 
Monerri et al., 2011). PfSUB1 prefers a hydrophobic residue in the P4 position and a 
small residue in the P2 position (Gly, Ala); P1 is preferably polar and all P′ positions  
should have an acidic tendency (see Figure 9). Alignments of SERA5 with all the other 
members of the SERA family indicated that other members, e.g. SERA6, putatively 
undergo processing by PfSUB1 (see 1.7). Despite extensive efforts a crystal structure 
of PfSUB1 is unfortunately not yet available.  
 
1.5.3.3 PfSUB2 
According to homology modelling of the active site groove of PfSUB2, this 
protease was proposed as a candidate for being responsible for the secondary 
processing and shedding of MSP1 during merozoite invasion (Barale et al., 1999). First 
insights into PfSUB2 activity and substrate specificity however were not gained before 
2005 when Harris et al. were able to identify the protease as the “sheddase” active 
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during merozoite invasion. In a very sophisticated approach PfSUB2 recombinant 
prodomain was incubated with parasite cultures in order to bind to and inhibit parasite 
derived mature PfSUB2. This assay indeed revealed PfSUB2-mediated shedding of the 
essential surface proteins MSP1 and AMA1. PfSUB2 was found to be secreted from 
micronemes during egress onto the anterior end of the merozoite surface. Upon 
invasion PfSUB2 translocates to the posterior pole of the merozoite. During this 
movement PfSUB2 “sheds” the ectodomains of MSP1 and AMA1 to disengage 
adhesin-complexes (Harris et al., 2005) and allows the merozoite to become engulfed 
by the RBC. Very recent unpublished data suggest that AMA1 shedding occurs in a 
sequence unspecific manner. The recognition motif appears to comprise the distance 
from the transmembrane domain rather an actual amino acid sequence (Anna Olivieri, 
Christine Collins and Michael Blackman, unpublished). A third physiological PfSUB2 
substrate was recently identified. Plasmodium thrombospondin related apical merozoite 
protein (PTRAMP) is located within the micronemes and relocated to the apical pole of 
the merozoite to then redistribute itself onto the entire surface upon invasion. Its role is 
unclear but involvement in invasion has been suggested. After its translocation 
PTRAMP undergoes shedding by PfSUB2 during invasion (Green et al., 2006). Despite 
extensive efforts recombinant PfSUB2 is not yet available. 
Early protease studies have shown that two different classes of serine 
proteases are required for invasion which leads on to the P. falciparum rhomboid 
proteases (Hadley et al., 1983). 
 
1.5.4 Serine proteases: Rhomboids 
An additional rather unusual group of serine proteases, the rhomboids has been 
recently identified in the fruit fly Drosophila melanogaster. Their uniqueness is 
conferred by the fact that rhomboids contain six to seven intramembrane domains and 
are capable of proteolytically cleaving substrates within a phospholipid bilayer or in 
juxtamembrane domains (Urban et al., 2001;Freeman, 2008;Freeman, 2009). 
Additionally unlike the other serine-type proteases, rhomboids use a catalytic dyad and 
are very conserved in eukaryotes and prokaryotes (Urban et al., 2002a;Urban et al., 
2002b). 
 
1.5.4.1 P. falciparum rhomboids 
Apicomplexan rhomboids (ROMs) are a well studied group of proteases. 
Studies in T. gondii give the best understood insight into the function of this family 
(Kim, 2004;O'Donnell et al., 2005). A role of rhomboids in invasion by protozoan 
parasites was first suggested in 2003 as a group of putative substrates was identified 
on the surface of T. gondii (Urban et al., 2003). The first experimental approach that 
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deepened the idea for a role for rhomboids throughout these steps was conducted by 
applying proteomic analysis of cleavage events prior to and during invasion (Zhou et 
al., 2004). Surface adhesin proteins, called TgMICs, which are released from T. gondii 
micronemes onto the parasite surface moments before parasite egress (Carruthers et 
al., 1999a), were shown to be processed by rhomboids. TgMIC2, TgMIC6 and 
TgMIC12 are proteolytically cleaved within their transmembrane domain by a protease 
called T. gondii microneme protein protease 1 (TgMPP1) (Carruthers et al., 2000;Opitz 
et al., 2002). TgMPP1 is conserved throughout Apicomplexa and encoded by a 
rhomboid gene. An uncleavable TgMIC2 mutant indicated that TgMPP1 processing is 
essential for parasite invasion (Brossier et al., 2003). It has now been suggested that 
TgROM5 might be the as yet unidentified MPP1 (Brossier et al., 2005). Combined with 
the first evidence listed above, genome wide analysis revealed that rhomboid genes 
are found in all apicomplexan parasites. P. falciparum encodes eight rhomboids 
(PfROM1, 3, 4, 6, 7, 8, 9, 10) with four being orthologues of T. gondii rhomboids 
(Dowse et al., 2005). PfROM1 and PfROM4 were shown to cleave a variety of 
substrates containing transmembrane domains and are possibly involved in all invasive 
stages of P. falciparum (Baker et al., 2006). PfROM4 processing of EBA-175 is 
essential as parasites expressing a cleavage site mutant cannot survive (O'Donnell et 
al., 2006). ROM1 is thought to be involved in the intracellular development of parasites. 
T. gondii parasites with conditionally knocked-down TgROM1 replicate significantly 
more slowly within the host cell (Brossier et al., 2008). In addition mutants of the rodent 
parasite P. berghei with PbROM1 knocked-out are incapable of forming oocysts and 
display a decreased hepatocyte invasion rate (Srinivasan et al., 2009). An extended 
role for rhomboids has recently been suggested as T. gondii AMA1 processing by 
TgROM4 induces a switch from invasive to replication mode (Santos et al., 2011). 
Finally, it has to be mentioned that although broad spectrum protease inhibitors reduce 
rhomboid activity no specific inhibitors have been identified to date (Urban et al., 2001). 
Rhomboids are clearly a very interesting, distinct and essential class of active serine 
proteases.  
 
1.5.5 Cysteine proteases 
Cysteine proteases perform an extensive variety of functions. They can be 
found in many organisms ranging from viruses to plants to humans. Their roles in 
plants involve proteolytic activity in growth, development and programmed cell-death, 
and therefore in many signalling pathways (Grudkowska et al., 2004). In humans, 
cysteine proteases are involved in protein degradation (lysosomes or proteasomes), 
bone resorption, and parts of the immune response and are implicated in several 
diseases such as proliferation of metastatic cells in cancer (Nomura et al., 2005). Many 
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parasitic diseases such as malaria are reliant on functional and regulated cysteine 
protease activity (McKerrow et al., 1999;McKerrow et al., 2006). The catalytic activity of 
cysteine proteases is similar to serine proteases with the Ser replaced by a Cys 
residue. All cysteine proteases are subdivided into clans. Similarity between different 
clans is very low although they are suggested to have developed from the same origin 
(MEROPS database: http://merops.sanger.ac.uk). Each clan is further sub-divided into 
families this time based on sequence and structural homologies. Probably the best 
known cysteine protease was first found as the active constituent in the latex of the fruit 
Carica papaya (papaya) and was therefore named papain. Papain formed the 
foundation of the protease clan CA. Clan CA, which includes all papain-like protease 
families, e.g. cathepsins (family C1) and calpains (family C2), and clan CD, including 
caspases (family C14) are the best studied cysteine protease clans (Barrett et al., 
2001;Rawlings et al., 2010). Although they all share a conserved catalytically active 
cysteine, activity is conferred by catalytic triads or catalytic dyads respectively for CA 
and CD with a Cys and a His residue forming the core of the protease motif. As 
described earlier for serine and other proteases (see 1.5.3), cysteine type proteases 
are usually expressed as zymogens or proproteins for precise regulation of proteolytic 
activity. The conserved protease activity depends on the thiol group of the Cys residue 
undergoing deprotonation by the imidazole ring of the His residue. The nucleophilic 
attack on the carbonyl carbon of the peptide bond is in then performed by the 
deprotonated anionic sulphur, forming a thioester intermediate between the new 
carboxy-terminus and Cys thiol. The incorporation of a water molecule induces the 
release of the new carboxy-terminus of the substrate and the regeneration of all the 
active site residues to their original electron balance. All proteases within clan CA 
(papain-like proteases) possess a catalytically active triad with the involvement of an 
additional Gln residue. The papain-like protease domain therefore comprises as 
follows: Gln, Cys, His and Asn/Asp (MEROPS database: http://merops.sanger.ac.uk). 
Other proteases such as caspases only require a catalytic dyad for full activity. 
 
1.5.5.1 The role of cysteine proteases in P. falciparum 
Sequencing of an ever increasing amount of Plasmodium spp. genomes and 
development of techniques to manipulate the parasites genomic information are 
probably the most influential advances in order to gain information about malarial 
cysteine proteases (Crabb, 2002). The first and most promising insights were derived 
from the previously mentioned protease inhibitor studies. These studies examined the 
function and role of cysteine proteases as a group throughout the parasites life-cycle 
rather than identifying a specific function (Rosenthal et al., 1987). For example the 
inhibition of different life-stages of P. falciparum cultures with cysteine protease 
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inhibitors such as leupeptin and E64 arrested parasite development. When analysed in 
greater detail it was observed that processes such as haemoglobin degradation were 
abolished (Shenai et al., 2002). Since the first studies emerged P. falciparum cysteine 
proteases have been shown to be involved in egress, invasion and growth and 
replication (Rosenthal et al., 1988;Greenbaum et al., 2002;Sabnis et al., 2003;Singh et 
al., 2006;Wang et al., 2011). Many more putative cysteine proteases, e.g. the SERAs 
(papain-like), calpains and cathepsins have since been identified in the P. falciparum 
genome with some currently undergoing thorough investigation (Wu et al., 2003). 
 
1.5.5.2 P. falciparum falcipains 
Falcipains were first biochemically characterised as members of the papain clan 
(Gln-Cys-His-Asn active site), localised to the FV and named trophozoite proteinases 
as their cysteine protease activity was revealed in trophozoite stages (Rosenthal et al., 
1988). Protease inhibitor studies clearly indicated the importance of cysteine proteases 
in haemoglobin digestion as the inhibition of these proteases led to extensive swelling 
of the FV in parasite cultures (Bailly et al., 1992). Soon after the first gene was 
characterised; the protease was named falcipain and it was shown to be a 
haemoglobinase (as are the plasmepsins; Rosenthal et al., 1992). Since then three 
additional falcipains have been identified. There are four falcipains in total: falcipain 1, 
which is encoded on chromosome 1, falcipain 2, falcipain 2′ and falcipain 3 all of which 
are encoded on chromosome 14 (Rosenthal, 2004). Falcipain 2 and falcipain 2′ share 
99% identity in catalytic regions and are expressed in earlier parasite asexual life 
stages (Singh et al., 2006). Falcipain 3, despite the ability to degrade haemoglobin in 
vitro, undergoes upregulation in the middle of the parasites erythrocytic development 
(Sijwali et al., 2001b). Experimental knockouts of falcipain 1 led to the conclusion that 
asexual RBC stages of P. falciparum do not require the protease to survive (Sijwali et 
al., 2004a). Genetic disruption leading to functional knockouts of falcipain 2 however 
resulted in a swollen FV indicating the impairment of haemoglobin digestion (Sijwali et 
al., 2004b). The knockout can be rescued by the expression of an additional, episomal 
copy of falcipain 2 (Armstrong et al., 2007). Interestingly in the falcipain 2 knockout 
parasites the nearly identical falcipain 2′ does not undergo upregulation. This appears 
surprising as falcipain 2 knockout lines, despite displaying a swollen FV, develop 
normally (Sijwali et al., 2004b). Additionally falcipain 2 also digests ankyrin and band 
4.1 at neutral pH in vitro (Dua et al., 2001;Hanspal et al., 2002). In combination with the 
fact that a peptide that inhibits recombinant falcipain 2 also inhibits egress and that 
falcipain 2 is also localised to the PV (Dhawan et al., 2003), the role of this cysteine 
protease appears to not be as well understood as previously thought and a function in 
egress cannot be excluded. Falcipain 2′ is also dispensable in the parasites 
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erythrocytic life stages (Blackman, 2008). Falcipain 3 on the other hand is refractory to 
genetic manipulation and is upregulated in falcipain 2 knockout lines. Its function, 
however, still remains unknown (Singh et al., 2006). All falcipains are expressed as 
proproteins with falcipain 2 displaying an unusually long prosequence (Shenai et al., 
2000). Falcipains appear to be involved in proteolytic cascades leading to haemoglobin 
hydrolysis as they serve as maturases for plasmepsins within the FV lumen (Drew et 
al., 2008). Despite falcipain 1, 2 and 2′ appearing to be dispensable for the parasite the 
essential nature of falcipain 3 makes this haemoglobinase an intriguing target for 
antimalarial development (Kerr et al., 2009;Teixeira et al., 2011). 
 
1.5.5.3 P. falciparum calpains 
Calpains (calcium ion-dependent papain-like cysteine protease) are Ca2+-
dependent multifunctional cysteine proteases which usually show regulated activity at a 
neutral pH. Calpains are ubiquitously expressed in birds and mammals and they are 
thought to be involved in cell cycle regulation and cytoskeletal remodelling. The P. 
falciparum calpain homologue is very poorly understood and is refractory to genetic 
disruption. This has led to the suggestion that this homologue displays an essential 
function for the parasite (Russo et al., 2009b). P. falciparum cultures maintained in the 
presence of specific calpain inhibitors experience significantly reduced merozoite 
invasion rates (Olaya et al., 1991). Of course an effect of the inhibitors on the RBC 
calpain, calpain-1, cannot be excluded. Intriguingly if RBCs undergo chemical- and 
immunodepletion of calpain-1, parasites are incapable of egress. However, after 
egress has been restored merozoites invade less efficiently (Chandramohanadas et al., 
2009). 
 
1.6 SERA family  
Two of the most abundant protease families in P. falciparum include the 
falcipains (papain-like cysteine proteases) and the aspartic proteases of the 
plasmepsin family. These were shown to mainly be involved in degradation of 
haemoglobin, but may also play a role in degradation of the RBC cytoskeleton 
(Rosenthal, 2002;Rosenthal, 2004). An additional group of putative Plasmodium spp. 
cysteine proteases is made up of the members of the SERA family. SERAs are 
composed of a papain-like central region with long N- and C-terminal extensions. The 
name of the SERA family is derived from a long stretch of Ser residues within the most 
highly-expressed (and first-identified) member of this group, SERA5 (Bzik et al., 1988). 
The SERA multigene family is nearly unique to Plasmodium, as only Theileria 
expresses one orthologue. 
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In recent years efforts have been made to investigate the origin of the SERAs. 
All Plasmodium species encode SERAs in their genomes. They are usually found in 
gene clusters. However, numbers of sera genes range from two in Plasmodium 
gallinaceum to 12 in P. vivax. The SERA family has recently been divided into four 
groups, depending on their putative fold and sequence homology (Arisue et al., 2011). 
Intriguingly within these groups there are two different types of SERAs. Some contain a 
Cys residue in the active site (groups I/II/III), like papain. Some however have the Cys 
substituted with a Ser residue (group IV). The evolutionary process causing the 
establishment of the unique SERAs and the substitution of a Ser in the active site 
remains unknown. As no SERA protease activity has convincingly been shown for any 
SERA family member it is difficult to speculate about the effect of the active site 
substitution. It is very interesting to observe that SERAs of the mammalian Plasmodia 
vary in numbers only in group IV, the serine type. All Plasmodium spp. have at least 
one member of group I to III, with the one exception of P. gallinaceum which encodes 
one member of group I and one ancestor of group II/III (Arisue et al., 2007;Arisue et al., 
2011). The gene number variation occurred most strongly in human, ape and monkey 
groups possibly indicating that adaption to different hosts led to evolution of the SERAs 
(see Figure 10, Table 1). Additionally some members of group IV have lost the central-
papain like domain. This might indicate that the serine-type SERAs do not require the 
papain-like domain to achieve their complete function. 
 
1.6.1 The SERA family of P. falciparum 
The SERA family was first discovered in the 1980s in an attempt to identify 
novel parasite antigens as vaccine candidates. In the very first studies a blood sample 
from an infected human individual was taken, cultured for several weeks and injected 
into mice and monoclonal antibodies were produced to explore which parasite antigens 
were detectable in those blood samples (Perrin et al., 1981;Perrin et al., 1982). These 
antibodies were then shown to inhibit P. falciparum parasite growth in vitro and 
conferred disease protection in Saimiri and Aotus monkeys (Perrin et al., 1984;Perrin et 
al., 1985;Siddiqui et al., 1987). In the search for the major antigens involved in this 
protection a 140 kDa protein was detected. This protein was named serine rich protein 
I (SERPI) and later SERA5, as more members of the multigene family were identified 
(Knapp et al., 1989). Protective immunity has now been established to be conferred by 
antibodies against a heterodimer comprised of the N- and C-terminus of SERA5. Since 
the early findings SERAs have been investigated as drug and vaccine targets. Nine 
sera genes were identified within the P. falciparum genome, with sera1-8 located on 
chromosome 2 in a tandem head-to-tail array (with sera4, 5 and 6 in the centre) and 
sera9 located on chromosome 9 (Gardner et al., 2002). In P. falciparum all seras 
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encoded on chromosome two are clustered between a conserved hypothetical protein 
and a putative iron-sulfur assembly protein gene (hesB; Gardner et al., 2002). All of 
these seras except sera8 are transcribed in the asexual blood stage forms, though not 
all have been detected at the protein level (e.g. sera1 and sera2). Expression levels of 
the seras vary extensively, with sera4, sera5 and sera6 the most abundantly 
transcribed (Aoki et al., 2002;Miller et al., 2002b). The SERA nomenclature is based on 
each gene’s position on the chromosome in relation to other seras. Therefore SERA 
orthologues throughout all Plasmodium species do not have the same names (see 
Figure 10). All the P. falciparum SERAs contain a central papain-like putative catalytic 
domain with a catalytic triad present in all nine (Hodder et al., 2003). Sequence identity 
within the P. falciparum SERA family is remarkably high and most variation can be 
found within the N-terminus (see Figure 11). The best example here is SERA5 with an 
extensive stretch of up to 37 Ser residues in the N-terminus which none of the other 
family members encode for. P. falciparum SERA1-5 and SERA9 are “serine-type” 
SERAs (SERAser) and form their own monophyletic group characterised by a 
substitution of the catalytic site Cys residue with a Ser residue (Kiefer et al., 
1996;Hodder et al., 2003;Bourgon et al., 2004). Despite this substitution, recombinant 
SERA5 was shown to possess weak catalytic activity (Hodder et al., 2003). However, it 
was previously shown that a substitution of the active site cysteine residue with a 
serine residue in other papain-like proteases (e.g. cathepsin L) interferes with 
enzymatic activity (Clark et al., 1978;Coulombe et al., 1996). On the other hand, the 
silicateins, which are expressed by the sponge Tethya aurantia, also show a Cys to Ser 
substitution like the SERAsers but are fully functional active hydrolases (Shimizu et al., 
1998;Muller et al., 2007). SERA6, 7 and 8 are “cysteine-type” SERAs (SERAcys), 
containing a canonical Cys residue in the predicted catalytic triad. SERA8 is not 
expressed in asexual stages and can only be found in mosquito stages of P. 
falciparum. SERA5 is the most abundant member of the SERA family in P. falciparum 
and is located in the PV (Delplace et al., 1987;Debrabant et al., 1992). This is of 
interest as P. falciparum proteases have been shown to be highly abundant in the PV 
(Nyalwidhe et al., 2006). The refractoriness to genetic disruption of sera5 and sera6 
(Miller et al., 2002b;McCoubrie et al., 2007) and also the inhibition of P. falciparum 
multiplication and growth by antibodies against SERA5 suggests that they play a major 
role in the parasite life-cycle (Pang et al., 1999). Additionally SERA5 has been shown 
to undergo extensive proteolytic processing just moments before egress. The protease 
responsible for the majority of this processing is PfSUB1, a key player in egress (see 
1.5.3.2). The most convincing evidence of the importance of the SERAs derives from a 
beautiful study by Aly and Matuschewski. The P. berghei orthologue of SERA8, ecp 1, 
was disrupted by single cross-over homologous recombination leading to two truncated 
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versions of the protein. The knockout had no effect on parasite growth in the asexual 
blood stages. The faulty ECP1 expression however affected the sexual P. berghei 
mosquito stages. Fully developed and viable sporozoites were incapable of rupturing 
the oocyst wall (Aly et al., 2005). Aly and Matuschewski proposed the involvement of 
ECP1 in the degradation of the inner oocyst wall as ecp1 knockouts showed an altered 
proteolytic processing pattern of the circumsporozoite protein (CSP), a highly abundant 
protein located on the surface of sporozoites. Although ECP1 has yet to be shown to 
have protease activity and the oocyst structure differs from that of the RBC, an 
important role in parasite egress was postulated for the putative SERA enzymes as 
orthologues of ECP1 (Dowse et al., 2008).  
In summary the SERA family members are most important from two different 
perspectives. First, as vaccine targets as they confer anti-disease immunity which is 
due to the postulated role of the most prominent family member SERA5 in invasion. 
Second, based on evidence derived from genetic manipulation and proteolytic 
processing studies they are of major importance for the release of parasites from their 
host cells and possibly for subsequent invasion.  
 
1.6.2 SERA5: a “serine-type” SERA  
SERA5 is one of the most abundant proteins in the P. falciparum trophozoite 
and schizont stage (Lasonder et al., 2002), reinforcing interest in this protein. SERA5 
was originally named P140, P126, P113 and SERP I and is by far the best studied and 
understood member of the SERA family. A first appearance in the spotlight can be 
dated back to the early 1980s. In the first studies, monkeys immunised with a 140 kDa 
molecule were partially protected against P. falciparum infection in vivo (Perrin et al., 
1981;Perrin et al., 1984). More recent data suggests that human plasma in endemic 
areas show high anti-SERA5 antibody titers (Okech et al., 2001;Okech et al., 2006). 
This is supported by earlier findings that SERA5 fragments induce protection against 
challenge infection (Inselburg et al., 1991). SERA5 antibodies not only confer anti-
disease immunity but also protect against egress or invasion in vitro (Chulay et al., 
1987;Fox et al., 1997;Pang et al., 1998;Pang et al., 1999). In addition Delplace et al. 
observed that a 126 kDa protein which is expressed in late schizont stages disappears 
and a 50 kDa fragment appears in culture supernatant of egressed P. falciparum 
merozoites in vitro (Delplace et al., 1985;Delplace et al., 1987;Delplace et al., 1988). 
This fragment was later shown to be SERA5. Discrepancies in the molecular weight 
derive from the observation that the molecular weight of SERA5 is predicted as 126 
kDa but it runs at around 130 kDa on an SDS-PAGE. SERA5 is expressed as a 
precursor protein and undergoes several proteolytic processing steps (Li et al., 
2002a;Yeoh et al., 2007). The 126 kDa precursor protein (a putative inactive zymogen) 
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is cleaved in a first event into two fragments of 47 kDa and 73 kDa (see Figure 12, 
SERA5st1). The latter is further processed near its C-terminal side releasing a 56 kDa 
and an 18 kDa fragment (see Figure 12, SERA5st2). Both events have been shown to 
be mediated by PfSUB1 (Yeoh et al., 2007;Arastu-Kapur et al., 2008). The 47 kDa 
region undergoes further cleavage to two 25 kDa fragments (see Figure 12, SERA5st3) 
although this third processing step appears to be allele-specific (Li et al., 2002b). The 
56 kDa fragment containing the putative catalytic domain is further processed near the 
C-terminus to a 50 kDa fragment, still carrying the catalytic domain, and a 6 kDa 
fragment (see Figure 12, SERA5stX). Proteolytic processing of SERA5 was shown to 
only be induced under naturally mediated egress. Manual and mechanically induced 
rupture of P. falciparum cultures only releases the precursor into the culture 
supernatant. This suggests that SERA5 processing does not occur randomly due to 
unspecific protease activity but is more likely to be a targeted and highly regulated 
step. 
The molecule mediating the 56 kDa to 50 kDa conversion event was identified 
as a leupeptin and E64 sensitive cysteine protease (Li et al., 2002a) and called 
Protease X (Michael Blackman, unpublished). The SERA5 50 kDa fragment is highly 
abundant in culture supernatant just after merozoite release whereas it cannot be 
detected in late schizonts. This suggests that the last SERA5 processing step 
coincides with schizont rupture (Yeoh et al., 2007). PfSUB1 processing sites are 
conserved within the other asexual stage P. falciparum SERAs (see Figure 13; Yeoh et 
al., 2007). Although SERA5 might be the most abundant protein of the SERA family 
(Aoki et al., 2002), recent data suggests that gene knockouts of the P. berghei 
orthologue of SERA5 (PbSERA2) have no effect on the parasite life-cycle but induce 
the up-regulation of the SERA6 orthologue (PbSERA3;Putrianti et al., 2009). There is 
also very recent evidence that SERA5 is an essential protein but is not an essential 
protease; Stallmach et al. have replaced the active site Ser with an Ala residue in P. 
falciparum cultures with no observable phenotype but were unsuccessful in deleting the 
entire sera5 gene (Robert Stallmach, unpublished). The question of what is the role of 
SERA5 remains, as it appears to be essential and is one of the most abundant proteins 
of P. falciparum. 
 
1.7 SERA6, a putative malarial cysteine protease 
SERA6 is the third most abundant of the SERA family members in the 
trophozoite and schizont parasite stages of P. falciparum (Lasonder et al., 2002). It was 
first described as SERP H by Knapp et al. in 1991 (Knapp et al., 1991) as a homologue 
of SERA5. Based on evidence derived from immuno EM, IFAs and a proteomic 
approach, SERA6 appears to be localised to the PV (Knapp et al., 1991;Aoki et al., 
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2002;Nyalwidhe et al., 2006). However, low-resolution immuno EM figures, unspecific 
IFA labelling and a low peptide count from proteomic approaches mean that further 
verification is required in order to convincingly confirm the exact subcellular localisation 
of SERA6. Expression levels peak late in the P. falciparum asexual life stages. 
SERA6 comprises 1031 amino acids and is encoded by 3096 bp over four 
exons (PlasmoDB: http://plasmodb.org/plasmo/) with a predicted N-terminal signal 
peptide targeting the protein into the secretory pathway (accession number PFB0335). 
It belongs to group III of the cysteine type SERAs (Arisue et al., 2011). The predicted 
molecular weight of the full-length SERA6 is around 120 kDa. The entire SERA6 
protein contains 29 cysteine residues. The best characterised SERA6 orthologue is P. 
berghei SERA3 and both SERA6 and PbSERA3 remain refractory to gene disruption 
(Miller et al., 2002b;Kooij et al., 2005;Arisue et al., 2007;Schmidt-Christensen et al., 
2008;Putrianti et al., 2009). 
The putative catalytic domain was identified via alignments with SERA5, P. 
falciparum SERAs and papain and includes the papain-like protease family canonical 
Cys, His and Asn residues within its predicted active site. Although they have one 
major discrepancy in the putative catalytic site, SERA5 and SERA6 exhibit an overall 
sequence identity of 40% (Baker et al., 2001). SERA6 processing has yet to be fully 
described although unpublished data by Aoki et al. supports the extensive cleavage of 
SERA4 and SERA6 (McCoubrie et al., 2007). Yeoh et al. further showed sequence 
conservation of the PfSUB1 cleavage sites across most P. falciparum SERAs, and 
suggested that SERA6 undergoes cleavage similar to SERA5 processing, however not 
necessarily in the same order and into different sized fragments (see Figure 14). In the 
latter study processing of SERA6 by recombinant PfSUB1 was proposed. Unfortunately 
antibodies used in this study were of poor specificity and strongly cross-reacted with 
other prominent SERA family members such as SERA4. Alignments with all P. 
falciparum SERAs and the known PfSUB1 processing sites suggest that SERA6 
undergoes processing by PfSUB1 at two distinct sites (see Figure 14, SERA6st1 and 
SERA6st2), releasing a central fragment carrying the papain-like domain. PfSUB1 
processing possibly instigates a conversion of SERA6 to an active protease. 
The putative catalytic region of SERA6 has a high degree of identity with the 
catalytic region of papain, and modelling of SERA6 based on the falcipains suggests 
that SERA6 should be an active cysteine protease. Together with the likely subcellular 
localisation of SERA6 to the PV, and the effect of cysteine protease inhibitors on 
egress, this strongly suggests that SERA6 indeed has all the attributes which are 
required for a cysteine protease activity with a possible role in egress.  
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1.7.1 SERA6 and its heterodimer of terminal fragments 
The N- and C-terminus of SERA5 remain connected via disulfide-bridges and 
translocate to the merozoite surface where they play an important role in merozoite 
invasion. The fate of the N- and C-terminus of SERA6 is unknown. Proteomic data 
show some SERA6 peptide counts from merozoite derived material (PlasmoDB: 
http://plasmodb.org/plasmo/). No experimental evidence of the translocation of the 
disulfide-linked termini to the merozoite surface has been established. 
 
1.7.2 SERA6 and its orthologues 
As described above, SERAs in 18 Plasmodium species have now been 
identified (Arisue et al., 2011). All of these species carry a sera6 orthologue in their 
genome with a high degree of identity (see Table 2). The overall high level of 
conservation between SERA6 and its orthologues possibly indicates an important 
conserved role for those putative cysteine proteases. This is supported by the fact that 
the variation in SERA numbers for Plasmodium species is due to group IV, the serine 
type SERAs. All the cysteine type SERAs are highly conserved and all known species 
encode one copy of groups I-III (see 1.6). The best studied SERA6 orthologue is P. 
berghei SERA3.  
 
1.7.3 P. berghei SERA3: A SERA6 model 
P. berghei orthologues of the P. falciparum SERAs have recently been 
identified followed by thorough investigation of the orthologues of SERA4, SERA5 and 
SERA6 (Arisue et al., 2007). PbSERA3 has been shown to be expressed very late in 
the hepatocyte stage of P. berghei and is located to the PV (Schmidt-Christensen et 
al., 2008;Putrianti et al., 2009). Processing of the putative protease moments before 
the liberation of merozoites has been suggested (Schmidt-Christensen et al., 2008). 
Interestingly PbSERA3 is refractory to genetic manipulation in in vitro cultures and the 
disruption of the SERA4 and SERA5 orthologues either separately or combined 
induces upregulation of PbSERA3 (Putrianti et al., 2009). The orthologues of P. 
falciparum SERA4 and SERA5 are expressed in blood stages. PbSERA3 mRNA could 
also be detected in asexual blood stage infections in the rodent host, although it 
undergoes strong upregulation in late hepatocyte stages (Schmidt-Christensen et al., 
2008;Putrianti et al., 2009). 
SERA6 and PbSERA3 share an overall identity of 54%. The papain-like 
protease domain is highly conserved with 67% identity (see Figure 15). Alignments with 
SERA5 and SERA6 reveal that PbSERA3 indeed has cleavage sites which are similar 
to the PfSUB1 recognition motif. Substrate peptides based on those sites were shown 
to be proteolytically processed by recombinant P. berghei SUB1 (Catherine Suarez, 
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unpublished). High sequence identity and possibly analogous processing patterns 
make PbSERA3 an intriguing model to improve the understanding of the biological role 
of SERA6 in the parasite life-cycle. 
 
1.8 Hypothesis and Aims 
1.8.1 Summary 
The active rupture of iRBCs by the human malaria parasite P. falciparum is an 
essential step in the parasite life-cycle, preceding re-invasion of non-infected RBCs. 
Convincing evidence shows that proteases are key players in this step, called egress, 
and therefore could serve as excellent targets for the development of new 
antimalarials. 
Serine repeat antigens (SERAs) are a family of proteins expressed in the 
asexual blood stage forms (Miller et al., 2002b) of Plasmodium spp. and all contain a 
central papain-like domain which identifies them as putative cysteine proteases. P. 
falciparum SERA6 is one of the most abundant SERAs in late parasite stages and its 
gene is refractory to disruption, suggesting an essential role for SERA6 in parasite 
survival. The timing of SERA6 expression and its putative localisation to the PV, a 
parasite induced vacuole in which the parasite develops and multiplies, make SERA6 
an intriguing target for further investigation. 
 
1.8.2 Working hypothesis  
Recent evidence and a variety of well conducted approaches have delivered 
very convincing evidence to postulate that SERA6 is a cysteine protease that 
contributes to a proteolytic cascade leading to malaria parasite egress through rupture 
of the PVM or the EPM. 
 
1.8.3 Main questions to address in this work 
The main aims of this study were firstly to verify previous findings of SERA6 
localisation, confirm its putative processing by PfSUB1, identify any enzymatic activity 
and investigate its role in parasite egress. Briefly, this work will explore: (A) SERA6 
localisation, (B) SERA6 processing, and (C) SERA6 proteolytic activity. Questions to 
be addressed are as follows: 
 
A) Is SERA6 a soluble PV protein? 
 
B) Is SERA6 a substrate of PfSUB1? 
I. Is SERA6 processing by PfSUB1 indispensable for parasite survival? 
 
C) Is SERA6 a cysteine protease? 
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I. Is the cleavage by PfSUB1 an activation event? 
II. Is SERA6 activity indispensable for parasite survival? 
 
 
A) SERA6: a soluble PV protein? 
It was first aimed to express recombinant SERA6 to provide a tool of utmost 
importance for further analysis, both for antibody production and for activity studies. 
Previously-produced SERA6 antibodies were non-specific and showed strong cross-
reactivity with other members of the SERA family (Yeoh et al., 2007). Several different 
recombinant SERA6 fragments corresponding to the N-terminus, C-terminus and the 
central domain were aimed to be expressed in E. coli and COS-7 cells. The fragments 
were as follows: P64 fragment (homologue to SERA5 P56), designated as SERA6 
Central1 (S6C1), P60 (homologue to SERA5 P50) fragments, termed SERA6 Central 2 
(S6C2), and the full-length SERA6 (S6-FL). Some of these fragments were later used 
in PfSUB1 processing studies. In order to confirm previous studies we attempted to 
localise SERA6 by analysing parasite cultures with two different approaches. Firstly, by 
IFA with the newly generated antibodies and colocalisation with markers for various 
subcellular compartments and organelles. Secondly, by biochemical fractionation of the 
parasite which separates the contents of the PV from contents of the RBC and parasite 
cytosol, followed by immunochemical detection.  
 
B) Is SERA6 a substrate of PfSUB1?  
SERA5 was previously shown to be cleaved by PfSUB1 at two sites and one 
additional allele specific site. Alignment of the SERA amino acid sequences (Yeoh et 
al., 2007) revealed that other SERAs possess similar putative cleavage sites. 
Consequently a putative cleavage of SERA6 by PfSUB1 can be proposed. This 
processing is intriguing from several aspects. Firstly, this processing possibly occurs 
within the PV only moments before egress (like SERA5) which may indicate a putative 
role for SERA6 in egress. Secondly, the processing by PfSUB1 might lead to the 
activation of SERA6 which in return hydrolyses its substrate in order for the parasite to 
escape from the RBC.  
To identify PfSUB1 processing sites in SERA6 it was aimed to employ rS6-FL 
(see above) in PfSUB1 processing assays. N-terminal sequencing would reveal the 
exact PfSUB1 processing sites in SERA6. Mutations would then be introduced at these 
processing sites in the recombinant SERA6, to specifically prevent cleavage by 
PfSUB1. To determine whether SERA6 is processed by PfSUB1 in the parasite, it was 
attempted to purify the endogenous protein from P. falciparum cultures and subjected 
to recombinant PfSUB1 processing assays.  
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I. Is SERA6 processing by PfSUB1 indispensable for parasite survival? 
It was tried to replace the predicted PfSUB1 processing sites in in vitro parasite 
cultures to inhibit processing and analyse the effect on possible phenotypes. Cleavage 
sites were altered by mutations of P2 and P1 residues or P4-P1 deletion designed to 
block PfSUB1 processing. Mutations were introduced for each site separately or in 
combination. SERA5 is known to undergo a final processing step by a leupeptin 
sensitive cysteine protease, called Protease X. Based on alignments it was proposed 
that SERA6 might undergo similar processing as it encodes for such a processing site. 
Additionally the Protease X processing site in the parasite was replaced in order to 
investigate the role of that processing step. 
 
C) Is SERA6 a cysteine protease activated by PfSUB1? 
I. Is the cleavage by PfSUB1 an activation event? 
Based on alignments with SERA5 it was predicted that SERA6 might be 
processed by PfSUB1 in order to be activated. To establish whether SERA6 is a 
cysteine protease it was attempted to express recombinant SERA6 either as the 
putatively activated fragment (S6C1, between predicted SERA6st1 and SERA6st2) or 
S6-FL. Recombinant expression of a putative active fragment included refolding of 
proteins derived from insoluble fractions and extensive testing of expression conditions 
and variation of expression hosts. Full-length SERA6 was subjected to cleavage 
assays with PfSUB1. This also aimed to verify whether PfSUB1 processing might be a 
SERA6 activation event leading to an active cysteine protease. SERA6 activity was 
tested on fluorogenic peptides, RBC ghosts, iRBC ghosts and zymograms with 
recombinant and parasite derived SERA6. As there was no specific inhibitor available 
controls were obtained by replacing the catalytic Cys with Ala in recombinantly derived 
SERA6. 
Additionally it was attempted to recombinantly express PbSERA3, a SERA6 
orthologue from the rodent malaria parasite P. berghei. The recombinant wild-type and 
Cys to Ala mutant were subjected to PfSUB1 activity assays and activity was 
assessed. 
 
II. Is SERA6 activity indispensable for parasite survival? 
In order to investigate SERA6 activity in the parasite it was attempted to replace 
the catalytic Cys with Ala in P. falciparum cultures by homologous recombination. 
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Table 1: Overview of all seras from 18 Plasmodium species  
Summary of all known sera genes from 18 Plasmodium species. Number of sera 
genes, number of pseudogenes and the parasite’s natural host are indicated. Data 
derived from Arisue et al., 2007 and Arisue et al., 2011.  
Species No. sera genes No. fragmented or pseudo sera genes Host 
P. malariae 10 3 Humans 
P. ovale 7 1 Humans 
P. cynomolgi 11 2 Asian Old world monkeys 
P. fieldi 9 2 Asian Old world monkeys 
P. simiovale 9 2 Asian Old world monkeys 
P. inui 7 4 Asian Old world monkeys 
P. hylobati 7 0 Gibbons 
P. coatneyi 7 1 Asian Old world monkeys 
P. knowlesi 6 0 
Humans 
Asian Old world 
monkeys 
P. fragile 5 2 Asian Old world monkeys 
P. gonderi 9 1 African Old world monkeys 
P. vivax 12 1 Humans 
P. berghei 5 0 Rodents 
P. yoelii 5 0 Rodents 
P. chabaudi 5 0 Rodents 
P. falciparum 9 0 Humans 
P. reichenowi (sera 
gene sequences not 
complete) 
8 0 Chimpanzees 
P. gallinaceum 3 0 Birds 
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Table 2: Overview of P. falciparum SERA6 orthologues 
Species SERA6 orthologue nomenclature Host 
P. malariae PmaSERA8 Humans 
P. ovale PovSERA5 Humans 
P. cynomolgi PcySERA9 Asian Old world monkeys 
P. fieldi PfiSERA7 Asian Old world monkeys 
P. simiovale PsoSERA7 Asian Old world monkeys 
P. inui PinSERA5 Asian Old world monkeys 
P. hylobati PhySERA5 Gibbons 
P. coatneyi PcoSERA5 Asian Old world monkeys 
P. knowlesi PknSERA4 Humans Asian Old world monkeys 
P. fragile PfrSERA3 Asian Old world monkeys 
P. gonderi PgoSERA7 African Old world monkeys 
P. vivax PviSERA10 Humans 
P. berghei PbSERA3 Rodents 
P. yoelii PyoSERA3 Rodents 
P. chabaudi PchSERA3 Rodents 
P. reichenowi (sera 
gene sequences not 
complete) 
PreSERA6 Chimpanzees 
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Figure 1: Global Malaria Distribution in 2007 
The map displays the global distribution of P. falciparum malaria in 2007. Low 
prevalence regions are marked in yellow and high endemic areas are marked in red. 
Countries with blue borders have reliable national health information system and very 
low P. falciparum infection rates Hay et al., 2010. 
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Figure 2: Development of chloroquine resistance 
Resistance to chloroquine originated in Southeast Asia. Chloroquine resistance first 
developed through a point mutation in the pfcrt gene which made the chloroquine mode 
of action ineffective. Areas of high prevalence of resistance are marked red, and 
numbers indicate the years in which resistance was first detected. Figure adapted from 
Wellems et al., 2009. 
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Figure 3: Schematic of the P. falciparum life-cycle  
The asexual cycle starts with the inoculation into human subcutaneous tissue of 
infective sporozoites by the female Anopheles vector. After the invasion of 
hepatocytes, parasites develop into exo-erythrocytic stage merozoites, followed by 
their release into the blood stream. These merozoites subsequently invade 
erythrocytes, initiating the intra-erythrocytic stage. This step is characterised by 
multiple cycles of RBC invasion, parasite growth and replication and discharge of fresh 
infective merozoites into the blood stream, ready to invade yet again. Triggered by a 
variety of conditions some of the parasites, however, follow a different path and 
develop into macro- and microgametocytes, which are essential for parasite 
transmission. Only those stages have the potential to begin gametogenesis in the 
mosquito after uptake by the dipteran vector in a blood meal. Fertilisation in the 
mosquito is followed by multiple rounds of asexual replication giving rise to new 
infective sporozoites that migrate to the mosquito’s salivary glands, ready to be injected 
into a new human host, thus completing the parasite life-cycle. Figure adapted from 
Miller et al., 2002a. RBC: red blood cell 
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Figure 4: Schematic of P. falciparum intra-erythrocytic stage 
Invasion of RBCs by merozoites. After the initial attachment and reorientation an 
electron-dense tight junction is formed between parasite and host cell and active 
invasion begins with the establishment of the PV surrounding the parasite (A/B). The 
parasite develops from ring (B) to trophozoite stage (C). The parasite matures and 
undergoes mitotic replication to form a schizont, containing new merozoites. Finally, 
merozoites are released from the iRBC into the blood stream (E). This step, like 
invasion, is a process actively governed by the parasite and termed egress. Figure 
adapted from Bannister et al., 2003. RBC: red blood cell 
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Figure 5: Ultrastructure of a P. falciparum merozoite 
P. falciparum merozoites contain highly specialised organelles for egress and invasion 
of RBCs. Two to three microtubules run along the longitudinal axis. Proteins released 
from micronemes and club-shaped rhoptries are essential in invasion. Dense granules 
are heterogeneous in their contents and might perform different roles in the parasite 
life-cycle. All subsets of dense granules, plus exonemes which release PfSUB1 prior 
egress, play a role in host cell modification. The apical pole of the merozoite contains 
polar rings that are constituted of microtubules. The merozoite surface is coated with 
merozoite surface proteins (MSPs) which are involved in invasion of RBCs. The 
apicoplast is a red algae derived essential organelle with importance in parasite 
metabolism. Merozoites measure ~1 µm in diameter in the longitudinal axis. Figure 
adapted from Silmon de Monerri, 2010. 
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Figure 6: Invasion of erythrocytes by P. falciparum merozoites 
The merozoite undergoes a primary weak attachment with the RBC which is mediated 
by surface receptors (A). The merozoite then re-orientates until the apical end reaches 
the RBC surface and the formation of a tight junction is established (B). These steps 
require highly regulated ligand-receptor interaction between the host cell and the 
merozoite. Translocation of tight junction components to the posterior pole of the 
merozoite pushes the merozoite into the RBC (C-E). Upon the start of the merozoite 
internalisation, merozoite surface adhesins are proteolytically released. The merozoite 
establishes a new compartment within the host cell (called the PV) during invasion. 
Figure adapted from Cowman et al., 2006. RBC: red blood cell 
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Figure 7: Detailed schematic of P. falciparum egress 
Mature and newly formed merozoites are surrounded by still intact PVM (A). The PVM 
breaks down and viable merozoites move freely within the RBC cytosol (B). Swelling of 
the RBC (C) and degradation of the RBC skeleton (D) lead to the release of viable and 
invasion ready merozoites. Figure adapted from Cowman et al., 2006. 
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Figure 8: Current models of parasite egress  
A) Non-explosive egress via local fusion of the PVM with the EPM (Winograd et al., 
1999) 
B) “Outside-in” model suggesting EPM rupture first and followed by PVM degradation 
as an exo-erythrocytic event (Salmon et al., 2001;Baumeister et al., 2006). 
C) “Inside-out” model in which the PVM rupture prior to EPM disintegration (Wickham 
et al., 2003)  
D) Explosive RBC rupture with preceding “flower” formation of schizonts (Glushakova 
et al., 2005). Figure adapted from Blackman, 2008. 
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Figure 9: PfSUB1 substrate specificity 
Graphical representation of a multiple sequence alignment of amino acid residues of 
known and predicted PfSUB1 cleavage sites (Silmon de Monerri, 2010;Silmon de 
Monerri et al., 2011). The height of each residue stack represents the extent of the 
sequence conservation at that position. The height of each residue within that stack 
indicates the relative frequency of each residue. The arrow indicates the position of the 
scissile-bond. The colours of the amino acid residues are according to the chemical 
properties of the side-chains. Black, small: G,A; red, acidic: D,E; blue, basic: K,R,H; 
orange, aliphatic: L,V,I; green, uncharged polar: S,T,Y,N,Q; purple, non-polar, non-
aliphatic: F,P.  
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Figure 10: Organisation of all known sera genes 
Seras of 18 Plasmodium species are displayed according to their localisation on the 
chromosome and in relation to their orthologues. Each horizontal line represents one 
parasite species. All the genes are clustered between a conserved hypothetical protein 
gene and an iron-sulfur assembly protein gene, except P. falciparum sera9, 
Plasmodium reichenowi sera9 and P. gallinaceum sera3 which are located elsewhere. 
High conservation of seras from group I-III, cysteine-type SERAs, (green) is evident. 
Truncated genes and gene number variety can only be found in group IV, the serine-
type SERAs (yellow). Figure adapted from Arisue et al., 2011. 
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Figure 11: Conserved and non-conserved domains of P. falciparum SERAs 
Consensus SERA structure for P. falciparum. Alignment was obtained with Clustal W. 
The overall structure shows the high degree of sequence conservation and homology 
between all P. falciparum SERAs (gray). All SERAs contain a considerable number of 
Cys residues, e.g. the sera6 gene encodes 29 Cys, which appear to be positionally 
conserved (yellow bars). The central papain-like domain however, confers the highest 
degree of homology (light blue). Putative catalytic residues are indicated. Figure 
adapted from Yeoh et al., 2007. 
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Figure 12: P. falciparum SERA5 undergoes extensive processing 
SERA5 has been shown to be processed by PfSUB1 at two different sites, as well as at 
an allele-specific third cleavage site near the N-terminus in certain strains. In a first 
step PfSUB1 cleaves SERA5 in the N-terminal region (SERA5st1) generating two 
fragments, P47 and P73. A second cleavage near the C-terminus frees two fragments: 
P56, which carries the putative catalytic domain, and P18 at the very C-terminus 
(SERA5st2). P47 and P18 remain as a heterodimer, linked via a disulfide bond, and 
undergo translocation to the merozoite surface, where they are thought to play a role in 
invasion. The N-terminal fragment of the heterodimer undergoes an additional allele 
specific processing by PfSUB1 at a third site (SERA5st3), generating two fragments 
called P25 and P25’. Release of P56 has been suggested to act as an activation event 
for the protease. In the final processing step at a position just downstream of site 2, 
called P50C (SERA5stX), SERA5 is processed by an unknown protease which is 
leupeptin and E64 sensitive, releasing P50 and a C-terminal 6 kDa fragment. S-S 
indicates disulfide bonds; Amino acid sequences of the PfSUB1 cleavage sites are 
displayed. Presumed catalytic triad of papain-like domain are indicated. The final 
processing site was identified in the host lab (Sharon Yeoh and Michael Blackman, 
unpublished data). 
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Figure 13: Conservation of processing sites in P. falciparum SERAs 
Based on alignments with known PfSUB1 processing sites in SERA5, other blood 
stage P. falciparum SERAs were shown to possess similar potential cleavage sites 
(Yeoh et al., 2007). SERA5 is processed by PfSUB1 at three sites (SERA5st1, 2, 3) 
and by a second protease at one site (SERA5stX, Sharon Yeoh and Michael 
Blackman, unpublished data). Predicted processing sites for all other intra-erythrocytic 
SERAs are indicated below SERA5st1 and 2 (labelled with st1 and st2). Unpublished 
data suggests that SERA6 also encodes an additional PfSUB1-independent cysteine 
protease processing site (labelled with stX). Blue: Central papain-like domain. 
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Figure 14: Predicted P. falciparum SERA6 processing by PfSUB1 and Protease X 
PfSUB1 cleavage sites of SERA6 were predicted via the alignment of all intra-
erythrocytic P. falciparum SERAs on the basis of the known SERA5 cleavage sites and 
the known PfSUB1 enzymatic binding pocket specificity (for sites SERA6st1 and 
SERA6st2). A first N-terminal cleavage site (SERA6st1) was predicted at the sequence 
VKAQ↓DDFN, releasing an N-terminal 38 kDa and C-terminal 76 kDa fragment. A 
second cleavage site (SERA6st2) is anticipated near the C-terminus at the amino acid 
sequence VHGQ↓SNES. Two fragments of 64 (S6C1) and 12 kDa would be generated. 
The 64 kDa fragment carries the putative catalytic domain and might have cysteine 
protease activity. An additional cleavage site (SERA6stX) for an unknown but leupeptin 
and E64 sensitive protease was modelled on the basis of the C-terminal SERA5 
cleavage site (unpublished data). This final step possibly releases a 60 kDa fragment 
(S6C2), still carrying the putative catalytic domain, and a 4 kDa C-terminal fragment. A 
third N-terminal PfSUB1 site (such as is found for SERA5 in certain strains) is not 
predicted. 
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Figure 15: SERA6 and PbSERA3 are highly conserved 
P. falciparum SERA6 and P. berghei SERA3 were aligned using Clustal W. Both 
SERAs share an overall identity of 54%. The central papain-like domains are 67% 
identical with the residues of the catalytic triad highly conserved (identical residues 
highlighted in blue, catalytic Cys residue in green). Putative PfSUB1 processing sites 
are conserved in both SERAs. The alignment suggests that PbSERA3 possibly 
undergoes a similar fate to SERA6 (red, arrow indicates scissile bond). 
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2 Materials and Methods 
2.1 Parasite and COS-7 cultures 
2.1.1 Maintenance and synchronisation of P. falciparum (Trager et al., 
1976;Lambros et al., 1979;Trager, 1994) 
Clone 3D7 of P. falciparum was cultured in plastic tissue flasks (Nunc™) in 
complete RPMI-1640 Albumax cell culture medium (Invitrogen™ GIBCO®), 
supplemented with 2 mM L-Glutamine. O+ human RBCs were obtained from the 
National Blood Bank and iRBCs were cultured at 1-2% hematocrit. Parasite cultures 
were regularly synchronised and enriched via density gradient centrifugation with 
Percoll (GE Healthcare) selecting for iRBC harbouring late parasite stages (schizonts) 
to a parasitaemia >90% (Rivadeneira et al., 1983;Dluzewski et al., 1984). Infected 
RBCs were harvested by centrifugation for 3 minutes (min) at 1,000 x g then 
resuspended in 4 ml of RPMI (no Albumax) and gently layered on top of a warm 63% 
Percoll-PBS solution. For separation the Percoll-parasite layer mix was centrifuged for 
11 minutes at 1,000 x g, then the top layer including the schizont iRBCs was removed 
and washed in Albumax free RPMI. The schizont pellet was resuspended in an 
appropriate volume of parasite cell culture medium supplemented by an appropriate 
volume of washed RBCs, transferred to sterile cell culture flasks, gassed with a 1% O2, 
3% CO2, N2 gas mixture and left for re-invasion for 2 hours (h) with gentle shaking. 
After invasion the cells were incubated with 5% sorbitol at 37°C for 8 min to lyse 
residual schizonts, then washed and recultured at 37°C. Parasitaemia was routinely 
assessed by thin blood films which were fixed with 100% methanol and stained with 
10% Giemsa (VWR International) for 5-10 min. Parasite stages were identified via oil-
immersion light microscopy. 
 
2.1.2 Preparation of mature schizont extracts 
Parasites were synchronised and highly mature schizonts were enriched as 
described in 2.1.1, then recultured and smeared every 20 min until first ring stages 
began to appear. The cultures were then pelleted at 1,000 x g for 3 min and stored in 
aliquots at -80°C until use. 
 
2.1.3 Genomic DNA extraction 
Genomic DNA from non-transfected and transfected parasite lines was 
obtained by lysis of a synchronous trophozoite culture with a parasitaemia of 5%. 
Parasites were pelleted, resuspended in 0.15% saponin (BDH Laboratory Supplies) in 
PBS, incubated at room temperature (RT) for 5 min and pelleted at 12,400 x g for 5 
min. DNA was extracted according to manufacturer’s instructions with a DNeasy Blood 
& Tissue Kit (Qiagen).  
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2.1.4 Continuous COS-7 culture 
COS-7 cells were thawed quickly from liquid N2 in a 37°C water bath and 
resuspended in 0.5 ml prewarmed Dulbecco’s modified Eagle 
medium/GlutaMAX/Pyruvate/Glucose (Invitrogen™ GIBCO®) containing 10% fetal calf 
serum (FCS), 4 mM L-Glutamine and 0.5% Penicillin/Streptomycin 10,000 units 
(Pen/Strep; SIGMA), referred to as complete DMEM. Cells were then transferred to a 
50 ml Falcon tube and a further 10 ml of complete DMEM was added before the mix 
was pelleted at 140 x g for 5 min. The supernatant was discarded, the pellet was 
resuspended in 40 ml complete DMEM and transferred to a 175 cm2 culture flask 
(Nunc™). Subsequently cells were incubated at 37°C with a continuous supplement of 
5% CO2. COS-7 cells were grown until confluent and passaged at intervals of 3 days. 
At the point of confluency the culture supernatant of COS-7 cells was taken off and 
cells were washed in 10 ml PBS A (Ca2+ and Mg2+ free). 5 ml pre-warmed trypsin-
ethylenediaminetetraacetic acid (EDTA; SIGMA) was added to the flask and incubated 
for 5 min at 37°C. To detach the cell layer the flask was tapped sharply for up to 5 
times and 5 ml of complete DMEM were added to stop trypsin activity. Cells were 
transferred into a 50 ml Falcon tube, pelleted at 140 x g for 5 min and supernatant was 
discarded. Passaged cells were resuspended in 10 ml PBS A and 50 µl were mixed 
with 100 µl PBS A and 100 µl Trypan blue (Invitrogen™). 15 µl of the mix was now 
added to a haemocytometer and cells were counted according to standard protocols to 
determine the quantity of cells per ml. To continue culturing, cells were counted and 
2x106 cells were seeded into a 175 cm2 flask. 
 
2.2 Molecular Biology Techniques 
All cloning for recombinant protein expression in Escherichia coli was performed 
using pET-30 Xa/LIC and pET-41 Ek/LIC Cloning Kits (Novagen) following the 
manufacturer’s instructions. Additionally the pSecTag_2A vector was used for COS-7 
cell expression and the pHH1-∆SERA4 vector was employed for cloning of parasite 
transfection constructs. Bac-to-Bac® Baculovirus Expression System with pFastBac1™ 
vector (Invitrogen™) was used according to the manufacturer’s instructions for cloning 
of recombinant bacmid DNA for subsequent insect cell expression. All insect cell 
transfection constructs were a kind gift from Michael Shea. 
 
2.2.1 DNA modifying enzymes 
Restriction endonucleases were obtained from New England Biolabs (NEB), 
Promega and Roche and all digests were performed using the manufacturer’s 
instructions. DNA fragments were gel extracted with QIAquick® Gel Extraction Kit 
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(Qiagen). Antarctic phosphatase (NEB) was used to remove 5′ phosphate groups from 
the plasmid backbone. 
 
2.2.2 Primers 
Primers were diluted to a 100 μM stock in dH20 and stored at -20ºC. Primers 
were used at a concentration of either 5 μM or 10 μM depending upon the enzyme 
used. A list of primers, the primer sequences and their use is shown in Table 5. 
 
2.2.3 Polymerase chain reaction (PCR)  
Platinum®Taq High fidelity DNA polymerase and Thermoprime Taq DNA 
polymerase (Thermo Scientific) were used for DNA amplification and screening 
respectively according to the manufacturer’s instructions (Mullis, 1990). 
Oligonucleotides were obtained from Eurogentec and SIGMA. A synthetic SERA6 wild-
type gene (synthSERA6 WT) recodonised for expression in Pichia pastoris (Geneart) 
was used for recombinant SERA6 expression. A synthetic PbSERA3 wild-type gene 
(synthPbSERA3 WT) recodonised for insect cell expression (Geneart) was used for 
recombinant PbSERA3 expression.  
 
2.2.4 E. coli strains and transformation 
The following E. coli strains were used for plasmid amplification, grown in 
lysogeny broth (LB): DH5α™ cells sub-cloning efficiency (Invitrogen™) or NovaBlue 
GigaSingles™ Competent Cells (Novagen). E. coli BL21-Gold DE3 cells (Stratagene), 
Shuffle®T7 Express lysY competent cells (NEB), Shuffle®T7 Express lysY competent 
cells containing the pG-KJE8 plasmid (generated during this work) and Origami™2-
DE3 pLysS (Novagen) were used for protein expression (see Table 7). MAX 
Efficiency® DH10Bac™ competent E. coli were used for transposing the gene of 
interest from pFastBac1™ into the recombinant bacmid DNA (Invitrogen™) for insect 
cell expression. 
  
2.2.5 Plasmid DNA preparation  
All DNA was purified using QIAquick® Mini-prep Kit or QIAquick® Plasmid Maxi 
Kit (Qiagen). DNA concentration was measured either semi quantitatively by staining 
with SYBR®Safe gel stain (Invitrogen™) following electrophoresis on 0.7% agarose 
gels or in a Nanodrop spectrophotometer (Thermo Scientific). All steps were performed 
according to the manufacturer’s instructions.  
 
2 Materials and Methods 
 
98 
 
2.2.6 DNA ligation 
DNA ligation was performed using either the Rapid DNA Ligation Kit (Roche) 
following the manufacturer’s instructions or using pET-30 Xa/LIC Cloning Kit (Novagen) 
and pET-41 Ek/LIC Cloning Kit (Novagen). 
 
2.2.7 Nucleotide sequencing 
Nucleotide sequencing was performed by Beckman Coulter Genomics. 
 
2.2.8 Integration PCR 
To assess whether constructs had integrated into the targeted P. falciparum 
endogenous locus PCR was performed (see 2.2.3) using extracted genomic DNA from 
transfected parasite lines (see 2.1.3).  
 
2.2.9 Southern hybridisation  
2.2.9.1 DNA preparation 
Genomic DNA extracted from transfected parasite lines (see 2.1.3) was 
digested with restriction enzymes to provide suitable sized DNA fragments for analysis. 
Digested DNA was separated on a 0.7% agarose gel (BioRad laboratories) containing 
a 1:20,000 dilution of SYBR® Safe DNA gel stain (Invitrogen™). DNA was exposed to 
UV on a transilluminator (UVP – Bio Doc-It) to nick the DNA in order to increase 
transfer efficiency. The agarose gel was incubated at room temperature with gentle 
agitation for 1 h in denaturing buffer (500 mM NaOH, 750 mM NaCl), rinsed in double-
distilled water (ddH2O) and incubated for 1 h in neutralising buffer (500 mM Tris-HCl pH 
7.4, 750 mM NaCl) followed by a 20 min incubation in saline-sodium citrate buffer 
(SCC) containing 150 mM NaCl and 15 mM sodium citrate pH 7. The DNA was 
transferred onto a Hybond N+ membrane (Amersham Biosciences) overnight by 
capillary action transfer as described by (Sambrook J., 1989). 
 
2.2.9.2 Hybridisation 
The DNA probe was amplified from synthSERA6 by PCR using specific primers 
(see Table 5) and purified using QIAQuick® PCR purification kit (Qiagen), then labelled 
with anti-Digoxigenin-AP Conjugate (DIG) following the manufacturer’s instructions 
using a DIG Luminescent Detection Kit (Roche). Hybridisation was done according to 
the manufacturer’s instructions using a DIG Luminescent Detection Kit (Roche). The 
Southern blot was visualised by exposure to BioMaxTM MR film (Kodak®) at -80°C. 
 
2.3  Vector construction  
All vectors designed and used in this work are displayed in Table 6. 
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2.3.1 Constructs for recombinant protein expression in E. coli 
(cloning and recombinant expression of PbS3C1 was conducted by Katarina 
Milutinovic) 
Various plasmids for heterologous protein expression were designed based on 
SUB1 cleavage site predictions for SERA6. Two PfSUB1 processing sites and 1 
Protease X processing site in SERA6 were previously predicted, based on known 
SERA5 processing sites (Yeoh et al., 2007). Inserts were amplified by PCR from 
synthSERA6. Site directed mutagenesis (SDM) to replace the putative catalytic Cys644 
with Ala644 in the synthSERA6 (referred to as synthSERA6 C644A) was conducted by 
using a QuickchangeII SDM kit (Agilent Technologies). Different constructs were 
obtained by amplification following the manufacturer’s instructions and performed using 
pET-30 Xa/LIC Cloning Kit (Novagen) or pET-41 Ek/LIC Cloning Kit (see Table 6 and 
Figure 16). The PbSERA3 central 1 (rPbS3C1, between PbSERA3st1 and 
PbSERA3st2) was amplified either from synthPbSERA3 WT or from a modified version 
of the gene in which the putative catalytic Cys639 was replaced via SDM with an Ala 
residue (synthPbSERA3 C639A). DNA was amplified using primer pair 
PbS3C1_fwd_pET30 and PbS3C1_rev_pET30 and cloned using a pET-30 Xa/LIC 
Cloning Kit (Novagen; see Figure 17A/C and Table 5). 
 
2.3.2 Constructs for recombinant transient expression of SERA6 and SERA6 
C644A in COS-7 cells 
DNA was amplified from synthSERA6 and synthSERA6 C644A. PCR was 
conducted according to standard procedure using the primer pair 
S6_FL_fwd_pSecTag2a_Sfi1 and S6_FL_rev_pSecTag2a_EcoR1, introducing a 5′ -
Sfi1 restriction site and a 3′ -EcoR1 restriction site into the PCR product. The 
pSecTag2A backbone was pre-digested with Sfi1 followed by EcoR1 and the insert 
was ligated into the vector using standard ligation methods (see 2.2.6 and Figure 18).  
 
2.3.3 Constructs for recombinant transient expression of PbSERA3 WT and 
PbSERA3 C639A mutant in Tricoplusiu ni BTI-Tn-5Bl-4 (Tn5) cells  
(all constructs were a kind gift from Michael Shea and Fiona Hackett) 
DNA for recombinant expression of full-length rPbSERA3 WT and full-length 
rPbSERA3 C639A in insect cells was amplified from synthPbSERA3 WT or 
synthPbSERA3 C639A respectively (see 2.3.1) using primers specific for full-length 
PbSERA3 and amplicons were subcloned into the pFastBac™ Vector (see Table 5 and 
Figure 17B). Recombinant baculovirus was prepared by recombination between the 
donor plasmid (pFastBac™) and the viral DNA (bacmid) via site-directed transposition 
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according to manufacturer’s instruction for the Bac-to-Bac® Baculovirus Expression 
System (Invitrogen™). Virus stocks were generated by transfecting Sf9 cells 
(Spodoptera frugiperda, obtained from Invitrogen™) with bacmid DNA for PbSERA3 or 
PbSERA3 C639A and assayed using standard methodology. 
 
2.3.4 Design of integration construct pHH-SERA6chim and derivatives  
(all constructs were designed in collaboration with Michael Shea based on pET-30 
Xa/LIC_S6FL)  
Plasmids for integration into the parasite genomic sera6 locus by single 
homologous recombination were based on the pHH1-∆SERA4 vector (Child et al., 
2010). A 1020 bp region of the sera6 gene downstream of the translational start site 
was amplified using primers SERA6-int-for and SERA6-int-rev (see Table 5) and 
ligated into the pHH1 backbone in place of the sera4 coding sequence. The remainder 
of the sera6 coding region (2406 bp) was excised from the synthSERA6 backbone and 
ligated in frame with the 3′ end of the sera6 sequence in the pHH1 vector to generate a 
plasmid containing a region of genomic sera6 to promote homologous recombination 
fused in frame to the rest of sera6 in recodonised form to allow expression of the gene 
following integration. The transfection vectors were designed to integrate into the sera6 
locus to produce a chimeric gene that would either reconstitute a coding sequence 
encoding the wild-type SERA6 protein (construct pHH-SERA6chim), or that would 
express a series of mutant forms of SERA6 modified at the predicted cleavage sites 
SERA6st1 (construct pHH-SERA6chim_mutS1), SERA6st2 deletion (pHH-
SERA6chim∆S2), SERA6st2 substitution (pHH-SERA6chim_mutS2), SERA6stX (pHH-
SERA6chim_mutSx), or combinations of these mutations (see Table 6 and Figure 19) 
Mutations were introduced by SDM using the QuickchangeII SDM kit (Agilent 
Technologies) according to the manufacturer’s protocol. The mutation for SERA6st1 
used primer SERA6-17 and consisted of the replacement of residues Ala378-Gln379 
with Leu368-Leu379. The mutation for SERA6st2 used primer SERA6-19 and 
consisted of the replacement of residues Gly935-Gln936 with Leu935-Leu936. The 
mutation for SERA6stX used primer SERA6-34 and consisted of the replacement of 
residues Tyr897-Phe898-Leu899 with Ala897-Ala898-Ala899.  
 
2.4 P. falciparum transfections 
Ring stage parasites at 5–10% parasitaemia were transfected by electroporation 
with 70 µg of plasmid DNA as described previously (Harris et al., 2005). Selection for 
lines carrying the plasmid was performed with 10 nM WR99210 (Jacobus 
Pharmaceuticals, New Jersey, USA). Selection of integrants was promoted by cycling 
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on and off drug selection (2.5 nM WR99210). The parasites were cultured off drug for 
three weeks followed by drug selection. 
 
2.5 Immunochemical Methods 
2.5.1 Protein separation via Sodium Dodecyl Sulfate Polyacrylamide gel 
electrophoresis (SDS-PAGE) (Laemmli, 1970) 
For disruption of protein disulfide bonds (reducing conditions), samples were 
diluted with 2x SDS sample buffer (62 mM Tris-HCl pH 6.8, 5% (v/v) glycerol, 3% (w/v) 
SDS, 100 mM dithiothreitol (DTT) and denatured at 95ºC for 5 min. Therefore all native 
protein interactions were completely eliminated, proteins denatured and finally charged 
with SDS but without entire protein dissolution (maintenance of primary structure). The 
proteins were separated via 7.5%, 10%, 12.5% or 15% resolving mini gels (Table 8), 
chromatographed at a constant current of 25 mA.  
 
2.5.2 Immunoblotting (Towbin et al., 1979;Sambrook J., 1989) 
Qualitative immunodetection was obtained by the standard application of 
immunoblotting under wet conditions. Molecules were transferred to Hybond-C 
nitrocellulose (GE Healthcare) membrane at 150 mA overnight. The membrane was 
blocked with 5% milk-PBS, followed by three washing steps with PBS-Tween-20 
(PBST). Primary antibodies were diluted in PBST, 1% (w/v) BSA and the blots were 
incubated with shaking for 90 min at RT or 4ºC overnight. Blots were then washed and 
incubated with PBST diluted secondary antibody which was coupled to horseradish 
peroxidise (HRP), for 30 min at room temperature. Enhanced chemiluminescence 
(ECL; Pierce; Ogata et al., 1983) was used to visualise the targeted protein on a 
BioMaxTM MR film (Kodak®). Exposure times varied depending on the abundance of 
the protein under investigation and the dilution and specificity of the different antibodies 
(see Table 9). 
 
2.5.3 Fixing and staining SDS-PAGE gels  
To visualise proteins of interest SDS-PAGE gels were fixed and stained with 
0.15% (w/v) Coomassie Brilliant Blue R-250, 45% (v/v) methanol, 45% (v/v) ddH20, 
9.85% (v/v) acetic acid for 5 min and destained with 5% (w/v) methanol and 10% (w/v) 
acetic acid overnight. After destaining was complete some SDS-PAGE gels were 
subjected to silver stain procedure with a PageSilver™ Silver Staining Kit (Fermentas) 
following manufacturer’s instructions. 
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2.5.4 Antigen preparation for antibody generation against recombinant SERA6 
central 1 (rS6C1) and recombinant C-terminus (rS6-Cterm) 
Antibodies against the rS6C1 fragment and the recombinant C-terminus of 
SERA6 (see Table 9) were generated in house. Solubilised inclusion bodies (IB, see 
2.6.4) were applied to a PD-10 Desalting Column equilibrated in PBS (Amersham 
Biosciences). The eluate was then injected into mice for polyclonal antibody generation 
(Malcolm Strath). Mouse sera were adsorbed against E. coli acetone powder to remove 
antibodies against bacterial contaminants, using 40 mg/ml acetone powder (Harlow et 
al., 1988). Rabbit antibodies were generated using rS6C1 (see Figure 16B) from 
recombinant expression with pET-30 Xa/LIC_S6C1 (Harlan laboratories). 
 
2.5.5 Sample preparation for N-terminal sequencing (Edman sequence 
analysis) of PfSUB1 processing sites of SERA6 
(in collaboration with Michael Shea) 
Recombinant SERA6 (rS6-FL; pET-30 Xa/LIC_S6FL), rS6-FLmutS1 (pET-30 
Xa/LIC_S6FL_S1), rS6-FLmutS2 (pET-30 Xa/LIC_S6FL_S2), and rS6-FLmutS1S2 
(pET-30 Xa/LIC_S6FL_S1S2) were expressed with N-terminal S- and 6xHis-tags using 
the pET-30 Xa/LIC system in E. coli. In all cases proteins were produced as IB which 
were washed and solubilised directly into SDS sample buffer in the presence of the 
reducing agent DTT (100 mM final concentration). Solubilised IB were separated by 
SDS-PAGE. The most abundant protein, corresponding to rS6-FL, was excised from 
the gel to separate it from breakdown products, then subjected to in-gel digestion with 
or without rPfSUB1 (Withers-Martinez et al., 2002). Gel pieces were then boiled in SDS 
sample buffer to solubilise the protein fragments, and again subjected to SDS-PAGE, 
followed by transfer of the polypeptide fragments to polyvinylidene fluoride (PVDF) 
membrane. N-terminal sequencing was performed by the Protein and Nucleic Acid 
(PNAC) facility at the Department of Biochemistry, University of Cambridge. 
 
2.5.6 Sample preparation for N-terminal sequencing (Edman sequence 
analysis) of PfSUB1 processing sites of rPbS3C1 
The recombinant PbSERA3 central 1 domain (between PbSERA3site1 and 
site2 referred to as rPbS3C1) was incubated with rPfSUB1 (Withers-Martinez et al., 
2002) at 37°C for 2 h, concentrated 20 fold with a Vivaspin 500, 10 kDa cut-off 
concentrator (VWR), resuspended in 5x SDS sample buffer (containing 100 mM DTT) 
and subjected to SDS-PAGE. This step was subsequently followed by transfer to PVDF 
membrane. N-terminal sequencing was performed by PNAC. 
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2.5.7 Indirect immunofluorescence analysis (IFA) 
Thin films of P. falciparum (various life stages) were air dried, fixed in 4% 
paraformaldehyde in PBS for 30 min at RT and permeabilised in 0.1% Triton X-100 
(TX-100; SIGMA) for 10 min. Fixed slides were then washed three times with PBS for 
10 min and blocked overnight at 4ºC in 3% (w/v) bovine serum albumin (BSA) in PBS. 
The following day slides were probed with the appropriate primary antibody (see Table 
9) for 30 min at 37ºC and then washed three times for 10 min in PBS. Slides were 
stained with 4',6-diamidino-2-phenylindole (DAPI;GIBCO®), mounted in Citifluor, and 
images collected using AxioVision 3.1 software on an Axioplan 2 Imaging system 
(Zeiss) using a Plan-APOCHROMAT 1006/1.4 oil immersion objective (Harris et al., 
2005).  
 
2.5.8 Immunoprecipitation 
Highly synchronous P. falciparum schizonts were enriched with Percoll, pelleted 
and stored in aliquots at -80°C. Pellets were thawed into ice cold 10 mM Tris-HCl pH 
8.2 containing cOmplete EDTA-free protease inhibitor cocktail (Roche) and 
supernatant was collected at 12,400 x g for 20 min at 4°C. Monoclonal antibody 1C9 
(α-S6-Nterm), previously generated against the SERA6 N-terminus, was added to the 
parasite supernatant and incubated on ice for 1 h, manually mixing every 15 min. The 
sample was then added to 20 µl of packed Protein G Sepharose (GH Healthcare) 
shaking for 1 hr at 4°C and the suspension was then washed 3 times in PBS. Elutions 
were conducted as follows: 3 washes in 50 mM Tris-HCl, 5 mM EDTA, 0.5% (v/v) TX-
100 pH 8.2, followed by 3 washes in 500 mM NaCl, 50 mM Tris-HCl, 5 mM EDTA, 
0.5% (v/v) TX-100, 1 mg/ml bovine serum albumin pH 8.2 and 3 washes in 1 M NaCl, 
50 mM Tris-HCl, 5 mM EDTA, 0.5% (v/v) TX-100, 1 mg/ml BSA pH 8.2. Beads were 
finally solubilised into SDS sample buffer. All the fractions were subjected to SDS-
PAGE. 
 
2.6 Recombinant Protein Expression  
2.6.1 Expression of recombinant protein in E. coli 
Shuffle T7 Express lysY cells and BL21-Gold DE3 cells were transformed with 
several constructs in order to produce recombinant SERA6 protein (see Figure 16). A 
single picked colony was grown at 30°C overnight in 5 ml LB medium (containing the 
appropriate antibiotic) and then diluted 50-fold the following day. Shuffle T7 Express 
lysY cells were induced when cells had grown to an optical density of 0.6 with 1 mM 
isopropyl β-D-1-thiogalactopyranoside (IPTG) at 16ºC overnight and BL21-Gold DE3 
cells were induced with 0.5 mM IPTG at 18°C. Following induction, bacteria were 
pelleted at 2,000 x g for 20 min and lysed in an appropriate volume of BugBuster 
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Master Mix (Novagen). Table 7 shows all recombinant E. coli expression conditions 
used. Recombinant PbS3C1 was produced by transformation of BL21-Gold DE3 cells 
based on the rPbS3C1 construct designed in this study (see Table 6 and Figure 17C). 
Recombinant PbS3C1 was a kind gift of Katarina Milutinovic. 
 
2.6.2 Transient expression of recombinant full-length SERA6 in COS-7 cells 
The day before the transfection experiment cells were passaged and seeded at 
1.2 x 107 cells per 175cm2 flask in order that the cells were at least 80% confluency the 
following day. On the day of transfection, 42 µg of pSecTag_2A_S6FL or 
pSecTag_2A_S6FL_C/A plasmid DNA (see Table 6 and Figure 18) were incubated 
with 84 µl FuGENE® HD Transfection Reagent (Roche) and the volume was adjusted 
to 2.1 ml with DMEM medium (free of serum and Pen/Strep). The mix was incubated at 
RT for 15 min. In the meantime 40 ml of complete DMEM was added to each flask 
containing the attached cells. The DNA transfection reagent mix was added dropwise 
to the culture flasks and incubated for 7 h at 37°C in an atmosphere of 5% CO2. After 
the incubation period the cells were washed 3 times with PBS A and finally 40 ml of 
serum free DMEM containing Pen/Strep, L-Glutamine, and 250 ng/µl tunicamycin 
(SIGMA) was added to each flask. After 4 days the supernatant was collected, residual 
cells were pelleted at 140 x g for 5 min and the supernatant was filtered through a 0.22 
µm diameter filter (Corning). The supernatant was then concentrated 16 fold and stored 
in aliquots at -80°C until further use. The adherent cells were collected by using cell 
scrapers (Costar), pelleted at 140 x g for 5 min, and stored at -80°C until further use. 
 
2.6.3 Transient expression of recombinant PbSERA3 in Tricoplusiu ni BTI-Tn-
5Bl-4 (Tn 5) cells  
(conducted by Fiona Hackett) 
High FiveTM cells (Invitrogen™) were grown in ESF 921 medium and 
transfected with the under see 2.3.3 (also see Figure 17) produced viral stocks as 
described by (Withers-Martinez et al., 2002). Tunicamycin was added at a final 
concentration of 500 ng/ml). Accumulation of secreted protein was monitored by 
Western blot using the mouse α-PbS3C1 antibody, raised against the central domain of 
PbSERA3 (kind gift from Volker Heussler). The medium was collected 72 h post-
infection, cells were pelleted by centrifugation at 2,100 x g for 10 min, supplemented 
with glycerol to 10% (v/v) and stored at -80°C until further use.  
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2.6.4 Inclusion body solubilisation 
All three recombinant SERA6 polypeptides rS6-FL, rS6C1 and rS6C2 were 
expressed in E. coli in a mainly insoluble form in IB. Following disruption of the bacteria 
with BugBuster Master Mix as described above, IB were washed twice in 50 mM Tris-
HCl pH 8.1, 2% (v/v) TX-100, 500 mM NaCl, 5 mM DTT and solubilised in either 8 M 
urea or 6 M guanidine-HCl in a buffer containing 250 mM NaCl (500 mM respectively), 
1 mM imidazole, 8 β-mercaptoethanol and 20 mM Tris-HCl pH 8.1. IB were solubilised 
at RT for 2 h and urea soluble and insoluble fractions were separated at 6,000 x g for 
25 min.  
 
2.6.5 Protein refolding 
After solubilisation of IB in 8 M urea the denatured proteins had to be refolded in 
order to gain their native fold. Rapid dilution experiments (20, 50 or 100 fold dilutions) 
were conducted under a variety of different refolding conditions (see Table 10) using 
the Quick Refolding Kit (Pierce) according to the manufacturer´s instructions as well as 
refolding protocols based on the folding of SERA5 and P. falciparum falcipains 
described elsewhere (Sijwali et al., 2001a;Hodder et al., 2003). A range of redox 
conditions were used at 4°C, RT or 37°C, and with incubation periods of up to 5 days. 
Refolding status was assessed via clear native PAGE (CN-PAGE). Lower gel and 
upper gel buffers were prepared using 1.5 M Tris-HCl pH 8.8 and 500 mM Tris-HCl pH 
6.8 respectively. 25 mM Tris-HCl pH 8.3 and 192 mM Glycine were used for the 
running buffer. Refolded samples were diluted into 2x native sample buffer, containing 
125 mM Tris-HCl pH 6.8, 20% (w/v) glycerol and 0.01% Bromophenol blue. CN-PAGE 
gels were run for 2 h at a constant current of 25 mA. Proteins were then visualised with 
either Coomassie Brilliant Blue R-250 or the PageSilver™ Silver Staining Kit 
(Fermentas). Immunoblotting of CN-PAGE was conducted as described previously. 
 
2.7 Protein purification 
2.7.1 His-tag affinity purification of recombinant protein 
Bacterial lysate (soluble BugBuster Master Mix fraction) or solubilised IB were 
incubated with Ni-NTA Superflow resin (Qiagen) rotating for 1 h at 4°C. The 
supernatant was removed after centrifugation at 12,400 x g for 1 min, and the resin 
was then washed 3 times by repeated resuspension in 300 mM NaCl, 50 mM NaH2PO4 
and 20 mM imidazole pH 8. Proteins were eluted using either increasing concentrations 
of imidazole or acidic pH in buffers based on the washing buffer. Fragments from 
solubilised IB were eluted using either 8 M urea, 100 mM NaH2PO4, 10 mM Tris-HCl at 
a pH of 5.9 for the first elution and pH 4.5 for the second elution. A different elution was 
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attempted using 8 M urea, 250 mM NaCl, 20 mM Tris-HCl pH 8.0, 1 M imidazole, 20 
mM β-mercaptoethanol. 
 
2.7.2 Anion exchange purification of E. coli derived rS6-FL and rS6C1 
Bacterial lysates (soluble BugBuster Master Mix fraction) were diluted 5 fold into 
either 20 mM HEPES pH 6.5 or 20 mM ethanolamine pH 9 and incubated on ice for 20 
min with either SP-Sepharose® Fast Flow (Amersham Biosciences) or Q-Sepharose® 
(Amersham Biosciences) respectively. The suspensions were then centrifuged at 
12,400 x g for 1 min and both supernatants were applied to Ni-NTA Superflow 
immediately, as described previously (see 2.7.1). 
 
2.7.3 Purification of parasite-derived SERA6 
To purify parasite derived full-length SERA6, 0.5 ml of frozen P. falciparum 
schizonts were thawed into 4 ml of ice-cold 10 mM Tris-HCl, pH 8.2, 10 mM EDTA, in 
the absence of protease inhibitors. Supernatant and membranes were separated by 
centrifugation at 10,000 x g for 15 min at 4°C. The cleared lysate was then filtered 
through 0.45 µm filter and 4 ml of supernatant was applied to the injection loop of a 
HiLoad 26/60 Superdex 200 prep-grade column (GE Healthcare), equilibrated as 
described elsewhere (Yeoh et al., 2007). Determination of elution fractions containing 
full-length SERA6 was conducted via Western blotting. After gel filtration all fractions 
containing SERA6 were pooled, diluted 3 fold into 20 mM Tris- HCl pH 8.2 and 
subjected to anion exchange purification as described elsewhere (Yeoh et al., 2007). 
The final product was referred to as parasite-derived semi-purified SERA6 (see Table 
6). 
 
2.7.4 Purification of rPbSERA3  
The in 10% (v/v) glycerol stored culture supernatant was thawed and 400 ml 
was mixed with 400 ml 50 mM Tris-HCl pH 8.2. A HiPrep16/10Q XL column (GE 
Healthcare) was equilibrated in 50 mM Tris-HCl pH 8.2. Supernatant was loaded onto 
the column at a flow rate of 4 ml/min followed by a wash step with 100 ml 50 mM Tris-
HCl pH 8.2. Recombinant PbSERA3 was eluted in 400 ml of 50 mM Tris-HCl pH 8.2 
with a gradient from 0-400 mM NaCl in 10 ml fractions at a flow rate of 2 ml/min. 
Analysis of rPbSERA3 fractions was conducted via Western blotting. A HiLoad 26/60 
Superdex 200 prep-grade column (GE Healthcare) was equilibrated overnight in 25 
mM HEPES, 150 mM NaCl and 12 mM CaCl2 pH 7.4. After anion-exchange 
chromatography rPbSERA3 containing fractions were pooled and 140 fold 
concentrated with 70 ml Centricon®Plus-70, cut-off 30 kDa (Millipore™), a volume of 
maximum 500 µl was loaded onto the column and sample was collected as described 
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elsewhere (Yeoh et al., 2007). Western blot analysis followed to determine rPbSERA3 
containing fractions. 
 
2.7.5 Purification of SERA6-central domain from parasite culture supernatant 
A parasite derived SERA6 central domain (SERA6-central; see Table 6) was pre-
purified from P. falciparum culture supernatant via anion-exchange as described 
elsewhere (Silmon de Monerri et al., 2011). It was then further purified through gel 
filtration using a HiLoad 26/60 Superdex 200 prep-grade column (GE Healthcare) with 
20 mM Tris-HCl pH 8.2, 150 mM NaCl, 1 mM DTT, 1 mM EDTA. 5 ml fractions were 
collected with settings as described previously (see 2.7.3). The SERA6-central domain 
was detected by Western blot analysis. 
 
2.8 Protein Biochemistry 
2.8.1 Saponin and Streptolysin O treatment 
Highly synchronous P. falciparum schizonts enriched with Percoll were divided 
into aliquots of 4 x 108 cells. Streptolysin O (SLO) was activated for 15 min at 37°C with 
10 mM DTT. Four hemolytic units (HU) of SLO were then added to one aliquot of 
enriched schizonts, incubated for 6 min at RT and membrane and soluble fractions 
were separated by centrifugation at 12,400 x g for 10 min at 4°C. For saponin lysis, 
saponin was prepared as a 0.15% (v/v) stock solution in PBS. Schizont pellets were re-
suspended in 10 cell volumes of sterile saponin and incubated at RT for 6 min. 
Membrane and soluble fractions were separated by centrifugation at 12,400 x g for 10 
min at 4°C. Different parasite fractions were diluted in sample buffer and subjected to 
SDS-PAGE and Western blotting and probed with various antibodies (see Table 9). 
 
2.8.2 PfSUB1 processing assays of parasite-derived semi-purified SERA6 
Full-length SERA6 was purified as described previously (Yeoh et al., 2007), 
concentrated and resuspended in PfSUB1 activity buffer containing 25 mM HEPES, 12 
mM CaCl2 pH 7.4 (see 2.7.3). Semi-purified full-length SERA6 was divided into aliquots 
of 80 µl and either no rPfSUB1, 10 µl rPfSUB1, 2 µl recombinant PfSUB1 prodomain 
(rPD) or 10 µl rPfSUB1 plus 2 µl rPD were added immediately before incubating at 
37°C (Withers-Martinez et al., 2002;Jean et al., 2003). Samples were taken after 30 
min, 1 h and 2 h and assayed via Western blotting. 
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2.8.3 SERA6 processing assay in vivo/egress inhibition assay 
2.8.3.1 Inhibition assays with trans-epoxysuccinyl-L-leucylamido-(4-
guanidino)butane (E64) 
Parasites at early schizont (2-4 nuclei) stage were enriched using Percoll, 
resuspended in 10 ml RPMI-1640 Albumax cell culture medium either with or without 
the addition of the cysteine protease inhibitor E64 (10 µM), and further cultured at 
37°C. Samples for IFA and Western blotting were taken after 3 h, 6 h, 9 h and 12 h. 
 
2.8.3.2 Inhibition assays with 4-[2-(fluorphenyl)-5-(1-methylpiperidine-4-yl)-1H 
pyrrol-3-yl]pyridine (compound 1) 
Early schizonts (2-4 nuclei) were enriched with Percoll and resuspended in 10 
ml RPMI-1640 Albumax cell culture medium which contained either 10 µM E64 and 2.5 
µM compound 1 (Dvorin et al., 2010) or E64 alone, and further cultured at 37°C. 
Compound 1 was stored at -20°C as a 10 mM stock solution in DMSO. Prior to use it 
was diluted 1:20 in DMSO to give a final concentration of 500 µM, then further diluted 
to 5 µM in RPMI-1640 Albumax cell culture medium, for assays. Samples for IFA and 
Western blotting were taken after 3 h, 6 h, 9 h and 12 h.  
 
2.8.4 Fluorogenic peptide assays 
SERA6 protease activity was assayed using peptidyl 7-amido-4-
methylcoumarin hydrochloride (AMC) fluorogenic substrates (available from the host 
lab, see Table 11) (Kanaoka, 1977). A total of 15 different AMC peptides were diluted 
with 25 mM HEPES, 150 mM NaCl, 1mM DTT pH 6.5 to a concentration of 10 µM in a 
volume of 50 µl and distributed in a 96 well plate. Crude bacterial lysates (soluble 
BugBuster Master Mix fraction) of rS6C1 wild-type and the rS6C1 C644A mutant were 
diluted 10 fold into the same buffer and 50 µl was added to each well leaving the AMC 
peptides at a concentration of 5 µM in 100 µl total volume. Fluorescence 
measurements were taken every 3 min for 10 min followed by further readings after 1 
h, 2 h and 3 h incubation at 37°C, using excitation and emission wavelengths of 380 
nm and 460 nm respectively. Additionally 3 internally quenched peptides (see Table 
11, A-C) were tested at a final concentration of 20 µM using excitation and emission 
wavelengths of 320 nm and 420 nm respectively. Additionally the parasite derived and 
with rPfSUB1 processed semi-purified SERA6 (see 2.8.2) was tested for activity 
against all the fluorogenic peptides under the above mentioned conditions. 
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2.8.5 SERA6-central activity assays 
SERA6-central was purified from P. falciparum culture supernatant as 
described under 2.7.5.  
 
2.8.5.1 Fluorogenic peptide assays 
A total of 18 fluorogenic peptides were screened as described under 2.8.4. 
AMC and internally quenched peptides were resuspended at 20 µM (10 µM final) and 
50 µM (25 µM final) respectively in 20 mM Tris-HCl pH 8.2, 150 mM NaCl, 1 mM DTT, 
1 mM EDTA and 1:2 diluted with the gel filtration purified SERA6-central (see 2.7.5). 
Increase in fluorescence was measured as described under 2.8.4. 
 
2.8.5.2 SERA6-central autocatalytic processing assays 
Parasite-derived SERA6-central (see 2.7.5) was concentrated 5 fold using a 
Vivaspin 500, 10 kDa cut-off concentrator (VWR) and incubated at 37°C overnight. 
Samples were separated on 12.5% SDS-PAGE and possible autocatalytic processing 
was assessed by Western blot analysis and Coomassie stain. 
 
2.8.5.3 SERA6-central proteolytic activity against RBC ghosts 
RBC ghosts were obtained by resuspending 100 µl of RBCs in 1 ml 5 mM ice-
cold KH2PO4, incubation on ice for 5 min and centrifugation at 12,400 x g for 20 min at 
4°C. Phases were carefully separated by discarding the supernatant, then the milky 
coloured ghost containing fraction was transferred to a new tube and washed several 
times in PBS A. The washed ghost fraction was finally resuspended in 25 mM HEPES, 
pH 6.4, 1 mM DTT or 20 mM Tris-HCl pH 8.2, 150 mM NaCl, 1 mM DTT and incubated 
at 37°C with SERA6-cntral. Samples were taken after 10 min, 30 min, 90 min and 3 h 
incubation, and analysed by SDS-PAGE followed by silver stain with the PageSilver™ 
Silver Staining Kit. 
 
2.8.5.4 SERA6-central activity screen with gelatin zymograms 
12.5% SDS-PAGE gels were prepared according to standard procedure (see 
2.5.1). During preparation of the running gel a gelatin stock solution (10 mg/ml in 
distilled H20) was added to produce a final concentration of 0.1% protein (1 mg/ml). To 
screen for SERA6-central activity purified protein was mixed with 2x SDS sample buffer 
(without DTT), incubated for 10 min at RT, and electrophoresed on SDS PAGE using 1 
x Tris-Glycine SDS running buffer according to the standard running conditions (see 
2.5.1). The SDS-polyacrylamide gel was then incubated in 1x zymogram renaturing 
buffer (2.5% (v/v) TX-100 in ddH20) for 30 min at RT (the buffer was exchanged once 
after 15 min). The zymogram renaturing buffer was discarded and replaced with one of 
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the following 1 x zymogram developing buffers: 25 mM HEPES pH 6.4, 1 mM DTT; 100 
mM NaAc pH 5.5, 0.05% NP-40, 1 mM DTT; 20 mM Tris-HCl pH 8.2, 150 mM DTT, 1 
mM EDTA; 20 mM Tris-HCl pH 8.2, 150 mM NaCl, 5 mM CaCl2, 1 mM DTT, 1 mM 
EDTA. The gels were equilibrated for 30 min at RT with gentle agitation then the buffer 
replaced with fresh developing buffer and incubated at 37°C overnight. The following 
day the gels were stained with Coomassie Brilliant Blue R-250 for 30 min, a 
concentration of 0.5% (w/v) was prepared instead of the usual concentration of 0.1% 
dye (to enhance sensitivity). Gels were destained with appropriate Coomassie 
destaining solution. Areas of protease activity appeared as clear bands against a dark 
blue background where the protease has digested the gelatin substrate which then 
diffused out of the gel. 
 
2.8.6 Recombinant PbSERA3 activity assays 
Recombinant PbSERA3 WT and rPbSERA3 C639A were purified as described 
previously (see 2.7.4). 30 µl of purified protein was incubated for 2 h at 37°C with 
rPfSUB1 (Withers-Martinez et al., 2002). Additionally several reagents or protease 
inhibitors were added individually, as follows: PD, 10, 20 or 100 µM E64, 20 µg/ml 
leupeptin, 20 µg/ml antipain, 1 µM PbICP (Rennenberg et al., 2010) or 2 µM chagasin. 
After incubation with rPfSUB1, rPbSERA3 WT was incubated with rPfSUB1-processed 
rPbSERA3 C639A in the presence or absence of E64. Next rPfSUB1 processed 
rSERA3 WT was incubated with rPfSUB1 processed rPbS3C1 to determine whether 
putative active rPbSERA3 WT processes in trans. All samples were analysed by 
Western blotting.  
 
2 Materials and Methods 
 
111 
 
Table 3: All in this work used tissues 
Product Manufacturer 
O+ Human RBCs National Blood Bank 
COS-7 cells Invitrogen, UK 
 
Table 4: Software and external services used in this work 
Software Manufacturer 
Adobe Photoshop Elements 5.0 Adobe Systems Incorporated 
Adobe Illustrator CS4 Adobe Systems Incorporated 
DNAStar Lasergene 8 DNASTAR Inc., Madison, USA 
AxioVision 3.1 software Carl Zeiss Ltd., Hertfordshire 
Primers Eurogentec Ltd., Southampton 
Sequencing Beckman Coulter Genomics, Essex 
N-terminal sequencing (Edman sequence analysis) PNAC facility, Cambridge 
Recodonised sera6 and Pbsera3 genes Geneart AG, Germany 
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Table 5: List of all primers used in this work 
Primer name Sequence (5′-3′) Function and Features 
SERA6-FL_fwd ggtattgagggtcgcgagggtaacaaggttacagttatc 
Forward amplification of full-
length SERA6 for pET-30 
Xa/LIC 
SERA6-FL_rev agaggagagttagagccttaaacataacagaagttacaa
tcttcacc 
Reverse amplification of full-
length SERA6 for pET-30 
Xa/LIC 
SERA6-P56_fwd ggtattgagggtcgcgatgacttcaacccaaacgagtaca
ag 
Forward amplification of SERA6 
central 1/2(S6C1/2) for pET-30 
Xa/LIC  
SERA6-P56_rev agaggagagttagagccttattgaccgtgaacgaaagcg
ttgtc 
Reverse amplification of SERA6 
central 1 (S6C1) for pET-30 
Xa/LIC 
SERA6-P50_rev agaggagagttagagccttacaagaagtaaacgttcttctt
ccagga 
Reverse amplification of SERA6 
central 2 (S6C2) for pET-30 
Xa/LIC 
P56_N-term_rev ctcgtcaacgttcttgatacagatagc 
Reverse amplification of SERA6 
central 1 (S6C1) N-terminus for 
pET-30 Xa/LIC 
P56internal_fwd gtgacactaactacgtttacgact Primer for PCR screen and 
sequencing 
S6_Cterm_fwd ggtattgagggtcgctctgatgaatccgacgagactaac Forward amplification of SERA6 
C-terminus for pET-30 Xa/LIC 
S6_FL_fwd_pET41_Ek_
LIC 
gacgacgacaagatggagggtaacaaggttacagttatc 
Forward amplification of full-
length SERA6 for pET-41 
Ek/LIC 
S6_FL_rev_pET41_Ek_
LIC 
gaggagaagcccggttaaacataacagaagttacaatctt
cacc 
Reverse amplification of full-
length SERA6 for pET-41 
Ek/LIC 
S6C1/2_fwd_pET41_Ek
_LIC 
gacgacgacaagatggatgacttcaacccaaacgagta
caag 
Forward amplification of SERA6 
central 1/2 (S6C1/2) for pET-41 
Ek/LIC  
S6C1_rev_pET41_Ek_L
IC 
gaggagaagcccggttattgaccgtgaacgaaagc 
gttgtc 
Reverse amplification of SERA6 
central 1 (S6C1) for pET-41 
Ek/LIC 
S6_FL_fwd_pSecTag_2 
A_Sfi1 
gagggcccagccggccgagggtaacaaggttacag 
ttatct 
Forward amplification of full-
length SERA6 for COS-7 cell 
expression 
S6_FL_rev_pSECTag_
2 A_EcoR1 
cccggattcttaaacataacagaagttacaatcttcac 
Reverse amplification of full-
length SERA6 for COS-7 cell 
expression 
SERA6-9 gctcgagattatcgttatgtccattattatgtgatatc Reverse amplification of SERA6 
promoter  
SERA6-15 gcagggaaactgtggtttggcttggatcttcgcttccaag 
Forward amplification to mutate 
catalytic Cys644 to Ala644 in 
synthetic SERA6 
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Primer name Sequence (5′-3′) Function and Features 
SERA6-16 cgtccctttgacaccaaaccgaacctagaag 
cgaaggttc 
Reverse amplification to mutate 
catalytic Cys644 to Ala644 in 
synthetic SERA6 
SERA6-17 gaagaaaaagatgaacgagatcaaggttaagttattggat
gacttcaacccaaacgagtacaagttg 
Forward amplification to 
mutate SERA6st1 from AQ to 
LL in synthetic SERA6 
SERA6-18 cttctttttctacttgctctagttccaattcaataacctactgaag
ttgggtttgctcatgttcaac 
Reverse amplification to mutate 
SERA6st1 in synthetic SERA6 
SERA6-19 gaacgattacgacaacgctttcgttcacttattatctgatgaa
tccgacgagactaacaaa 
Forward amplification to mutate 
SERA6st2 from GQ to LL in 
synthetic SERA6 
SERA6-20 cttgctaatgctgttgcgaaagcaagtgaataatagactact
taggctgctctgattgttt 
Reverse amplification to mutate 
SERA6st2 in synthetic SERA6 
SERA6_int_for cagtatacatgatatgtccttaattttttagcttt Forward amplification to 
integrate SERA6synth 
SERA6_int_rev ctcacccttgtgctcaacatcaatccttg Reverse amplification to 
integrate SERA6synth 
SERA6_5UTRb aaaagtaaaagaccaaatgata Forward amplification covering 
start codon endogenous 
SERA6-34 gtcctggaagaagaacgttgccgccgcgagacacaaca
ctgacttcatg 
Forward amplification to mutate 
Protease X site from YFL to 
AAA in synthetic SERA6 
SERA6-35 catgaagtcagtgttgtgtctcgcggcggcaacgttcttcttc
caggac 
Reverse amplification to mutate 
Protease X site in synthetic 
SERA6 
SERA6-37 aagtaggagtcggacttagaa 
Reverse amplification from 3 ′ to 
check for integration of 
SERA6st1 
SERA6-38 ctgtgatatcacataataatggac 
Forward amplification for 
Southern probe to check for 
integration of pHH-SERA6chim  
SERA6-39 cagatgatgattcagttggaag 
Reverse amplification for 
Southern probe to check for 
integration of pHH-SERA6chim 
PbS3C1_fwd_pET30 Ggtattgagggtcgctccgacgaggactccaaggaaaa
cgac 
Forward amplification of 
PbSERA3 central1 (PbS3C1) 
for pET-30 Xa/LIC 
PbS3C1_rev_pET30 agaggagagttagagccttactgtcctgacacgtccaggtt 
Reverse amplification of 
PbSERA3 central1 for pET-30 
Xa/LIC 
PbSERA3-1 ggcaactgctccctggcctggctgttcgcttc 
Forward amplification to mutate 
catalytic Cys639 to Ala639 in 
synthetic PbSERA3 
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Primer name Sequence (5′-3′) Function and Features 
PbSERA3-2 gaagcgaacagccaggccagggagcagttgcc 
Reverse amplification to mutate 
catalytic Cys639 to Ala639 in 
synthetic PbSERA3 
PbSERA3-3 gcgtctgctcaagaccaacg 
Forward amplification to 
sequence over catalytic site in 
synthetic PbSERA3 
PbSERA3-4 gacaagcttggtaccgcatgc 
Reverse amplification including 
HindIII after stop in pFast-
PbSERA3 for insect cell 
expression 
PbSERA3-5 gtatacatttcttacatctatgccgacgaagtgatcgagtcc
c 
Forward chimera of melittin and 
full-length PbSERA3 
PbSERA3-6 gggactcgatcacttcgtcggcatagatgtaagaaatgtat
ac 
Reverse chimera of melittin and 
full-length PbSERA3 
PbSERA3-7 gttttccttgcccttctggtc 
Reverse for sequencing over 
the start site in full-length 
PbSERA3 
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Table 6: Overview of all constructs used in this work  
This table includes all constructs that were designed by the author, obtained as kind 
gifts and plasmids that were designed and cloned in collaboration with Michael Shea. 
The table is a complete overview of all constructs for recombinant protein expression 
and for single homologous recombination in the parasite and special features thereof. 
Vector and product name are different in some cases and product names are labelled 
in italics and bold. Recombinant proteins will referred to as their product names 
throughout this work. 
Vector name/Product 
name Important features Function Source 
Protein expression 
constructs 
   
synthSERA6 WT 
Synthetic and recodonised 
SERA6 
Expression of 
recombinant full-
length SERA6 in P. 
pastoris 
This study and 
kind gift from Dr. 
Sharon Yeoh 
synthSERA6 C644A Synthetic and recodonised 
SERA6 C644A 
Expression of 
recombinant full-
length SERA6 
catalytic 
Cys644Ala644 
mutant in P. pastoris 
This study 
pET-30 Xa/LIC_S6FL 
or 
rS6-FL 
N-terminal S- and His- tagged 
S6-FL 
T7 promotor 
N-terminal S- and 
His-tagged full-
length SERA6 for 
protein expression in 
E. coli 
This study 
pET-30 Xa/LIC_S6C1 
or 
rS6C1 
N-terminal S- and His-tagged 
S6C1 
T7 promotor 
N-terminal S- and 
His-tagged SERA6 
central domain 1 
(S6C1) between 
SERA6st1 and 
SERA6st2 for protein 
expression in E. coli 
and antibody 
production 
This study 
pET-30 
Xa/LIC_S6C1_C/A 
or 
rS6C1 C644A 
N-terminal S- and His-tagged 
S6C1-C644A 
T7 promotor 
as rS6C1 with 
catalytic 
Cys644Ala644 
mutant 
This study 
pET-30 Xa/LIC_S6C2 
or 
rS6C2 
N-terminal S- and His- tagged 
S6C2 
T7 promotor 
N-terminal S- and 
His- tagged SERA6 
central domain 2 
(S6C2) between 
SERA6st1 and 
SERA6stX 
This study 
pET-30 Xa/LIC_S6Cterm 
or 
rS6-Cterm 
N-terminal S- and His-tagged 
S6C-terminus 
T7 promotor 
N-terminal S- and 
His-tagged SERA6 
C-terminus between 
SERA6st2 and 
SERA6 very C-
terminus for 
recombinant 
expression in E. coli 
This study 
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Vector name/Product 
name Important features Function Source 
and antibody 
production 
pET-41 Ek/LIC_S6FL 
not applied in any 
experiments 
N-terminal GST-, S- and His-
tagged S6-FL 
T7 promotor 
N-terminal GST-, S- 
and His-tagged full-
length SERA6 for 
protein expression in 
E. coli 
This study 
pET-41 EK/LIC_S6C1 
not applied in any 
experiments 
N-terminal GST-, S- and His-
tagged S6C1 
T7 promotor 
N-terminal GST-, S- 
and His-tagged 
SERA6 central 
domain 1 (S6C1) 
between SERA6st1 
and SERA6st2 for 
protein expression in 
E. coli 
This study 
pSecTag-2A_S6FL 
or 
rSERA6 WT 
N-terminal Ig κ-chainleader 
sequence 
SV40 promotor and origin 
CMV promoter 
Full-length SERA6 
wild-type for soluble 
protein expression in 
COS-7 cells 
This study  
pSecTag_2A_S6FL_C/A 
or 
rSERA6 C644A 
N-terminal Ig κ-chainleader 
sequence  
SV40 promotor and origin 
CMV promoter 
Full-length SERA6 
catalytic 
Cys644Ala644 
mutant for soluble 
protein expression in 
COS-7 cells 
This study 
pFastBac1™PbSERA3 
or 
rPbSERA3 WT 
N-terminal PbSERA3 signal 
peptide 
Full-length 
PbSERA3 for 
expression in Tn5 
cells with its own 
signal peptide 
Kind gift from 
Michael Shea 
and Fiona 
Hackett 
pFastBac1™PbSERA3 
C/A 
or 
rPbSERA3 C639A 
N-terminal PbSERA3 C639A 
signal peptide 
Full-length 
PbSERA3 catalytic 
Cys639Ala639 
mutant for 
expression in Tn5 
cells with its own 
signal peptide 
Kind gift from 
Michael Shea 
pET-30 
Xa/LIC_S6FL_S1 
or 
rS6-FLmutS1 
N-terminal S- and His-tagged S6-
FL SERA6st1 mutant 
T7 promotor 
Full-length 
SERA6st1 mutant for 
protein expression in 
E. coli 
Collaboration 
with Michael 
Shea  
pET-30 
Xa/LIC_S6FL_S2 
or 
rS6-FLmutS2 
N-terminal S- and His-tagged S6-
FL SERA6st2 mutant 
T7 promotor 
Full-length 
SERA6st2 mutant for 
protein expression in 
E. coli 
Collaboration 
with Michael 
Shea  
pET-30 
Xa/LIC_S6FL_S1S2 
or 
rS6-FLmutS1S2 
N-terminal S- and His-tagged S6-
FL SERA6st1 and st2 mutant 
T7 promotor 
Full-length 
SERA6st1 and st2 
mutant for protein 
expression in E. coli 
Collaboration 
with Michael 
Shea  
    
Transfection 
constructs    
2 Materials and Methods 
 
117 
 
Vector name/Product 
name Important features Function Source 
pHH-SERA6chim 
chimera between endogenous 
sera6 and synthSERA6 encoding 
the C-terminal 2406 bp of SERA6 
Single homologous 
recombination of 
SERA6 chimera: 
wild-type positive 
control 
Collaboration 
with Michael 
Shea based on 
pET-30 Xa/LIC 
constructs, pHH 
plasmid from 
(Child et al., 
2010) 
pHH-SERA6chimC/A 
chimera between endogenous 
sera6 and synthSERA6 C644A 
Single homologous 
recombination of 
SERA6 chimera: 
catalytic 
Cys644Ala644 
mutant 
Collaboration 
with Michael 
Shea based on 
pET-30 Xa/LIC 
constructs, pHH 
plasmid from 
(Child et al., 
2010) 
pHH-SERA6chim_mutS1 
chimera between endogenous 
sera6 and synthSERA6 
SERA6st1 mutant 
Single homologous 
recombination of 
SERA6 chimera: 
SERA6st1 VKAQ 
DDFN P2/P1 
replaced with LL 
Collaboration 
with Michael 
Shea based on 
pET-30 Xa/LIC 
constructs, pHH 
plasmid from 
(Child et al., 
2010) 
pHH-SERA6chim∆S2 
chimera between endogenous 
sera6 and synthSERA6 deletion 
of SERA6st2 
Single homologous 
recombination of 
SERA6 chimera: 
SERA6st2 deleted 
P4-P1 
Collaboration 
with Michael 
Shea based on 
pET-30 Xa/LIC 
constructs, pHH 
plasmid from 
(Child et al., 
2010) 
pHH-
SERA6chim_mutS1∆S2 
chimera between endogenous 
sera6 and synthSERA6 
SERA6st1 mutant and deletion of 
SERA6st2 
Single homologous 
recombination of 
SERA6 chimera: 
SERA6st1 deleted 
P2/P1 replaced with 
LL and SERA6st2 
P4-P1 deleted 
Collaboration 
with Michael 
Shea based on 
pET-30 Xa/LIC 
constructs, pHH 
plasmid from 
(Child et al., 
2010) 
pHH-SERA6chim_mutSx 
chimera between endogenous 
sera6 and synthSERA6 
SERA6stX mutant 
Single homologous 
recombination of 
SERA6 chimera: 
SERA6stX replaced 
P3-P1 with AAA 
Collaboration 
with Michael 
Shea based on 
pET-30 Xa/LIC 
constructs pHH 
plasmid from 
(Child et al., 
2010) 
pHH-SERA6chim_mutS2 
chimera between endogenous 
sera6 and synthSERA6 
SERA6st2 mutant 
Single homologous 
recombination of 
SERA6 chimera: 
SERA6st2 P2/P1 
replaced with LL 
Collaboration 
with Michael 
Shea based on 
pET-30 Xa/LIC 
constructs, pHH 
plasmid from 
(Child et al., 
2010) 
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Vector name/Product 
name Important features Function Source 
pHH-
SERA6chim_mutS2Sx 
chimera between endogenous 
sera6 and synthSERA6 
SERA6st2 and SERA6stX mutant 
Single homologous 
recombination of 
SERA6 chimera: 
SERA6st2 P2/P1 
replaced with LL and 
SERA6stX P3-P1 
replaced with AAA 
Collaboration 
with Michael 
Shea based on 
pET-30 Xa/LIC 
constructs, pHH 
plasmid from 
(Child et al., 
2010) 
pHH-
SERA6chim_mutS1S2 
chimera between endogenous 
sera6 and synthSERA6 
SERA6st1 and SERA6st2 mutant 
Single homologous 
recombination of 
SERA6 chimera: 
SERA6st1 and st2 
P2/P1 replaced with 
LL 
Collaboration 
with Michael 
Shea based on 
pET-30 Xa/LIC 
constructs, pHH 
plasmid from 
(Child et al., 
2010) 
pHH-
SERA6chim_mutS1S2Sx 
chimera between endogenous 
sera6 and synthSERA6 
SERA6st1, SERA6st2 and 
SERA6stX mutant 
Single homologous 
recombination of 
SERA6 chimera: 
SERA6st1 and 
SERA6st2 P2/P1 
replaced with LL; 
SERA6stX P3-P1 
replaced with AAA 
Collaboration 
with Michael 
Shea based on 
pET-30 Xa/LIC 
constructs, pHH 
plasmid from 
(Child et al., 
2010) 
pHH-
SERA6chim_mutS1Sx 
chimera between endogenous 
sera6 and synthSERA6 
SERA6st1 and SERA6stX mutant 
Single homologous 
recombination of 
SERA6 chimera: 
SERA6st1 P2/P1 
replaced with LL; 
SERA6stX P3-P1 
replaced with AAA 
Collaboration 
with Michael 
Shea based on 
pET-30 Xa/LIC 
constructs, pHH 
plasmids from 
(Child et al., 
2010) 
Parasite-derived 
SERA6    
SERA6-central Small central SERA6 fragment , 
contains papain-like domain 
/ 
P. falciparum 
culture 
supernatant 
Semi-purified SERA6 Full-length SERA6  / 
P. falciparum late 
stage schizonts 
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Table 7: Overview of various E. coli expression conditions and respective 
plasmid constructs 
E. coli strain Constructs Conditions 
BL21-Gold DE3 
pET-30 Xa/LIC_S6FL 
pET-30 Xa/LIC_S6C1 
pET-30 Xa/LIC_S6C2 
0.1, 0.5, 1 mM IPTG 
18°C, RT, 28°C, 37°C 
4 or 6 hours  
Origami™2-DE3 pLysS 
pET-30 Xa/LIC_S6FL 
pET-30 Xa/LIC_S6C1 
pET-30 Xa/LIC_S6C2 
1 mM IPTG 
RT, 30°C, 37°C  
4 or 6 hours 
Shuffle®T7 Express lysY  
pET-30 Xa/LIC_S6FL 
pET-30 Xa/LIC_S6C1 
pET-30 Xa/LIC_S6C2 
pET-41 Ek/LIC_S6FL 
pET-41 EK/LIC_S6C1 
0.1, 0.5, 1 mM IPTG 
16°C, 30°C, 37°C 
overnight 
In presence of a protease 
inhibitor cocktail (Roche) or 
any of the following protease 
inhibitor: Pepstatin, TPCK, 
Aprotinin, EDTA, E64, 
Leupeptin, PHMB, 
Chymostatin, Antipain  
or in presence of 20 mM 
proline or at pH 5.5 
Shuffle®T7 Express lysY containing 
plasmid pG-KJE8 (dnaK-dnaJ-grpE- 
groES-groEL) 
pET-30 Xa/LIC_S6FL 
pET-30 Xa/LIC_S6C1 
pET-30 Xa/LIC_S6C1_C/A 
pET-30 Xa/LIC_S6Cterm 
pET-41 Ek/LIC_S6FL 
pET-41 EK/LIC_S6C1 
0.1, 0.5, 1 mM IPTG 
16°C, 30°C, 37°C 
overnight 
TPCK: N-tosyl-L-phenylalanine chloromethyl ketone; PHMB: p-hydroxymercuribenzoate 
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Table 8: Recipes for SDS-PAGE stacking and resolving gels 
Stacking gel 4 % 
dH2O 23.66 ml 
Upper gel buffer 
500 mM Tris-HCl pH 6.8  10 ml 
Acrylamide solution (30% gel) 6.34 ml 
10% APS (ammonium persulphate) 160 µl 
TEMED (N,N,N’,N’-Tetramethyl-1-,2-
diaminomethane) 
52 µl 
 
Resolving gel 7.5% 10% 12.5% 15% 
dH2O 32 ml 26.6 ml 21.25 ml 16 ml 
Lower gel buffer 
1.5 M Tris-HCl pH 
8.8 
16 ml 16 ml 16 ml 16 ml 
Acrylamide 
solution (30% gel) 16 ml 21.4 ml 26.75 ml 32 ml 
10% APS 
(ammonium 
persulphate) 
400 µl 400 µl 400 µl 400 µl 
TEMED(N,N,N’,N’-
Tetramethyl-1-,2-
diaminomethane) 
60 µl 60 µl 60 µl 60 µl 
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Table 9: Overview of all antibodies produced and used throughout this work  
Primary 
antibodies Type Target Dilution for IFA 
Dilution 
for 
Western 
Manufacturer 
Human X509 mAb 
3D7 allele 
PfMSP1-42 1:10,000 N/A In house 
Mouse α-S6 
central 1 (α-S6C1) 
polyclonal 
SERA6-S6 
central 1 
(S6C1) 
1:1,000 1:500 In house 
Rabbit α-S6 
central 1 (α-S6C1) 
polyclonal 
SERA6-S6 
central 1 
(S6C1) 
1:1,000 1:1,000 Harlan 
Laboratories 
Mouse 1C9 (α-N-
term) 
mAb SERA6-N 
terminus 
N/A 1:1,000 In house 
Mouse α-C-term polyclonal 
SERA6-C-
terminus 
(after 
SERA6st2) 
N/A 1:500 In house 
Mouse 24C6.1F1 mAb SERA5-P50 1:1,000 1:2,000 Jean-Francois 
Dubremetz 
Rabbit α-PfSERA5 polyclonal 
Full-length 
SERA5 
1:1,000 1:10,000 Harlan 
Laboratories 
Rabbit α-Aldolase polyclonal 
Arabidopsis 
thaliana 
fructose-1,6 
bisphosphate 
aldolase 
N/A 1:2,000 Agrisera 
Rabbit α-AMA1 polyclonal 
PfAMA1-
Ectodomain 1:1,000 N/A In house 
Mouse α-
PbSERA3 (α-
PbS3C1) 
polyclonal 
PbSERA3 
central 
aa620-874 
N/A 1:3,000 
Volker 
Heussler 
Secondary 
antibodies      
Goat α-mouse-
HRP conjugate 
polyclonal Mouse IgG N/A 1:10,000 BioRad 
Goat α-rabbit polyclonal Rabbit IgG N/A 1:10,000 BioRad 
Alexa Fluor 594 α-
mouse 
polyclonal Mouse IgG 1:1,000 N/A Invitrogen 
Alexa Fluor 488 α-
mouse 
polyclonal Mouse IgG 1:1,000 N/A Invitrogen 
Alexa Fluor 594 α-
rabbit 
Polyclonal Rabbit IgG 1:1,000 N/A Invitrogen 
Alexa Fluor 488 α-
rabbit 
polyclonal Rabbit IgG 1:1,000 N/A Invitrogen 
Alexa Fluor 594 α-
human 
polyclonal Human IgG 1:1,000 N/A Invitrogen 
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Table 10: Summary of all attempted rS6C1 refolding conditions  
Buffer 
Reduced 
Glutathione 
(GSH) 
Oxidised 
Glutathione 
(GSSG) 
Nvoy Polyethylene glycol (PEG) 
Ethylenediaminetetraacetic 
acid (EDTA) 
Refolding 
Kit, Buffers 
1-9 
2 mM, 1mM 
 
0.2 mM, 1 
mM, 0.4 mM 
/ / with and without 1 mM 
Refolding 
Kit, buffer 
3 
2 mM 0.2 mM 0.1% 
0.2 mM, 0.13 
mM, 0.7 mM with and without 1 mM 
(Hodder et 
al., 2003) 1 mM (1:0.4) 
0.25 
mM(1:0.4) 
0.1% / / 
(Sijwali et 
al., 2001a) 2 mM, 1 mM 1 mM / / / 
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Table 11: List of all fluorogenic peptides used to screen for SERA6 activity 
Peptide No. Peptide sequence Peptide No. Peptide sequence 
1 
7-(Glutaryl-L-
Phenylalanine)-AMC 11 Nα-benzoyl-Arg-AMC 
2 
Acetyl-Asp-Glu-Val-Asp-
AMC 
12 Ac-Asp-Glu-Val-Asp-AMC 
3 Nα-benzoyl-DL-Arg-AMC 13 2-Gly-Gly-Leu-AMC 
4 Nα-benzoyl-L-Arg-AMC 14 2-Gly-Met-Leu-AMC 
5 
N-t-BOC-Ile-Glu-Gly-Arg-
AMC 15 Suc-Leu-Leu-Val-Tyr-AMC 
6 Ac-Val-Glu-Ile-Asp-AMC 16 nGP-AMC 
7 Z-Gly-Gly-Leu-AMC 
A (TACE substrate 
IV) Abz-LAQAVRSSSR-Dpa 
8 BOC-Arg-Val-Arg-Arg-AMC B (β-Secretease 
substrate VII) 
Abz-VKMDAE-EDDnp 
10 Ac-Trp-Glu-His-Asp-AMC 
C (Cathepsin B 
substrate) Abz-GIVRAK(Dnp)-OH 
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Figure 16: Schematic of all SERA6 constructs used for recombinant expression 
in E. coli 
SynthSERA6 WT and C644A mutant genes with SERA6st1, SERA6st2 and SERA6stX 
are displayed with relevant amino acid positions of predicted protease processing sites 
(A). According to predicted processing sites various SERA6 fragments were amplified 
from synthSERA6 and expressed with pET-30 Xa/LIC and pET-41 EK/LIC. All in E. coli 
expressed proteins are named according to name of the protein product including 
various processing site mutants (B, C). The recombinant proteins were used for 
antibody production, protease activity screens and N-terminal sequencing. 
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Figure 17: Schematic of PbSERA3 constructs used for recombinant expression 
in E. coli and insect cells 
SynthPbSERA3 WT and C639A mutant genes are displayed with relevant amino acid 
positions of predicted PbSERA3st1 and PbSERA3st2 (A). Full-length PbSERA3 was 
amplified from the synthPbSERA3 and expressed in Tn5 cells (B). PbS3C1 (fragment 
between PbSERA3st1 and PbSERA3st2) was expressed with pET-30 Xa/LIC (C). 
Schematics are labelled according to the name of the protein product. Recombinant 
material was then used for antibody production or protease activity screens. 
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Figure 18: Schematic of SERA6 expression construct in COS-7 cells 
Full-length SERA6 was amplified from synthSERA6 WT and synthSERA6 C644A and 
expressed in COS-7 cells with pSecTag_2A. The recombinant protein was then used 
for PfSUB1 processing assays. 
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Figure 19: Schematic of all SERA6 transfection constructs for P. falciparum 
transfections 
The various SERA6 integration constructs (designed by Michael Shea) are shown. To 
address the question of the importance of SERA6 processing, putative PfSUB1 and 
Protease X processing sites were modified in a manner predicted to block processing, 
either as a single-site mutants or in various combinations (A). A SERA6 wild-type 
chimera integrant served as control for each transfection. The integration strategy is 
based on single homologous recombination between the constructs and the 
endogenous sera6 locus, producing a chimeric gene (B).  
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3 SERA6: a soluble PV protein 
3.1 Introduction 
As previously described, SERA5 is a soluble PV protein which undergoes 
extensive proteolytic processing by PfSUB1 just moments before egress (Knapp et al., 
1989;Aoki et al., 2002;Miller et al., 2002b;Yeoh et al., 2007). It is the best studied and 
characterised P. falciparum SERA family member. However, very little information 
about the other SERA family members is available. Although SERA6 has a Cys residue 
in its active site and it appears to be essential for parasite survival (Miller et al., 2002b), 
only a few studies have investigated its role during the parasite life-cycle. It is important 
to determine the subcellular localisation of SERA6 in order to gain more information 
about its function as it may be specific to its localisation. Although some previous 
studies have attempted to identify the exact localisation of SERA6, low-resolution 
pictures and cross-reactive antibodies complicated the matter (Knapp et al., 1991;Aoki 
et al., 2002;Yeoh et al., 2007). SERA5 has successfully been expressed in bacterial 
cell systems for antibody production and crystallisation of the central domain (Hodder 
et al., 2009). Therefore, it was attempted to express various fragments of SERA6 in 
bacterial cell systems in order to produce reliable and specific antibodies as a tool for 
investigating the role of SERA6. It was also considered that obtaining recombinantly 
expressed and correctly folded protein would be useful for activity studies.  
Cysteine proteases often undergo extensive hydrolytic processing in order to 
become activated (Coulombe et al., 1996). SERA5 is processed by PfSUB1 in at least 
two positions. Therefore, it was hypothesised for SERA5 that cleavage by PfSUB1 
might be an activation event releasing a 56 kDa protease fragment. The last step is 
suggested to be followed by an additional processing step (mediated by Protease X) 
releasing a 50 kDa fragment indicating a possible inactivation event (Blackman, 2008). 
Alignments with SERA5 show that SERA6 might undergo a similar processing pattern 
which possibly indicates an activation event. The aim of this section of the study was to 
express various SERA6 fragments in a recombinant form in a heterologous system to 
then raise antibodies. These antibodies were then applied in biochemical and 
immunochemical approaches in order to establish that SERA6 localises to the PV.  
 
3.2 Results 
3.2.1 Bacterial expression of three recombinant SERA6 fragments (rS6-FL, 
rS6C1, rS6C2) results in insoluble proteins which were used for antibody 
production  
The production of specific antibodies as a first step on the road to SERA6 
characterisation was a primary aim of this work, for that SERA6 was expressed 
recombinantly. Based on the anticipated PfSUB1 cleavage sites (Yeoh et al., 2007), 
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and one additional C-terminal cleavage site (unpublished data), three different SERA6 
fragments rS6-FL, rS6C1, rS6C2 (representing the predicted processing products of 
SERA6) were aimed to be expressed, each with N-terminal 6xHis and S-tag for 
purification (see Figure 20).  
An extensive variety of expression systems was approached in this study and in 
collaboration (Andrea Ruecker: E. coli expression systems, COS-7 cell expression 
system; Michael Shea: yeast expression system, insect cell expression systems, wheat 
germ cell-free system). All heterologous expression systems applied previously and in 
this study are displayed in Table 12. The pET-30 Xa/LIC was the system of choice for 
expression in E. coli. The advantage of this system lies within the 3′ 5′ exonuclease 
activity of the T4 DNA polymerase which creates specific base pair overhangs that 
replace any ligation steps. In order to tackle the A/T-rich nature of the P. falciparum 
genome, the sera6 gene was recodonised (for expression in P. pastoris) and all 
amplifications were conducted using the synthetic gene as a template. The insoluble 
fractions or IB usually harbour proteins that are misfolded or not folded at all. The 
expected molecular mass of the rS6-FL, rS6C1 and rS6C2 polypeptides are 
approximately 126 kDa, 70 kDa and 66 kDa respectively. All fragments were expected 
to display a slightly increased molecular weight due to the presence of N-terminal tags 
(all fragments possess one N-terminal 6xHis- and S-tag).  
In a first attempt, E. coli BL21-Gold DE3 cells were transformed with constructs 
designed to express rS6-FL, rS6C1, rS6C2. Induction with IPTG for 4 hours at 37°C 
was approached in a first step to obtain soluble proteins of interest. The cells were 
collected and lysed with BugBuster Master Mix in order to separate soluble proteins 
from proteins expressed in IB (referred to as insoluble fraction) and subjected to SDS-
PAGE followed by Coomassie staining; non-induced samples served as controls. 
Correctly refolded proteins should be detected in the soluble fraction. Although all three 
SERA6 fragments were expressed, the majority of each protein preparation appeared 
to be in inclusion bodies. A clear band appeared for each fragment in the insoluble 
fraction compared to the non-induced samples (see Figure 21A and B, fragments 
indicated with arrows a-c). To test whether any proteins, even small amounts, were 
expressed in the soluble fraction, the insoluble and soluble fractions were also 
analysed by Western blot, detecting with commercial α-His antibodies. The non-
induced control showed that both rS6C1 and rS6C2 undergo leaky expression (see 
Figure 21C, asterisks), which can result in increased misfolding of recombinant 
proteins (Cabrita et al., 2004). Signals for both rS6C1 and rS6C2 fragments appeared 
in both the insoluble and soluble fractions, suggesting that a small amount is soluble 
(see Figure 21D). Breakdown products were detected with the α-His antibodies in 
samples from both fragments and in insoluble fraction of rS6-FL. The recombinant 
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protein bands appear stronger in the insoluble fraction, indicating that the majority of 
recombinant protein is incorrectly folded. Only very weak Western blot signals were 
detected in the rS6-FL samples, which was surprising as a strong band of the expected 
molecular mass was detected on a Coomassie Blue stained SDS-polyacrylamide gel 
(see Figure 21B). This was possibly due to poor transfer of the rather large 
recombinant protein onto the nitrocellulose membrane.  
In attempts to improve protein quantity and quality a range of induction 
conditions and times were examined. Additionally, protein expression was induced in 
the presence of protease inhibitors in order to prevent protease mediated breakdown 
(for an overview of all attempted conditions see Table 13). Shuffle T7 Express lysY 
cells express a chromosomal copy of a disulfide-isomerase in the bacterial cytoplasm 
which is known to improve folding of recombinant proteins and usually located in the 
periplasm. All conditions (as displayed in Table 13) were then analysed by a first 
screen on SDS-polyacrylamide gels stained with Coomassie Blue followed by Western 
blotting with a commercial α-His antibody. The results of this experiment showed that 
expression in Shuffle T7 Express lysY cells successfully improved the solubility of 
rS6C1 and rS6C2. Both SERA6 fragments showed increased expression levels in 
Shuffle T7 Express lysY cells compared to BL21-Gold DE3 cells, with a reduction of 
breakdown products upon overnight induction at 18°C (see Figure 22). Despite multiple 
attempts to obtain soluble protein using different expression conditions and different 
bacterial expression strains, the recombinant proteins were again predominantly 
recovered in IB. Therefore, it was decided to solubilise and refold the denatured 
proteins. Refolding of the purified protein was attempted using a variety of refolding 
conditions based on previous refolding efforts published for SERA5, falcipains and 
general refolding methods and will be analysed in chapter 5 (Sijwali et al., 
2001a;Hodder et al., 2003). Despite numerous attempts using different solubilisation 
protocols, no correctly refolded SERA6 was recovered (see chapter 5). The focus for 
purification was therefore directed towards the small amount of protein which was 
expressed in soluble form in the bacterial cytosol (see Figure 22).  
Regardless of the protein solubility, different protein purification techniques 
(Nickel-Histidine chelation, cation-anion exchange and gel filtration) failed to purify 
rSERA6-FL and rS6C1 from large scale expression preparations (see Figure 23A). The 
previous observation that the expression of rSERA6 was accompanied by breakdown 
products appeared to have a strong impact on the purification process, and the 
breakdown products were purified preferentially instead of the actual protein (see 
Figure 23A, arrow). It was therefore decided to solubilise rSERA6 from IB in 8 M urea 
to at least obtain enough material in order to raise antibodies (see Figure 23B). The 
rS6C1 was solubilised in 8 M urea, applied to a PD-10 desalting column and eluted 
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with PBS. Further purification from the eluted material failed as SERA6 was copurified 
with other proteins and breakdown products (data not shown). Therefore the PD-10 
eluate and unpurified rS6C1 was used to immunise mice and rabbits (immunisation of 
mice was conducted by Malcolm Strath), thus raising antibodies against the central 
SERA6 domain, which contains the putative catalytic domain. As purification of rS6C1 
antigen before immunisation was insufficient, the resulting mouse and rabbit polyclonal 
α-S6C1 antibodies were pre-absorbed with E. coli acetone powder in order to minimise 
any cross-reactivity with E. coli derived antigens. 
 
3.2.2 Bacterial expression of the recombinant SERA6 C-terminus results in 
soluble protein and antibody production 
The N- and C-terminal fragments of SERA5 produced upon PfSUB1-mediated 
processing are translocated to the merozoite surface where they are thought to play an 
important role in processes following egress (Li et al., 2002b). The N- and C-termini of 
SERA6 might undergo a similar fate. Antibodies against the extreme N-terminus, the 
conserved C-terminus and the putative catalytic domain were therefore required for 
differential characterisation and analysis of SERA6 localisation and proteolytic 
processing. A construct was designed to express a small C-terminal 6xHis- and S-
tagged peptide (rS6-Cterm) based on the putative PfSUB1 processing sites (see Figure 
20). This was expressed in a soluble form and was successfully purified by Nickel-
Histidine chelation followed by buffer exchange, before immunisation of mice (see 
Figure 24A, asterisk). Although the rS6-Cterm is only 18 kDa in molecular weight, a 
prominent breakdown product was observed. Western blot performed with a 
commercial α-His antibody revealed that N-terminal tags were present on the 
breakdown fragments (see Figure 24B). However, the breakdown products did not 
interfere with protein purification; they were copurified and coinjected into mice and 
antibodies were raised for further experiments (immunisation of mice was conducted by 
Malcolm Strath). The resulting polyclonal α-S6-Cterm antibodies displayed a very low 
titer constituting challenges for further experiments.  
 
3.2.3 SERA6 antibodies recognise various SERA6 fragments 
In the previous sections antibodies were raised against the recombinant SERA6 
central region between the two predicted PfSUB1 cleavage sites (mouse and rabbit 
polyclonal α-S6C1), and the recombinant C-terminus (mouse polyclonal α-S6-Cterm) 
(see Figure 25A).  
The aim of this section was to test and verify the functionality and specificity of 
the previously produced antibodies on recombinant SERA6 and parasite extracts. A 
polyclonal antibody raised against the N-terminal region of SERA6 was produced prior 
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to this work by immunisation with an E. coli-derived GST-fused to an N-terminal region 
of SERA6 and based on a construct as described elsewhere (Miller et al., 2002b) 
(conducted by Michael Shea). A monoclonal SERA6 antibody 1C9 (α-S6-Nterm, 
serotyped IgG) was also available in the lab (work conducted by Malcolm Strath). In 
total, three different antibodies were generated to investigate the fate of SERA6. All are 
expected to recognise full-length SERA6 before the putative cleavage by PfSUB1, as 
well as their cognate fragments after PfSUB1 processing.  
To examine reactivity of the antibodies with parasite-derived SERA6, total 
schizont lysates were separated by SDS-PAGE and probed in Western blots with the 
antibodies. As shown in Figure 25B, the three different antibodies all recognised a 
single band at approximately 135 kDa in the schizont lysates, presumably 
corresponding to full-length SERA6. The expected molecular weight of SERA6 is 
approximately 120 kDa, but these results agree with earlier findings that SERA6 
migrates slower than expected on SDS-PAGE (Knapp et al., 1991). In order to validate 
the specificity of the antibodies for SERA6, the nitrocellulose membranes were stripped 
and reprobed with a monoclonal antibody against SERA5 (mAb 24C6.1F1); SERA5 
was detected as a band clearly distinct from SERA6 (see Figure 25B). Weak bands 
appearing in some of the schizont lysates are ascribed to low-level processing of 
SERA5 (see Figure 25B, asterisks). As SERA5 is the most abundant SERA, the results 
suggest that the antibodies specifically recognise SERA6 with no cross-reactivity with 
other members of the SERA family.  
 
3.2.4 Antibodies against SERA6 are of low efficiency in immunoprecipitation 
To analyse the processing by PfSUB1 and to determine SERA6 protease 
activity, an efficient system for the purification of SERA6 was required. The next set of 
experiments therefore focused on whether the α-SERA6 antibodies could be used to 
immunoprecipitate SERA6 from parasite lysates.  
Frozen schizonts were subjected to hypotonic lysis in ice cold buffer and the 
soluble fraction was incubated with the monoclonal α-S6-Nterm antibody. To bind 
antibody-antigen complexes, the sample was then incubated with protein G beads and 
bound antigen was eluted in a buffer containing 500 mM NaCl. All samples were then 
analysed by Western blot with α-S6C1 antibodies. As shown in Figure 26A, although 
not all parasite-derived SERA6 was bound by the antibodies, a small amount of protein 
was eluted (see Figure 26A). Reprobing the same nitrocellulose membrane with 
polyclonal SERA5 antibodies (24C6.1F1) detected a second band below SERA6 (see 
Figure 26B). A signal for SERA6 was still visible in Western blots with SERA5 
antibodies as both antibodies were raised in mice. As expected in a non cross-linked 
assay, the IgG of the N-terminal mouse antibody was also eluted and detected with 
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polyclonal mouse α-S6C1 (see Figure 26A, asterisk). At this point the rabbit polyclonal 
was not yet available. 
In a next step it was attempted to cross-link the N-terminal antibody and the 
protein G sepharose. Cross-linking between primary amines of protein G and 
monoclonal α-S6-Nterm was unsuccessful as the antigen binding site of the antibody 
appeared to be inaccessible to SERA6 after cross-linking (data not shown). Therefore, 
to ensure that SERA6 would be eluted without the corresponding antibody, different 
elution conditions were explored showing that the antibody and SERA6 could be 
recovered in different elution fractions (see Figure 26C/D).  
Despite successful separation of the antibody and SERA6, immunoprecipitation 
never recovered sufficient material in order to progress with the characterisation of 
SERA6 processing or activity assays. In conclusion it can be said that the 
immunoprecipitation was unsuccessful and other purification methods have to be 
applied in order to obtain purified SERA6 protein. 
 
3.2.5 Immunofluorescence assays of late stage schizonts suggest that SERA6 
is localised in the PV 
Having produced antibodies specific for SERA6, the next part of the work set 
about using them to examine the subcellular localisation of the protein in the parasite. 
As a first approach, the polyclonal rabbit α-S6C1 antibodies were used to probe fixed 
smears of mature schizonts in immunofluorescence analysis (IFA). A marker for the 
merozoite surface protein MSP1 and antibodies against SERA5, a PV protein, were 
included in the IFA experiments. In a first set of experiments fixed schizont smears 
were dually labelled with SERA5 (mAb 24C6.1F1) and SERA6. The results of this set 
of experiments indicated that in highly segmented schizonts, the α-SERA6 signal 
largely shows a similar pattern as the α-SERA5 signal, possibly suggesting a PV 
localisation (see Figure 27A/B). However, signals for α-SERA5 and α-SERA6 were not 
completely identical; whilst the SERA6 signal was observed in a similar pattern to the 
α-SERA5 antibody, towards the central region of the schizonts, in 71% (of 106 
schizonts) of all dual-labelled schizonts the α-SERA6 signal also showed a strong 
accumulation towards the edges of the PV, where the α-SERA5 signal was not visible. 
These results suggest a possible PV localisation of SERA6 but with a slightly different 
distribution from SERA5 in this compartment.  
Next antibodies against SERA6 and MSP1 were used for dual labelling of fixed 
schizont smears. Antibodies against MSP1 label the surface of merozoites within the 
schizont and therefore permit a visualisation of schizont morphology similar to the 
differential interference contrast microscopy used by Glushakova et al. (Glushakova et 
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al., 2005;Glushakova et al., 2010). Highly segmented but tightly packed schizonts may 
be indicative of an intact PVM, while highly segmented schizonts with more diffuse 
merozoite localisations might indicate that the PVM has already ruptured. SERA6 
shows a broadly different pattern to MSP1 with only slight similarities of the antibody 
signals due perhaps to the nature of the iRBC morphology. In segmented but densely 
packed schizonts SERA6 is distributed throughout the PV (see Figure 27C). In IFAs 
performed on highly segmented schizonts with merozoites spread further apart, 
suggesting rupture of PVM but EPM still intact, SERA6 could not be detected in 21% 
(of 102 schizonts) of these schizonts respectively (see Figure 27D). The data therefore 
suggested that SERA6 may escape from the iRBC after PVM rupture but prior the 
rupture of the EPM. The observed pattern is due to the lack of SERA6 and not antibody 
effects as of two juxtaposed schizonts one showed a clear SERA6 signal, but the one 
which appeared to have egressed, did not. The latter showed MSP1 staining indicating 
that the antibodies were distributed efficiently (see Figure 27E). Therefore the question 
arose whether SERA6 underwent processing to full-fill its putative proteolytic function 
and then escaped from the iRBC before the rupture of the PVM. Colocalisation studies 
using antibodies against the N- and C-termini may elucidate this matter. However, it 
was not possible to obtain clear IFA signals with these antibodies presumably as both 
the N- and C-terminal antibody titers were very low. These antibodies only recognise 
SERA6 in IFAs of parasite strains expressing an additional episomal copy of SERA6 
(conducted by Michael Shea).  
Finally, the central domain of SERA6 is not detectable (using rabbit α-S6C1 
antibodies) on the surface of free merozoites (see Figure 27F). To summarise: SERA6 
appeared to be located to the PV in a manner similar to SERA5. However, a small 
percentage shows subcellular localisation distinct from SERA5, with distribution 
possibly towards the PVM. Antibodies against the SERA6 central domain did not show 
any signal in very late stage parasites, suggesting that the processed SERA6 was not 
retained in the PV after PVM breakdown. 
 
3.2.5.1 Early results suggest that the subcellular distribution of SERA6 is 
conserved in P. knowlesi 
SERA6 appears to be conserved throughout Plasmodium species and IFAs 
were performed on fixed schizont smears of a different Plasmodium species, P. 
knowlesi, using the rabbit α-S6C1 antibodies. P. knowlesi was successfully cultured 
and maintained in human RBCs (Robert Moon, unpublished) and highly synchronous 
late stage parasites were used for IFAs. Interestingly, the observed localisations were 
similar to P. falciparum SERA6, suggesting high levels of conservation between the 
central domain of SERA6 and its P. knowlesi orthologue (see Figure 28). Parasites 
3 SERA6: a soluble PV protein 
 
139 
 
were dually labelled with rabbit α-S6C1 and mouse α-PkMSP19 (which labelled the 
surface of merozoites). Although the staining pattern of PkMSP19 was somewhat 
diffuse, some merozoite surface boundaries could be observed (see Figure 28). The 
initial results from IFAs on P. knowlesi schizonts suggest that the subcellular 
distribution of SERA6 may be conserved in other Plasmodium species. 
 
3.2.6 Biochemical fractionation of infected RBCs confirms SERA6 as a soluble 
PV protein 
Colocalisation studies of SERA5 and SERA6 through IFAs suggested that 
SERA6 is located in the PV albeit in a somewhat different pattern to SERA5, a soluble 
PV protein. In this section it was attempted to confirm these previous findings by a 
complementary approach. To do this two different chemical iRBC fractionation steps 
were performed and then analysed by Western blot. The approach was based on the 
biochemical properties of the pore-forming streptolysin O (SLO), which only introduces 
pores into the EPM and saponin, a cholesterol-dependent detergent which forms pores 
in the EPM and the PVM (for a detailed overview see Figure 29A). Depending on the 
subcellular localisation of SERA6 it can then be detected in different fractions 
Highly synchronous P. falciparum schizont cultures were enriched by Percoll 
gradient centrifugation and divided into aliquots of 4x108 cells. Either saponin or SLO 
were added for 6 min at RT. All soluble P. falciparum proteins resident in the PV should 
appear in the soluble fraction after saponin treatment but in the insoluble fraction after 
SLO treatment (see Figure 29A for detailed overview). The different fractions obtained 
after centrifugation were then separated by SDS-PAGE and examined by Western blot. 
The Western blots were probed with several different antibodies. SERA5 (mAb 
24C6.1F1) was used as a control for a soluble PV protein and SERA6 (rabbit 
polyclonal α-S6C1) was expected to be detected in a similar manner. Antibodies raised 
against aldolase of Arabidopsis thaliana also recognise P. falciparum aldolase (a 
soluble parasite cytosol protein). The α-Aldolase antibody was therefore applied as 
control to ensure that the parasite plasma membrane (PPM) was still intact. 
Additionally to test that SLO did form pores in the EPM one SDS-polyacrylamide gel 
was stained with Coomassie Blue to determine the release of haemoglobin. 
As seen in Figure 29B signals for full-length SERA6 and processed fragments 
were detected mainly in the insoluble SLO fraction and the soluble saponin fraction 
(see Figure 29B, top left panel). SERA5 display a similar profile to SERA6 (see Figure 
29B, top right panel). Both proteins were detected in the fractions which contain soluble 
PV proteins. Aldolase could only be detected in the insoluble fractions, guaranteeing 
that no contents of the parasite cytosol could be found in any other fraction (see Figure 
29B, bottom left panel). Additionally, the release of haemoglobin into the soluble SLO 
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and saponin fractions (see Figure 29B, bottom right) verified the completion of the 
respective permeabilisation steps. Therefore, the results agree with previous findings 
and suggest that SERA6 is mainly present as a soluble protein in the PV. However, a 
small proportion of SERA6 can consistently (in 6 independent experiments) be 
detected in the membrane fractions after saponin treatment, possibly suggesting 
association of SERA6 with membranes. This observation is supported by the result that 
SERA6 appeared to translocate towards the edges of possibly the PVM in IFAs.  
Here, the earlier findings of Knapp et al. that SERA6 accumulates in the PV 
were confirmed, by IFA and biochemical fractionation of iRBCs (Knapp et al., 1991). 
SERA6 showed PV localisation in late stage schizonts with a partial membrane 
association. 
 
3.3 Discussion 
In this part of the study antibodies specific to three different SERA6 fragments 
were designed, produced and verified as a tool for further characterisation. In addition, 
work in this part of the study aimed to produce soluble recombinant SERA6 for activity 
and processing studies. Finally and most importantly the subcellular localisation of 
SERA6 to the PV was confirmed by using two distinct approaches: IFAs and 
biochemical fractionation of iRBCs.  
The data suggests that recombinant expression of SERA6 might be a long and 
winding road. It has previously been shown that expression of cysteine-rich malaria 
proteins and putative malarial proteases coincides very often with insolubility and 
expression or refolding challenges (Shenai et al., 2000;Rosenthal, 2004;Kumar et al., 
2007). A small number of malarial proteases which appeared challenging for 
recombinant expression at the very first attempts have later been produced in large 
amounts. However, it cannot be assumed that this will be the case for the SERA family. 
After many years of work across several laboratories, SERA5 has only been expressed 
as its putative catalytic domain (Hodder et al., 2003;Hodder et al., 2009) and twice as 
full-length protein (Li et al., 2002a; Robert Stallmach, unpublished). The high proportion 
of Cys residues in SERA6 is likely to have caused the insolubility. Previous work in the 
host lab included not only a diverse range of expression conditions in one system but 
investigation of a variety of distinct pro-and eukaryotic expression systems for SERA6, 
without success. A final approach was taken by expressing recombinant SERA6 in the 
green monkey kidney cell lines (COS-7) in order to obtain protein for activity assays 
(see chapter 5). 
However, expression trials have not been completely futile. First and most 
importantly, antibodies against various SERA6 fragments were produced and these 
constituted the key tools which were required for further SERA6 characterisation. As it 
3 SERA6: a soluble PV protein 
 
141 
 
was very challenging to purify recombinant full-length SERA6, the application of the 
monoclonal antibody for immunoprecipitation and purification of parasite SERA6 
became even more important. It was possible to purify parasite SERA6 from highly 
synchronous late stage schizonts and to separate the protein from the antibody used 
for the immunoprecipitation. Unfortunately, the monoclonal N-terminal antibody could 
not be immobilised on Protein G or any other resins to facilitate purification as this 
presumably prevented epitope binding to SERA6. In addition, not enough material was 
recovered from these approaches. The focus therefore shifted towards the purification 
of parasite-derived SERA6 through large scale gel filtration followed by anion-
exchange chromatography. These appeared more promising as parasite-derived 
SERA5 was successfully purified with these methods (Yeoh et al., 2007) (see chapter 
4).  
It has to be emphasised that SERA6 was previously, but not very convincingly, 
shown to be localised to the PV as a homologue to SERA5 (Knapp et al., 1991). To 
gain certainty, the localisation was repeated in this study with two distinct approaches. 
The results showed that SERA6 showed a similar subcellular but slightly distinct 
localisation to SERA5. Although both proteins displayed overlapping signal distribution 
in a PV lumen-like pattern, SERA6 additionally showed a concentration in its 
distribution towards what seemed to be the edges of the iRBC, perhaps suggesting a 
tendency to associate with the PVM. Interestingly, biochemical fractionation supported 
this, with a small amount of SERA6 being retained in the membrane fraction. SERA6 
staining was observed in late stage schizonts which appeared to have an intact PVM. 
As described above, late stage schizonts with a possibly ruptured PVM but intact EPM 
lost the signal for the central SERA6 domain. These results suggest a putative spatial 
and temporal co-incidence between the putative SERA6 processing and the liberation 
of merozoites from iRBCs. This was further confirmed as no α-SERA6 signal was 
detected in IFAs of late stage schizonts which were egress-inhibited with E64 (data not 
shown). Although E64 was shown to inhibit parasite egress some data suggest that it 
does not prevent the breakdown of the PVM (Salmon et al., 2001;Gelhaus et al., 
2005;Glushakova et al., 2008).  
The timing of the breakdown of the PVM during or prior egress is unknown. 
Many theories have been established which describe the fusion between the EPM and 
the PVM or even a breakdown of the EPM prior to PVM rupture preceding parasite 
egress (Winograd et al., 1999;Salmon et al., 2001;Soni et al., 2005). More recently very 
convincing evidence indicated that the PVM disintegrates before EPM rupture 
(Glushakova et al., 2005;Glushakova et al., 2008). Most studies are based on labelling 
of PVM proteins as a marker for egress. However, in order to address and follow the 
question of the events leading to parasite release a P. falciparum endogenous PVM 
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marker has to be established. P. falciparum exported protein 1 (EXP1) which is 
inserted in the PVM could serve as an appropriate candidate (Simmons et al., 
1987;Kara et al., 1988;Spielmann et al., 2006). Parasite lines expressing for example 
an epitope-tagged EXP1 could allow for colocalisation studies with SERA6 in order to 
explore whether SERA6 is associated with the PVM. Additionally, the question of 
whether the central SERA6 signal disappears with PVM rupture could be further 
explored. The results suggest that, considering SERA6 as an active cysteine protease 
located in the PV and possibly escaping before EPM rupture, it may be involved in a 
cascade leading to PVM breakdown. However, an accumulation towards the edges 
could also imply an interaction of SERA6 with the EPM. 
Intriguingly, the subcellular localisation of SERA6 and its P. knowlesi orthologue 
appeared to be conserved. The orthologue also shows a distribution across the PV with 
an accumulation towards the edges. As P. knowlesi merozoites are considerably larger 
than P. falciparum merozoites this could contribute towards the understanding of the 
subcellular localisation of a SERA6 orthologue (Lee et al., 2009). Future work is 
required to analyse whether the observed pattern is representing PkSERA4, the 
SERA6 orthologue of P. knowlesi, or whether the α-S6C1 indeed cross-reacts with 
another P. knowlesi orthologue. SERA6 and PkSERA4 share 51% identity that is 
mainly found within the central domain, including the papain-like protease domain. This 
perhaps suggests similar functions for the central domains of SERA6 and PkSERA4, 
indicating once more that PkSERA4 might serve as a model to identify the protease 
activity of SERA6 and its orthologues. The analysis of the subcellular localisation of 
PkSERA4 however requires further verification through additional biochemical analysis. 
Localisation of another SERA6 orthologue, PbSERA3, also revealed the protein to be 
hosted within the space of the PV in hepatic schizonts (Schmidt-Christensen et al., 
2008;Putrianti et al., 2009) further supporting the findings from this chapter. Work in 
this section also aimed to address the fate of the SERA6 N- and C-termini. Despite 
antibody titers in both the N- and C-terminal antibodies being sufficient to recognise 
full-length SERA6 in parasite-derived material via Western blotting, they failed to detect 
the SERA6 in IFAs (data not shown). Using antibodies against the SERA6 central 
domain, SERA6 or at least the central domain were never detected on the surface of 
merozoites. Due to the limitations that arise by using optical microscopy in combination 
with the small diameter of schizont stage iRBCs, final conclusions on the colocalisation 
of SERA5 and SERA6 cannot be drawn. Future colocalisation studies for example with 
high resolution immuno electron microscopy will be required to finalise the analysis of 
the exact spatial distribution of SERA6.  
It was therefore decided to examine the subcellular localisation of SERA6 with 
an additional approach. Infected RBCs were fractionated with saponin or SLO 
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(Ansorge et al., 1996) to separate the parasite from contents of the PV and the host 
cell cytosol or from the host cell cytosol respectively. The data showed that SERA6 is 
indeed located to the PV and therefore confirmed the IFA results. Therefore it can be 
summarised that SERA6 is a soluble PV protein which is in agreement with previous 
findings (Knapp et al., 1991;Aoki et al., 2002). However, a small proportion of SERA6 
remained associated with membranes in the biochemical fractionation of iRBCs, hinting 
at the above suggested membrane association.  
The PV is a parasite compartment of particular interest. Its function is poorly 
understood but it is known that it serves as a transit and sorting compartment for 
protein transport and nutritional uptake (Ansorge et al., 1996;Ansorge et al., 
1997;Lingelbach et al., 1998). A recent study suggested that a large proportion of 
proteins located within the PV are proteases (Nyalwidhe et al., 2006). Its surrounding 
membrane, the PVM, constitutes the contact interface between the parasite and the 
host cell. The protease PfSUB1, which plays a major role in egress, was the first 
protease found to be discharged into the PV (Yeoh et al., 2007). The PV lumen is small 
in diameter, making it perfect for processes which are spatially and temporally tightly 
regulated such as egress (Eksi et al., 2011). Recent studies demonstrated that the 
cysteine protease inhibitor E64 does not prevent breakdown of the PVM but inhibits 
egress and rupture of the EPM (Glushakova et al., 2008) which theoretically excludes a 
role of cysteine proteases in this step. In this study, it was also observed that the 
cysteine protease inhibitor E64 may not prevent the rupture of the PVM which would 
suggest that SERA6 might not be involved in the disintegration of the PVM.  
Homology modelling of the SERA5 papain-like domain with the protease 
domains of falcipain 2 and falcipain 3 (Chrislaine Withers-Martinez, unpublished) has 
suggested that the entrance to the S2 pocket in SERA5 is restricted by the aromatic 
ring of the Tyr735 residue. This Tyr residue is conserved in SERA6 (Tyr783) and 
PbSERA3 (Tyr780). E64 requires binding to the S subsites to then covalently bind to 
the active site Cys (Varughese et al., 1989). The Tyr residue in the S2-pocket restricts 
the access of E64 to the catalytic Cys residue. E64 is unlikely to fit into the SERA6 
active trough and is therefore an unsuitable inhibitor. Unusually high concentrations of 
E64 may therefore be required for inhibition of SERA6. Together with the findings from 
this section, it is possible that SERA6 is firstly expressed as a soluble PV protein and 
upon processing by PfSUB1 it may relocate to its place of function to trigger the 
breakdown of the PVM or EPM as an active cysteine protease. 
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Table 12: Overview of all heterologous expression systems used for SERA6 
Expression system Expression construct Application 
P. pastoris (Michael Shea, 
preceding this work) 
rS6-FL: Cterm 6xHis-tag 
rS6C1: no tag 
rS6C2: no tag 
Protein for antibody production 
and activity assays 
E. coli 
rS6-FL: Nterm 6xHis-tag, S-tag or 
GST-tag 
rS6C1: Nterm 6xHis-tag, S-tag or 
GST-tag 
rS6C1 C644A: Nterm 6xHis-tag, S-
tag 
rS6C2 Nterm: 6xHis-tag, S-tag or 
GST-tag 
Protein for antibody production and 
activity assays 
Wheat germ cell-free 
system (Michael Shea) rS6C2: Nterm 6xHis-tag, S-tag Protein for activity assays 
Insect cells (Michael Shea) 
rS6-FL: Cterm 6xHis-tag and V5 
epitope 
rS6C1: Cterm 6xHis-tag and V5 
epitope 
rS6C2: Cterm 6xHis-tag and V5 
epitope 
rS6-FL: no tag 
Protein for antibody production and 
activity assays 
COS-7 cells 
rS6-FL: no tag 
rS6-FL C644A: no tag Protein for activity assays 
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Table 13: Summary of all in this part applied bacterial expression systems and 
expression conditions 
E. coli strain  Construct  Expression conditions  
BL21-DE3 Gold  
rS6-FL: Nterm 6xHis-tag, S-tag 
or GST-tag or Thioredoxin-tag 
rS6C1: Nterm 6xHis-tag, S-tag or 
GST-tag 
rS6C1 C644A: Nterm 6xHis-tag, 
S-tag 
rS6C2: Nterm 6xHis-tag, S-tag 
0.1, 0.5, 1 mM IPTG 
18°C, RT, 28°C, 37°C 
4 or 6 hours  
Origami2-DE3 pLysS  
rS6-FL: Nterm 6xHis-tag, S-tag 
rS6C1: Nterm 6xHis-tag, S-tag 
rS6C2: Nterm 6xHis-tag, S-tag 
1 mM IPTG 
RT, 30°C, 37°C  
4 or 6 hours 
Shuffle ®T7 Express lysY  
rS6-FL: Nterm 6xHis-tag, S-tag 
rS6C1: Nterm 6xHis-tag, S-tag 
rS6C1 C644A: Nterm 6xHis-tag, 
S-tag 
rS6C2: Nterm 6xHis-tag, S-tag 
0.1, 0.5, 1 mM IPTG 
16°C, 30°C, 37°C 
overnight 
In presence of a protease 
inhibitor cocktail (Roche) or any 
of the following protease inhibitor: 
Pepstatin, TPCK, Aprotinin, 
EDTA, E64, Leupeptin, pHMB, 
Chymostatin, Antipain  
or in presence of 20 mM proline 
or at pH 5.5 
Shuffle ® T7 Express lysY 
containing the plasmid pG-KJE8 
(dnaK, dnaJ, grpE, groES, groEL) 
rS6C1: Nterm 6xHis-tag, S-tag 
0.1, 0.5, 1 mM IPTG 
16°C, 30°C, 37°C 
overnight 
TPCK: N-tosyl-L-phenylalanine chloromethyl ketone; pHMB: p-
hydroxymercuribenzoate 
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Figure 20: All SERA6 constructs for generation of antibodies 
The four different constructs used in this section were based on the predicted SERA6 
PfSUB1 cleavage sites (SERA6st1 and SERA6st2) and a third cleavage by an 
unknown leupeptin sensitive protease called Protease X (SERA6stX). The putative 
papain-like catalytic domain is indicated with its three active site residues: Cysteine 
(Cys644), Histidine (His810) and Asparagine (Asn835). The N-terminal 6xHis- and S-
tags for purification are shown in red. The molecular weights of the constructs are 
approximately 126 kDa (rS6-FL), 70 kDa (rS6C1), 66 kDa (rS6C2) and 18 kDa (rS6-
Cterm). The fragments were amplified from a recodonised SERA6 gene between the 
indicated amino acid residues (aa). N: N-terminus; C: C-terminus 
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Figure 21: Three different SERA6 fragments are expressed in the insoluble 
fraction in E. coli 
BL21-Gold DE3 cells were transformed with expression plasmids for expression of rS6-
FL, rS6C1 and rS6C2 and induced overnight. The cells were then lysed and soluble 
fraction (sol) and inclusion bodies (IB, insoluble fraction) were subjected to SDS-PAGE, 
and stained with Coomassie Blue to visualise expression patterns. Non-induced 
samples, taken prior to addition of IPTG, were separated via SDS-PAGE and stained 
with Coomassie Blue (A). All SERA6 fragments are mainly expressed in IB (B, a-c); 
breakdown products can be observed, particularly for rS6C1 and rS6C2. Western blots 
of the non-induced control showed that E. coli transformed with constructs for 
expression of rS6C1 and rS6C2 undergo leaky expression, showing that the fragments 
were expressed before the induction with IPTG (C, asterisks). This can cause 
increased misfolding of recombinant proteins. It appeared that rS6C1 and rS6C2 were 
expressed as insoluble and soluble proteins as bands for both fragments were present 
in both fractions (D). The breakdown fragments appeared to be carrying the N-terminal 
tags as they were detected with a commercial α-His antibody (D). Recombinant S6-FL 
could not be detected in insoluble or soluble form suggesting poor transfer from the 
SDS-polyacrylamide gel to the nitrocellulose membrane. IB: inclusion bodies; sol: 
soluble fraction after lysis with BugBuster Master Mix 
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Figure 22: Expression of rS6C1 and rS6C2 in Shuffle cells improved protein 
solubility  
In order to improve the solubility of the recombinant protein, Shuffle T7 Express lysY 
and BL21-Gold DE3 cells harbouring the relevant expression plasmids were induced 
under various conditions. The soluble fractions (sol) obtained after lysis with BugBuster 
Master Mix were subjected to SDS-PAGE (identical loadings) and detected by Western 
blotting with commercial α-His antibodies. sol: soluble fraction after BugBuster Master 
Mix lysis 
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Figure 23: Purification of rS6C1 for antibody production 
Recombinant S6-FL and rS6C1 were expressed in Shuffle T7 Express lysY cells 
overnight at 18°C. Cells were pelleted, solubilised in BugBuster Master Mix at RT and 
samples were subjected to SDS-PAGE. The majority of rS6-FL and rS6C1 appeared to 
not bind to the nickel resin and only a small amount was observed in the eluted fraction 
(A, a/b). The N-terminal tag containing breakdown products were copurified and 
constituted the largest protein quantity in the eluate (A, arrow). Despite numerous 
attempts, purification failed and focus was directed towards protein expressed in IB. All 
three SERA6 fragments were expressed in Shuffle T7 Express lysY cells at 18°C 
overnight and IB were washed several times followed by solubilisation in 8 M urea and 
fractions were separated by centrifugation. Very little recombinant protein was seen in 
the soluble fraction after BugBuster Master Mix lysis which was loaded as control (B, 
sol). The majority of rS6-FL and rS6C1 was detected in the urea fraction whereas only 
half of rS6C2 appeared to be solubilised (B, a-c). In 8 M urea solubilised rS6C1 was 
applied to a PD-10 desalting column and urea was exchanged for PBS and subjected 
to mice immunisation. sol: soluble fraction after BugBuster Master Mix lysis; UB: 
unbound after Nickel-Histidine chelation; EL: eluted fraction; urea: solubilised in urea; 
urea ins: insoluble after urea solubilisation 
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Figure 24: Recombinant expression of the SERA6 C-terminus leads to soluble 
protein and antibody production 
A small C-terminal 6xHis- and S-tagged peptide was successfully expressed, purified 
and used for antibody production. The portion of SERA6 C-terminus used for 
recombinant expression was designed based on alignments with known PfSUB1 
processing sites in SERA5. The soluble recombinant C-terminus (rS6-Cterm) was 
obtained by expression in Shuffle T7 Express lysY cells and purified using Nickel-
Histidine chelation. All samples were separated via SDS-PAGE. The rS6-Cterm was 
successfully purified (A, asterisk) albeit not without the copurification of the previously 
described breakdown products (B, asterisk). Despite several attempts the separation of 
the rS6-Cterm and the breakdown products was unsuccessful and the eluted fraction 
was used in mice immunisations in order to raise antibodies. sol: soluble fraction after 
BugBuster Master Mix lysis; UB: unbound after Nickel-Histidine chelation; EL: eluted 
fraction; Western blot probed with α-His antibodies 
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Figure 25: SERA6 is specifically recognised by antibodies raised against three 
different regions of the protein 
Schematic of SERA6 protein, showing the putative catalytic residues (C644, H810, 
N835) in the shaded papain-like domain and the predicted SERA6st1 (VKAQ↓DDFN) 
and SERA6st2 (VHGQ↓SNES). The signal peptide is indicated by a black box. The 
three different antibodies were raised against the N-terminal region (α-S6-Nterm), the 
central region (α-S6C1) and the C-terminal region (α-S6-Cterm). The bars show the 
regions of SERA6 used for immunisation (A).  
To test the specificity of the antibodies schizont lysates were probed by Western blot 
using monoclonal antibodies raised against rSERA5 (α-SERA5, mAb 24C6.1F1), 
rSERA6 central region (α-S6C1), rSERA6 C-terminus (α-S6-Cterm) or rSERA6 N-
terminus (α-S6-Nterm, mAb 1C9). A single major band is observed at approximately 
135 kDa for SERA6 and 120 kDa for SERA5. Membranes were subsequently stripped 
and reprobed with α-SERA5 or α-SERA6 to confirm that the antibodies did not cross-
react. Faint bands at lower molecular weights may indicate early processing products 
of SERA5 (asterisks). downward-pointing arrow indicates site of cleavage 
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Figure 26: Antibodies against SERA6 show low affinity in immunoprecipitation 
Frozen schizont samples were hypotonically lysed and incubated with the monoclonal 
α-S6-Nterm antibody followed by incubation with Protein G beads. The unbound 
fraction was collected after centrifugation and the beads were several times washed in 
PBS followed by an elution step with 2x SDS sample buffer and Western blot analysis. 
SERA6 was detected in the elution fraction (A, probed with polyclonal rabbit α-S6C1). 
The nitrocellulose membrane was then stripped and reprobed with monoclonal α-
SERA5 antibodies (mAb 24C6.1F1) to verify that SERA6 and not SERA5 was 
immunoprecipitated (B). The appearance of a band in the wash fractions and second 
band below SERA6 confirmed these findings.  
In a next step it was attempted to establish appropriate conditions to separate the 
antibody and SERA6 in different elution fractions. Samples were prepared as 
mentioned above. The beads were pelleted, unbound material was collected (UB) the 
resin was washed using 1. PBS (wash1) followed by 50 mM Tris-HCl, 5 mM EDTA, 
0.5% (v/v) Tx-100 pH 8.2 containing either no added salt (wash2), 500 mM NaCl 
(wash3) or 1 M NaCl (wash4). After the final wash beads were directly diluted in 2x 
SDS sample buffer. SERA6 can be detected in the 500 mM NaCl fraction without the 
presence of the antibody (C, probed with rabbit α-S6C1 antibody) as antibody can be 
found in the final fraction (D, EL, probed with mouse α-S6C1). Half of the SERA6 can 
be detected in the unbound fraction (C) which might me due to the lack of a sufficient 
amount of Protein G or insufficient binding between the antibody and the antigen. total: 
total schizont lysate; ST: start; UB: unbound; EL: elution in 2xSDS sample buffer 
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Figure 27: Immunofluorescence microscopy suggests that SERA6 localises to 
the PV of schizonts 
Fixed schizont smears were probed using polyclonal rabbit α-SERA6 (α-S6C1) 
antibodies (green), as well as monoclonal α-SERA5 (mAb 24C6.1F1, PV marker) or 
monoclonal α-MSP1 (mAb X509, labels the merozoite surface) antibodies (red). Nuclei 
were stained with DAPI. SERA6 partially showed a similar distribution with the PV 
marker SERA5 but it appeared as if it displayed a stronger staining at the periphery of 
the iRBC (A, late schizont and B, early schizont). The SERA6 signal appeared to 
surround the merozoites (α-MSP1, C-F). In some late schizonts, SERA6 staining was 
absent (D). This may be the result of diffusion of SERA6 out of the PV after 
permeabilisation or breakdown of the PVM during late schizont stages but with a still 
intact EPM. The observed staining patterns were not due to antibody effects as of two 
juxtaposed schizonts one was labelled and the other schizont was not (E). No signal 
against the central domain of SERA6 (α-S6C1) was observed on the surface of 
merozoites (F). 
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Figure 28: The SERA6 P. knowlesi orthologue displays similar subcellular 
localisation 
P. knowlesi parasites were grown in human blood and fixed schizont smears were 
probed using polyclonal rabbit α-S6C1 antibodies (green) as well as antibodies against 
P. knowlesi MSP19 which labelled the surface of merozoites (mouse polyclonal, red). 
Treatment with the SERA6 central antibody gave a similar signal distribution in P. 
knowlesi and the above described pattern of P. falciparum late stage parasites, with an 
accumulation towards the parasite periphery. The cross-reactivity of the antibody with 
P. knowlesi parasites was due to the fact that it was raised against the SERA6 central 
domain, which is highly conserved between both SERAs. The signal for the P. knowlesi 
SERA6 orthologue appeared to surround the merozoites with the same pattern as 
SERA6 but without display of overlapping signal distribution with PkMSP19. 
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Figure 29: Biochemical fractionation of iRBCs suggests that SERA6 is a soluble 
protein localised to the PV 
Overview of the methods used for biochemical fractionation of iRBCs (A). Upper half of 
schematic: SLO permeabilises the EPM leading to the release of soluble cytosolic 
iRBC material. Bottom half of schematic: saponin permeabilises both the EPM and 
PVM, leading to the release of soluble RBC and PV material.  
Schizonts were fractionated with SLO or saponin. Pellet and supernatants were 
separated by SDS-PAGE and probed by Western blot using rabbit α-S6C1 (B, top left 
panel), α-SERA5 (B, top right panel) or α-Aldolase (B, bottom left panel). The samples 
were also stained with Coomassie Blue to reveal the major protein species at 16 kDa, 
haemoglobin (B, bottom right panel). SERA6 was present in the pellet fraction after 
SLO treatment (pel), but in the supernatant after saponin treatment (sup), suggesting 
that SERA6 is a soluble PV protein. A small amount of SERA6 remained in the saponin 
pellet fraction. SERA5, a known PV protein, served as a positive control. Aldolase, a 
cytosolic parasite protein, served as control for parasite lysis. Haemoglobin, a soluble 
RBC protein, served as a control for SLO and saponin permeabilisation of the RBC. 
EPM: erythrocyte plasma membrane; PVM: parasitophorous vacuole membrane; total: 
total schizont lysate; pel: pellet; sup: supernatant 
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4 SERA6 processing by PfSUB1 is indispensable in the parasite 
4.1 Introduction 
The aims of the work described in this chapter were to examine the processing of 
SERA6 by PfSUB1 in vitro and in the parasite and to determine the physiological 
relevance of this processing. The experimental approaches were as follows: in vitro 
processing of SERA6 was first analysed by processing both rSERA6 derived from 
COS-7 cells and parasite-derived SERA6 with rPfSUB1. These results were then used 
to investigate SERA6 processing in the parasite. Next, identification of the PfSUB1 
processing sites was attempted by N-terminal sequencing of processed rSERA6 
(Edman, 1949). This was followed by addressing the question of whether SERA6 
processing by PfSUB1 is important for parasite survival by attempting to modify 
processing sites in the genomic sera6 gene. In a final step it was attempted to verify 
the conservation of PfSUB1 processing within SERA6 and its orthologue PbSERA3 to 
establish PbSERA3 as a model for SERA6. 
 
4.2 Results 
4.2.1 Processing of recombinant SERA6 by recombinant PfSUB1 generates 
fragments of predicted molecular masses 
As recombinant expression of soluble and correctly folded SERA6 in bacteria 
proved challenging (see 3.2), extensive efforts were made to explore a variety of 
alternative expression strategies. COS-7 cells are derived from green monkey kidney 
cells and express the large T antigen of the simian vacuolating virus 40 (SV40) which 
increases replication and transcription efficiency of vectors carrying the SV40 promotor 
and origin of replication (Gluzman, 1981).  
To attempt expression of SERA6 using the COS-7 cell system, the SERA6 WT 
coding sequence and rSERA6 C644A were cloned into the pSecTag_2A vector, in both 
cases fused to the plasmid-derived murine N-terminal Ig κ leader sequence to ensure 
secretion of the recombinant protein (Coloma et al., 1992). The constructs were 
transfected into COS-7 cells and a variety of small scale expression conditions 
examined to identify the conditions that led to the highest amount of rSERA6 secreted 
into the culture supernatant. As it is unknown whether any Plasmodium proteins 
undergo N- or O- linked glycosylation in the parasite the transfected COS-7 cells were 
cultures in the presence of tunicamycin to prevent N-glycosylation during the 
expression of rSERA6 in COS-7 cells (Ulhoa et al., 2001). Recombinant expression 
samples, including supernatants and cells, were collected at 2, 3 or 4 days after 
transfection and analysed by Western blot using rabbit α-S6C1. The same Western 
blot also included a schizont extract control, which was obtained by lysing late stage 
schizonts directly with SDS sample buffer. As shown in Figure 30, highest quantities of 
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soluble recombinant protein were obtained after transient expression for 4 days. 
However, Figure 30 also shows that the majority of rSERA6 accumulated 
intracellularly. Only a small proportion of the total rSERA6 was secreted into the culture 
supernatant. This was detected by Western blot examination of 4-day culture 
supernatants as a closely-spaced doublet. The lower band of this doublet comigrated 
with the full-length SERA6 signal detected in schizont samples (see Figure 30A, 
asterisk). The top band of the doublet was predicted to be glycosylated form of 
rSERA6, perhaps resulting from inefficient blockade of glycosylation by tunicamycin. To 
attempt to increase the efficiency of the tunicamycin treatment, it was therefore decided 
to examine whether an increase in the concentration of tunicamycin could completely 
prevent production of the higher molecular mass component of the doublet. As shown 
in Figure 30B, it was indeed found that increasing tunicamycin levels in the expression 
experiments resulted in secretion of only a single form of rSERA6 corresponding to the 
faster-migrating component of the doublet, consistent with it now efficiently blocking N-
glycosylation of the secreted protein . 
Having shown successful expression of soluble rSERA6, it was now possible to 
investigate its proteolytic processing by rPfSUB1. The rSERA6 containing COS-7 cell 
culture supernatants were concentrated, resuspended in PfSUB1 activity buffer and 
incubated in the presence of rPfSUB1. To ensure that any rSERA6 processing 
observed was solely due to rPfSUB1 and not contaminating proteases, samples of the 
rSERA6 were also incubated either alone or with both rPfSUB1 and rPD, a potent and 
selective inhibitor of PfSUB1. Mixtures were incubated at 37°C and samples taken at 
different time points were analysed by Western blot using the rabbit α-S6C1. As shown 
in Figure 31, these experiments showed that incubation of either rSERA6 WT or 
rSERA6 C644A with rPfSUB1 resulted in conversion of the presumed full-length 135 
kDa rSERA6 to a ~75 kDa fragment (see Figure 31, c), via two intermediate products 
of ~125 and ~100 kDa (see Figure 31, a and b respectively). Minimal processing of 
SERA6 was observed in the additional presence of rPD, consistent with the observed 
processing being derived from rPfSUB1 activity, rather than from contaminating 
proteases; the very low level processing observed in the rPD sample is assumed to be 
due to an incorrect ratio of rPfSUB1 and the inhibitory rPD, under which conditions 
rPfSUB1 would be incompletely inhibited.  
As described above, an in silico analysis of SERA6 cleavage sites predicted 
processed fragments of ~120 kDa (full-length), ~78 kDa and ~64 kDa. The ~78 kDa 
fragment was expected to be seen after processing at SERA6st1 and the ~64 kDa was 
predicted to appear after processing at SERA6st1 and SERAst2, both forms contain 
the central papain-like protease domain. As it is known that full-length SERA6 migrates 
slower than predicted on SDS-polyacrylamide gels under reducing conditions (Knapp 
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et al., 1991), the fragments observed at ~135 kDa, ~100 kDa and 75 kDa might 
therefore resemble the predicted SERA6 forms. In conclusion the results from this 
section demonstrated for the first time that rSERA6 can be a substrate for PfSUB1. The 
data also suggested that SERA6 might be processed at the predicted cleavage sites 
based on predicted molecular masses. 
 
4.2.2 Parasite-derived SERA6 is processed by PfSUB1 in vitro 
The results from the previous section showed that rSERA6 can be processed 
by rPfSUB1 in vitro, leading to three different fragments detectable by Western blot 
with antibodies specific for α-S6C1. The next set of experiments aimed to examine the 
important question of whether SERA6 processing by PfSUB1 also occurs in the 
parasite. This was approached in two ways - firstly, by analysing the processing of 
parasite-derived SERA6 in vitro; and secondly, by comparing these processed samples 
with mature schizont extracts on Western blots, harvested under conditions where 
PfSUB1 discharge into the PV would likely have taken place at least to some extent, 
potentially exposing the endogenous SERA6 to the protease.  
Before processing of parasite-derived SERA6 could be analysed in vitro the 
protein had to be purified from parasite extracts. Synchronous late stage 3D7 parasites 
(harvested 42 hours post-invasion) were hypotonically lysed and the extracts submitted 
to size-exclusion chromatography followed by anion-exchange chromatography, as 
previously described for SERA5 (Yeoh et al., 2007). As seen in Figure 32 SERA6 was 
successfully purified. The anion-exchange chromatography peak fractions (fractions 33 
and 34) that contained parasite-derived SERA6 were then pooled, concentrated and 
resuspended in PfSUB1 activity buffer. The preparations are subsequently referred to 
as parasite-derived SERA6.  
To address the question of whether parasite-derived SERA6 can be processed 
by rPfSUB1 in vitro, samples of parasite-derived SERA6 were then incubated with 
rPfSUB1. To ensure that any processing seen was solely due to rPfSUB1 and not 
contaminating proteases, possibly copurified with parasite-derived SERA6, samples of 
parasite-derived SERA6 were also incubated alone or with both rPfSUB1 and rPD. 
Samples of the digests were taken at different time points and analysed by Western 
blot using the rabbit α-S6C1. Figure 33A shows that processing by rPfSUB1 was 
detectable after 30 min, whereas the control preparations showed no or very little 
proteolysis. The SERA6 processing seen was not caused by contaminating proteases, 
as samples lacking rPfSUB1 were stable even after two hours at 37°C. The sample 
containing both rPfSUB1 and rPD showed slight processing, but this was probably the 
result of adding the enzyme moments before the rPD. Processing appeared not to go 
to completion in the presence of rPfSUB1 as even after two hours several fragments 
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could be observed. The results demonstrated that parasite-derived SERA6 was 
processed by rPfSUB1. The processing fragments observed at ~125, ~100 kDa and 
~75 kDa appear identical to the processing fragments of COS-7 cell derived SERA6. 
 
4.2.3 PfSUB1 is responsible for SERA6 processing in the parasite 
Although the above experiments showed that parasite-derived SERA6 can be 
processed in vitro by rPfSUB1, the important question remained whether this also 
occurred under endogenous conditions in the parasite. It was therefore decided to 
assay whether the pattern of processing that appeared during SERA6 processing in 
vitro can also be observed in very late stage 3D7 parasites where it was anticipated 
that release of PfSUB1 into the PV would have commenced. If PfSUB1 was 
responsible for processing of endogenous SERA6 in the parasite, it would be predicted 
that SERA6 fragments from late stage schizonts and the in vitro processed parasite-
derived SERA6 would comigrate on Western blot. Late stage schizonts were obtained 
by monitoring synchronised parasite cultures from 36 hours post invasion onwards 
assessing the maturity of the schizonts by examination of Giemsa stained smears 
every 60 min. At the first signs of schizont rupture, the parasite cultures were collected, 
pelleted and extracted in sample buffer to produce schizont extracts. These were then 
examined by Western blot in comparison with in vitro-processed parasite-derived 
SERA6. Figure 33B shows that the in vitro processing fragments and fragments from 
the processing in the parasite appeared to comigrate at least partially. This suggests 
that the processing of SERA6 observed in vitro mimics endogenous SERA6 processing 
in the parasite.  
The results shown above were the first ones to imply that endogenous SERA6 
is indeed processed by PfSUB1 in the parasite. To further explore whether in vitro 
processing of SERA6 is similar to the processing pattern of endogenous SERA6 in the 
parasite, further assays were done to examine whether products of COS-7 cell derived 
rSERA6 processed by rPfSUB1 comigrate with endogenous SERA6 fragments from 
schizont extracts. COS-7 cell derived rSERA6 was processed with rPfSUB1 and 
samples taken at four different time points were compared to schizont extracts by 
Western blot. As shown in Figure 33C all the bands corresponding to processed 
fragments of rSERA6 comigrate with bands visible in schizont extracts. This suggested 
that processing of COS-7 cell derived SERA6 in vitro was indeed similar to 
endogenous SERA6 processing in the parasite. In conclusion the assays performed in 
this section have shown that PfSUB1 appears to process SERA6 in the parasite.  
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4.2.4 Confirmation of previously predicted PfSUB1 cleavage sites and 
identification of an additional and previously unpredicted N-terminal 
processing site  
Having confirmed that endogenous SERA6 is indeed cleaved by PfSUB1 in 
vitro and in the parasite it was important to establish the precise identity of the PfSUB1 
cleavage sites in SERA6. It was also noted that the appearance of a SERA6 fragment 
at ~125 kDa (just below full-length SERA6) during all processing assays indicated that 
SERA6 may contain a third PfSUB1 processing site. N-terminal sequencing is the only 
direct way to precisely determine protease cleavage sites after proteolytic processing. 
Therefore it was attempted to N-terminally sequence the fragments of rSERA6 
produced following digestion with rPfSUB1 to identify all PfSUB1 processing sites. In 
anticipation that cleavage occurred at the predicted sites, a number of rSERA6 mutants 
were designed containing mutations expected to block PfSUB1 processing. This had 
the advantage that the cleavage sites were not only confirmed by N-terminal 
processing but it could also be shown that the alteration of the predicted cleavage sites 
prevented PfSUB1 processing 
PfSUB1 has previously been shown to be incapable of cleaving peptides with a 
Leu residue in the P2 or P1 position (Koussis et al., 2009). Accordingly, the following 
mutations (see Figure 34A) were introduced into the predicted PfSUB1 cleavage sites 
in SERA6: SERA6st1 (VKAQ↓DDFN to VKLLDDFN) to generate rS6-FLmutS1; 
SERA6st2 (VHGQ↓SNES to VHLLSNES) to generate rS6-FLmutS2 or both (rS6-
FLmutS1S2). As rS6-FLmutS1S2 had both PfSUB1 processing sites altered, this 
recombinant protein was not expected to undergo any processing at all by rPfSUB1. All 
three mutants and SERA6 WT were expressed as IB in E. coli, and the proteins 
purified by excision from an SDS-polyacrylamide gel. The purified proteins were then 
in-gel digested with rPfSUB1, the digestion products separated by SDS-PAGE, 
transferred onto a PVDF membrane (suitable for N-terminal processing) and stained 
with Coomassie Blue (see Figure 34B for an experimental overview of this protocol).  
Analysis of the Coomassie Blue stained SDS-polyacrylamide gels showed that 
the SERA6 WT (~135 kDa) was digested to a terminal product of ~75 kDa (seeFigure 
35A, a). Recombinant S6-FLmutS1 was cleaved to form a larger final product of 110 
kDa via an intermediate of 125 kDa (see Figure 35A, b). Recombinant S6-FLmutS2 
was cleaved to a final product of 100 kDa (see Figure 35A, c). Surprisingly rS6-
FLmutS1S2 (which was predicted to not undergo any processing) was also processed 
to a ~125 kDa product, indicating the presence of a third unpredicted PfSUB1 
processing site (see Figure 35A, d). A small 14 kDa processing fragment, possibly 
representing the C-terminus of rSERA6, was only present in digests of rS6-FL or rS6-
FLmutS1, (see Figure 35A, bottom panel, e). The results suggested that alterations 
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made to the PfSUB1 cleavage sites in SERA6 indeed affected processing in those 
sites.  
N-terminal sequencing was then performed on the various digestion products to 
determine the sequence of the PfSUB1 cleavage sites. The results of these are shown 
in Figure 35B. The two previously predicted sites were confirmed, and one extra 
cleavage site in the N-terminus (SERA6st3) identified as VVSS↓SESG (see Figure 
35B). In conclusion results from this section have shown that SERA6 is processed by 
PfSUB1 in three, and not as predicted, two processing sites. These results were 
verified by showing that the alteration of these sites prevent PfSUB1 processing of 
SERA6 in vitro. 
 
4.2.5 Processing of SERA6 by PfSUB1 at at least one site is indispensable for 
parasite survival  
Having shown that SERA6 is processed by PfSUB1 in the parasite, it was 
decided to address the biological importance of this by attempting to selectively perturb 
processing of endogenous SERA6 in the parasite. The results from the previous 
section showed that the modification of the PfSUB1 processing sites in SERA6 blocked 
processing of the recombinant protein in vitro. Therefore to prevent PfSUB1 processing 
in the endogenous SERA6, the above identified SERA6 cleavage sites were partially 
replaced or deleted in the genomic sera6 gene in the 3D7 P. falciparum clone using 
single homologous recombination. If the maturation of SERA6 was required for parasite 
survival the integration of modified processing sites would not be tolerated and no 
homologous recombination events would be detected in those parasite lines. If 
however the processing at one or several sites was dispensable the respective parasite 
lines should integrate the modified processing sites and homologous recombination 
events would be detected. 
To perform the targeted recombination experiments, a transfection plasmid was 
designed based on previously used strategies (Yeoh et al., 2007;Child et al., 2010). 
This involves production of a chimeric gene consisting of an N-terminal genomic 
segment of the sera6 gene fused in frame to the C-terminal domain of a recodonised 
sera6 gene. Integration of this construct into the sera6 locus would be expected to 
reconstitute the entire sera6 coding sequence in the form of a chimeric gene. Given 
that the recodonised sera6 gene shares only little nucleotide identity with the genomic 
sera6, no recombination should occur downstream of the fusion between the genomic 
and the recodonised sera6, enabling the incorporation of desired mutations into the 
recodonised sequence. This approach also conferred advantage for the subsequent 
analysis of integrated lines. Nine integration constructs were produced, each containing 
mutations designed to alter the amino acid sequence of the PfSUB1 processing sites, 
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either individually or in combination. One additional construct (SERA6chim) was 
designed to leave the processing sites unaltered, thereby serving as a control to show 
that the sera6 locus is accessible to homologous recombination. See Figure 36A for an 
overview of the construct design, whilst Table 6 shows an overview of all transfection 
constructs. 
Each plasmid was transfected into 3D7 P. falciparum parasites on at least 3 
independent occasions and the parasite cultures subjected to drug cycling to select for 
parasites in which integration has taken place. After two to four drug cycles, genomic 
DNA from the parasite lines was examined using a diagnostic PCR to test whether 
transfected plasmids had integrated as expected into the targeted sera6 locus. The 
primers used for the diagnostic PCR were designed to bind to recodonised sera6 and 
were unlikely to anneal to genomic sera6 making the identification of integrant lines 
more specific (see Figure 36A).  
According to the results from the PCR (see Figure 36B), integration was 
detected for: the SERA6 WT (pHH-SERA6chim) as well as SERA6st2 deletion (pHH-
SERA6chim∆S2, -SNES), SERA6st2 partial substitution (pHH-SERA6chim_mutS2, 
SERA6st2: VHLLSNES) and the combination of SERA6st2 partial replacement and 
SERA6stX (pHH-SERA6chim_mutS2Sx, SERA6st2: VHLLSNES, SERA6stX: 
VAAARHNP). Southern blot analysis was then performed in an attempt to confirm the 
integration of the PCR positive parasite lines. As shown in Figure 36C one band at 
~3.3 kbp which is specific for a successfully integrated sera6 locus was detected by 
Southern blot analysis for: pHH-SERA6chim, pHH-SERA6chim∆S2, pHH-
SERA6chim_mutS2 and pHH-SERA6chim_mutS2Sx. The same Figure also showed a 
band which was indicative for the presence of the transfection plasmid or the genomic 
and unmodified sera6 gene as both would be detected at ~9.5 kbp (see Figure 36C, 
asterisk).  
Collectively, the results of this analysis showed that SERA6st1 appeared to be 
completely refractory to genetic disruption whereas SERA6st2 deletion and partial 
substitution were tolerated by the parasite. SERA6stX was refractory to genetic 
manipulation except in combination with the SERA6st2 substitution, which is surprising 
as SERA6stX was not integrated individually. Therefore some but not all PfSUB1 
processing sites appeared to be required for parasite survival. 
 
4.2.6 Recombinant PbSERA3 serves as a substrate for PfSUB1 
4.2.6.1 Recombinant PbSERA3 undergoes processing by PfSUB1 
Expression of P. falciparum SERA6 has proven to be difficult. In order to further 
explore the function of this protein it was decided to attempt expression of the P. 
berghei orthologue, PbSERA3. Recombinant PbSERA3 could not only give further 
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insights into the proteolytic maturation pattern of the “Cys-type” SERA family members, 
it might also be used to screen for proteolytic activity. Identifying the proteolytic activity 
of rPbSERA3 will beneficial for identifying a variety of substrates. These substrates 
could then be used to screen for the proteolytic activity of SERA6.  
Alignments between PbSERA3 and SERA6 revealed that both carry PfSUB1 
processing sites in similar locations (see Figure 15). This suggested that PbSERA3 
was likely to undergo processing by PfSUB1  at two sites similar to SERA6 (SERA6st1 
and SERA6st2) which will be referred to as PbSERA3st1 and PbSERA3st2. Two 
different PbSERA3 constructs for recombinant expression in insect cells were 
designed: One construct reconstituted the full-length PbSERA3 wild-type (called 
rPbSERA3 WT); the second construct had the putatively catalytic Cys residue 
substituted with an Ala residue creating a catalytic site mutant (called rPbSERA3 
C639A). The rPbSERA3 C639A mutant was aimed to be used in activity studies of 
rPbSERA3 which will be described and discussed in chapter 5. Recombinant 
PbSERA3 WT and rPbSERA3 C639A were transiently expressed in insect cells (Tn5 
cells) in the presence of tunicamycin and supernatants containing the recombinant 
protein were collected after three days. The recombinant protein was purified using 
anion-exchange chromatography followed by size-exclusion chromatography and 
eluted in PfSUB1 activity buffer. Fractions were analysed by Western Blot with α-
PbS3C1 antibodies (against the central PbSERA3 domain). Figure 37A showed that 
both recombinant proteins were eluted between fraction 31 and 33 on the final 
chromatography step (see Figure 37A). 
To next examine processing of PbSERA3 by PfSUB1, the purified proteins were 
subjected to processing assays with rPfSUB1, following a procedure similar to that 
used to examine recombinant and parasite-derived SERA6 (see 4.2.1). To ensure that 
any processing observed was due to rPfSUB1 and not contaminating proteases, 
samples of the rPbSERA3 were also incubated alone or in the presence of both 
rPfSUB1 and rPD. Figure 37B shows that both rPbSERA3 proteins were processed by 
rPfSUB1, with the full-length rPbSERA3 being converted efficiently to a fragment at 
~100 kDa followed by a further conversion to fragments of ~75 kDa and ~48 kDa (see 
Figure 37B, arrows a-c). Interestingly, rPbSERA3 WT but not rPbSERA3 C639A were 
further converted to a fragment of ~42 kDa (see Figure 37B, arrows d-e). It was 
suggested that the 75 kDa fragment might correspond to the same fragment in SERA6, 
S6C1, and will now be referred to as PbS3C1. The results showed that both proteins 
are substrates for PfSUB1, although with a processing pattern that was not consistent 
with the predicted pattern.  
 
4 SERA6 processing by PfSUB1 is indispensable in the parasite 
 
174 
 
4.2.6.2 Recombinant PbSERA3 undergoes processing by PfSUB1 in an 
additional and unpredicted internal processing site 
The results of the previous section implied that rPbSERA3 WT and rPbSERA3 
C639A are both processed by rPfSUB1. Only two PfSUB1 cleavage sites were 
originally predicted within PbSERA3, but the results showed that both rPbSERA3 
proteins were processed at more than two sites as several fragments appeared during 
the rPfSUB1 processing assay. As rPbSERA3 should serve as a model for SERA6 it 
was important to establish a clear understanding of the processing of rPbSERA3. 
Therefore the next set of experiments attempted to identify the protease responsible for 
the processing step leading to the 48 kDa fragment. The appearance of a 42 kDa 
rPbSERA3 WT form will be discussed in chapter 5. The 48 kDa fragment was found to 
contain the central-papain like domain as it was repeatedly detected with antibodies 
which were raised against this central PbSERA3 domain. It was therefore likely that the 
48 kDa fragment was the product of an additional processing of PbS3C1 (PbSERA3 
between both predicted PfSUB1 cleavage sites). To test whether rPfSUB1 was 
responsible for this, a construct for the recombinant expression of PbS3C1 was 
designed. The resulting protein would precisely span the PbSERA3 sequence between 
the predicted PbSERA3st1 and PbSERA3st2 and it would also carry an N-terminal 
6xHis-tag followed by an S-tag (see Figure 38A). It was expected that if the 48 kDa 
fragment was the product after processing rPbSERA3 WT between PbSERAst1 and 
PbSERA3st2, rPbS3C1 should be processed by PfSUB1 to a product of the same 
molecular mass as the 48 kDa fragment. The recombinant rPbS3C1 was expressed in 
E. coli where it accumulated in insoluble IB, the IB were solubilised and rPbS3C1 
purified by Nickel-Histidine chelation. The rPbS3C1 was then incubated with rPfSUB1 
at 37°C, samples were taken at two time points and analysed by Western blot with α-
PbS3C1 antibodies. As seen in Figure 38B the unprocessed rPbS3C1 was detected at 
~66 kDa. Samples containing rPbS3C1 and rPfSUB1 showed a major fragment 
appearing at ~48 kDa and the 66 kDa band was detected with only a very faint signal 
(see Figure 38B, left hand panel). Further examination of the same samples showed 
that the processed rPbS3C1 no longer reacted with the 6xHis-specific monoclonal 
antibody. This was due to the loss of the N-terminal 6xHis-tag suggesting that the 
processing took place at the N-terminal end of the rPbS3C1 (see Figure 38B, right 
hand panel). The results demonstrated that rPbS3C1 is cleaved by rPfSUB1 causing 
the appearance of a 48 kDa fragment.  
To attempt to identify this third PfSUB1 processing site, samples of rPbS3C1 
digested with rPfSUB1 were examined by N-terminal sequence analysis. The N-
terminal sequence of the ~48 kDa digestion product was identified (see Figure 38C) 
consistent with cleavage taking place at the motif AIGQ↓NEEP (the downward-pointing 
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arrow indicates the site of cleavage). In summary, this analysis established that 
PbSERA3 undergoes proteolytic processing by PfSUB1 at at least three sites.  
 
4.3 Discussion 
4.3.1 Challenges of recombinant SERA6 expression  
Recombinant protein expression is often accompanied by multiple challenges 
especially in proteins as cysteine rich as SERA6. Throughout this study six 
heterologous expression systems were tested to obtain soluble and correctly refolded 
SERA6. Most approaches led to insoluble protein or no protein expression at all. The 
most promising strategies turned out to be expression in bacterial cells and COS-7 
cells. Bacterial cells produced very high protein quantities which were however 
insoluble. Extensive investigation into improvement of the bacterial expression 
conditions did not lead to soluble SERA6 and most purification attempts were 
unsuccessful. COS-7 cells secreted soluble full-length SERA6 into the culture 
supernatant but in very low quantities. Considerable efforts were made towards the 
improvement of expression conditions in COS-7 cells in order to increase soluble 
protein amounts. As the transfection efficiency was rather low (5%, the cells were 
transfected at three independent occasions) a variety of transfection methods were 
applied, e.g. electroporation or different concentrations of the transfection reagent. It is 
known that alteration of these conditions can have a huge impact on protein solubility 
and protein quantities. However, the increase to a transfection efficiency of 50% (the 
cells were transfected at three independent occasions) did not lead to an increase in 
recombinant protein amounts or elevated secretion levels. Despite these attempts to 
improve secretion levels the majority of the recombinant full-length SERA6 protein 
remained intracellular. As the COS-7 cells were grown attached to sterile culture flasks 
the transfection efficiency in future experiments may be increased by using cells 
cultured in suspension. This would increase the access to the cell surface area to 
internalise the plasmid vector. 
 
4.3.2 SERA6 is processed by PfSUB1 in vitro and the parasite 
The results from this chapter suggested that recombinant and parasite-derived 
SERA6 both undergo cleavage by rPfSUB1 in vitro. Further work showed that SERA6 
processing patterns in vitro and in the parasite were mostly identical, strongly 
suggesting that PfSUB1 is responsible for cleaving SERA6 in the parasite. At the 
beginning of this work it was predicted that SERA6 undergoes processing by rPfSUB1 
in two sites. Cleavage at these two steps would be expected to convert the full-length 
SERA6 (120 kDa) via an intermediate of ~90 or ~76 kDa (depending on the order of 
PfSUB1 cleavage) to a final fragment of ~64 kDa which contains the putative catalytic 
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domain. The experimental results from this chapter indicate that the three major 
fragments observed during PfSUB1 processing are ~125 kDa, ~100 kDa and ~75 kDa 
(based on migration on SDS-polyacrylamide gels). Full-length SERA6 migrated at ~135 
kDa, larger than the predicted 120 kDa. The appearance of a band at ~125 kDa was 
not predicted as an event caused by PfSUB1. This suggested that SERA6 contains an 
additional PfSUB1 cleavage site on the N-terminus, similar to that observed for some 
allelic forms of SERA5 (Li et al., 2002b). It can be excluded that this step might have 
been an in vitro processing artefact as bands of the same molecular weight appeared 
during processing in the parasite. This event is likely to be the first SERA6 cleavage 
step as the 125 kDa fragment disappeared during processing assays and smaller 
products accumulated. Results from N-terminal sequencing revealed that the putative 
catalytic fragment of 64 kDa may correspond to the observed 75 kDa band. Therefore it 
can be proposed that full-length SERA6 (135 kDa) is processed by PfSUB1 at 
SERA6st3 to a fragment of 125 kDa. This is then followed by a second processing step 
in SERA6st1 to a fragment at 100 kDa. The PfSUB1 processing is then finalised after 
the cleavage at SERA6st2 to release a 75 kDa fragment (see Figure 39).  
In the parasite, it is likely that SERA6 could also undergo further processing by 
different proteases or through autocatalytic processing. This is supported by findings 
that in some processing assays endogenous SERA6 was additionally processed to 
several smaller fragments. SERA5 also undergoes further processing from P56 to P50 
which is caused by a leupeptin sensitive cysteine protease called Protease X (Sharon 
Yeoh and Michael Blackman, unpublished). It may be that SERA6 also undergoes 
processing by Protease X. 
The data from this chapter suggests that SERA6 processing occurs very late in 
the parasite life-cycle, only moments before egress. This is supported by the findings 
that continuous monitoring of late stage parasite cultures by Giemsa staining and 
Western blot analysis only showed first signs of SERA6 processing once the first 
merozoites started to escape. 
 
4.3.3 Partial SERA6 processing by PfSUB1 is crucial for parasite survival 
Work in this chapter demonstrated that SERA6 is processed by PfSUB1 at three sites. 
As SERA6 was previously shown to be indispensable for the parasite (Miller et al., 
2002b) the question was asked whether the proteolytic maturation of SERA6 was also 
required for parasite survival in vitro. Therefore it was aimed to modify the endogenous 
SERA6st1, SERA6st2 and SERA6stX individually or mixed in all possible 
combinations. The results suggested that the processing of SERA6st1, which is located 
upstream of the central papain-like protease domain, appeared to be important 
independently whether transfected individually or in combination. The modification of 
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SERA6st2 appeared to be tolerated by the transfected parasite lines. Whether 
modifications of SERA6stX are detrimental to the parasite is unknown as the alteration 
of this site appeared to be tolerated in combination with modifications to SERA6st2 but 
not if SERA6stX was altered individually. The parasite lines which appeared to tolerate 
blocking of PfSUB1 processing have yet to be cloned. This would then allow for the 
analysis of the effect of the processing site alterations; particularly to answer the 
question of whether processing by PfSUB1 is in fact inhibited. This is important as 
similar transfection approaches in SERA5 showed that SERA5 still underwent 
processing in cloned SERA5st2 mutant parasite lines (Christine Collins, unpublished). 
It therefore may be that SERA6st2 mutant lines still undergo processing by PfSUB1. If, 
however, SERA6st2 is not processed but parasites survive, this would indicate that 
processing at SERA6st1 alone is sufficient for SERA6 to function normally. 
Interestingly it was also shown that the alteration of the processing sites in vitro 
completely blocked the cleavage of rSERA6 by rPfSUB1. This might imply that SERA6 
is not expected to be still processed in the integrated mutant lines. However, it cannot 
be excluded that other endogenous proteases cleave SERA6 in case of an incomplete 
PfSUB1 proteolysis to ensure correct SERA6 processing. Again this could be tested 
with cloned lines of the cleavage site mutant parasites. Towards this SERA6 could be 
purified from the mutant parasite clones and cleaved with rPfSUB1 in vitro in order to 
investigate the processing pattern by comparison to wild-type SERA6. Shedding light 
on SERA6 protease activity will provide insights into the importance of PfSUB1 
processing.  
 
4.3.4 Future tools to dissect SERA6 processing in the parasite are required 
SERA5 processing in the parasite was first identified by the accumulation of the 
50 kDa fragment in culture supernatants. These first results were followed by pulse-
chase experiments combined with a time course that revealed the pattern of SERA5 
processing in parasites (Delplace et al., 1985;Delplace et al., 1987;Debrabant et al., 
1992). SERA5 is one of the most abundant proteins of the parasite and tracking of 
various fragments was possible due to the fact that all fragments were readily visible on 
Coomassie Blue stained SDS-polyacrylamide gels following affinity purification. In 
addition the characterisation of SERA5 processing was facilitated by highly specific 
antibodies which improved immunoprecipitation after pulse-chase experiments. In this 
work, most approaches that led to the characterisation of SERA5 processing in the 
parasite were tried but were unsuccessful for SERA6. Additionally antibodies produced 
in this work were not suitable for immunoprecipitation. Pulse-chase experiments were 
conducted during this work but many proteins and not exclusively SERA6 were 
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immunoprecipitated (data not shown). Additional approaches to epitope-tag the C-
terminus of sera6 in the parasite were unsuccessful (Michael Shea, unpublished).  
To entirely characterise SERA6 processing in the parasite two things have to be 
achieved: firstly, improvement of the SERA6 antibodies to enable future SERA6 
immunoprecipitation from the parasite; secondly the detection of parasite SERA6 by 
tagging the genomic locus. Recent work by Stallmach et al. successfully replaced the 6 
kDa fragment of SERA5, between SERA5st2 and SERA5stX, with a tandem affinity 
purification (TAP)-tag in the parasite (Robert Stallmach, unpublished). As the 
replacement of the 6 kDa fragment appeared to be tolerated by the parasite this might 
be a future approach for tagging endogenous SERA6 and following its processing. 
However, replacing the 6 kDa fragment might have an impact on SERA6 function as a 
putative protease and has to be considered with caution. Additionally, antibodies raised 
against the 6 kDa fragment may also improve the understanding of SERA6 processing 
in the parasite.  
In summary: the improvement of antibody specificity, tagging the endogenous 
SERA6 and the production of new antibodies specific for the 6 kDa SERA6 fragment 
could potentially provide new tools to dissect SERA6 processing events in the parasite. 
 
4.3.5 PbSERA3 is a substrate for PfSUB1  
As the recombinant expression of SERA6 remained challenging PbSERA3 was 
hoped to be applicable as a SERA6 model in order to determine protease activity of the 
“Cys-type” SERAs. PbSERA3 was recently shown to be located in the PV of liver stage 
schizonts. It was also shown to be expressed in blood stages of the rodent malaria 
parasite (Schmidt-Christensen et al., 2008;Putrianti et al., 2009). To ensure that 
PbSERA3 was in fact not only the SERA6 orthologue but also displayed similar 
processing patterns, the recombinant protein was subjected to rPfSUB1 processing 
assays. Recombinant PbSERA3 WT and the corresponding C639A mutant were found 
to be both processed by rPfSUB1 in a similar manner to SERA6. Intriguingly they were 
then further converted to a smaller form (~48 kDa). This form still contained the 
putative catalytic region, as it was detected by antibodies against the central PbSERA3 
domain. N-terminal sequencing revealed that this was due to processing by PfSUB1 at 
a previously unpredicted site. Cleavage at this site was probably due to the presence of 
a small residue in P2 position and some amino acids with acidic and charged tendency 
in the P′ -positions probably allowed processing of this unusual site (Koussis, 
2009;Koussis et al., 2009;Silmon de Monerri, 2010;Silmon de Monerri et al., 2011). 
This step was not observed in the rSERA6. It could therefore be argued that these 
results make PbSERA3 an inappropriate SERA6 model. However, these findings 
turned later out to be very informative and will be thoroughly analysed and discussed in 
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chapter 5. It is unknown whether P. berghei SUB1 processes PbSERA3 in an identical 
manner to PfSUB1, but fluorogenic peptide substrates based on PbSERA3st1 and 
PbSERA3st2 were processed by PbSUB1 in vitro (Catherine Suarez, unpublished).  
As SERA6 and PbSERA3 undergo PfSUB1 processing in a similar manner, it 
was decided that rPbSERA3 will be applied as a model for SERA6 in future work and in 
the next part of this study. 
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Table 14: Modifications introduced to SERA6 processing sites  
Transfection 
constructs 
Subsite Modification 
pHH-SERA6chim  
SERA6st1: VKAQ↓DDFN 
SERA6st2: VHGQ↓SNES 
SERA6stX: VYFL↓RHNP  
Wild-type 
pHH-SERA6chim_mutS1 
SERA6st1: VKLLDDFN 
SERA6st2: VHGQ↓SNES 
SERA6st2: VYFL↓RHNP 
site 1 P2-1 LL 
pHH-SERA6chim∆S2 
SERA6st1: VKAQ↓DDFN 
SERA6st2: -SNES 
SERA6stX: VYFL↓RHNP 
site 2 deletion 
deletion of P4-1 
pHH-
SERA6chim_mutS1∆S2 
SERA6st1: VKLLDDFN 
SERA6st2: -SNES 
SERA6stX: VYFL↓RHNP 
site 1 P2-1 LL, site 
2 deletion deletion 
of P4-1 
pHH-SERA6chim_mutSx 
SERA6st1: VKAQ↓DDFN 
SERA6st2: VHGQ↓SNES 
SERA6stX: VAAARHNP 
site X P3-1 AAA 
pHH-SERA6chim_mutS2 
SERA6st1: VKAQ↓DDFN 
SERA6st2: VHLLSNES 
SERA6stX: VYFL↓RHNP 
site 2 P2-1 LL 
pHH-
SERA6chim_mutS2Sx 
SERA6st1: VKAQ↓DDFN 
SERA6st2: VHLLSNES 
SERA6stX: VAAARHNP 
site 2 P2-1 LL,  
site X P3-1 AAA 
pHH-
SERA6chim_mutS1S2 
SERA6st1: VKLLDDFN 
SERA6st2: VHLLSNES 
SERA6stX: VYFL↓RHNP 
site 1 P2-1 LL,  
site 2 P2-1 LL 
pHH-
SERA6chim_mutS1S2Sx 
SERA6st1: VKLLDDFN 
SERA6st2: VHLLSNES 
SERA6stX: VAAARHNP 
site 1 P2-1 LL,  
site 2 P2-1 LL 
site X P3-1 AAA 
pHH-
SERA6chim_mutS1Sx 
SERA6st1: VKLLDDFN 
SERA6st2: VHGQ↓SNES 
SERA6stX: VAAA↓RHNP 
site 1 P2-1 LL,  
site X P3-1 AAA 
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Figure 30: Recombinant SERA6 is secreted into COS-7 cell culture supernatant 
Recombinant SERA6 WT was transiently expressed from two to four days in COS-7 in 
culture medium not containing any fetal calf serum but in the presence of tunicamycin. 
The culture supernatant (sup) was harvested, pelleted and several fold concentrated. 
The remaining attached COS-7 cells were washed in PBS and harvested by scraping 
the cells off the culture flask. The cells were then collected and lysed in SDS sample 
buffer. Sup and COS-7 cells (pel) were separated by SDS-PAGE and analysed by 
Western blot using rabbit α-S6C1, total schizont extracts served as positive control 
(schiz). The majority of rSERA6 WT was expressed intracellular (A, rSERA6 WT pel). 
Optimal levels of secreted protein expression were obtained after four days (A, rSERA6 
WT sup). The appearance of two bands in rSERA6 WT supernatants may have been 
due to glycosylation, indicating an insufficient concentration of tunicamycin. The lower 
band which appeared in rSERA6 WT sup samples after four days (A, asterisk) 
comigrates with full-length SERA6 from the schiz control. This band might display 
unglycosylated SERA6. Next, rSERA6 WT and rSERA6 C644A were expressed in the 
presence of a 2 fold increased tunicamycin concentration. The culture supernatants 
were harvested after four days, concentrated 16-fold and analysed by Western blot 
using rabbit α-S6C1 (B). Only one band appeared this time suggesting that 
tunicamycin concentration was sufficient.  
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Figure 31: Recombinant and soluble SERA6 is processed by PfSUB1 at at least 
two sites 
After the expression and secretion in COS-7 cell culture supernatant rSERA6 WT and 
rSERA6 C644A were processed with rPfSUB1. The rSERA6 containing COS-7 cell 
culture supernatants were concentrated and resuspended in PfSUB1 activity buffer and 
incubated in the presence of rPfSUB1. As controls both rSERA6 were incubated at 
37°C alone or in presence of rPfSUB1 and the rPD. Samples were taken after 0, 10, 30 
and 120 min, separated by SDS-PAGE followed by Western blot analysis with rabbit α-
S6C1. Full-length SERA6 (~135 kDa) was gradually processed to a fragment at ~75 
kDa (c) over two intermediates at ~125 kDa (a) and ~100 kDa (b). Recombinant 
SERA6 was stable by itself and mainly stable in the presence of the rPD. Slight 
processing occurred due to reduced inhibitory activity of the rPD. The central SERA6 
antibody cross-reacted with the rPD which derived from the fact that the antibody was 
raised against a 6xHis-tag recombinant SERA6 and the rPD also carries a 6xHis-tag 
(asterisk). rPD: recombinant PfSUB1 prodomain 
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Figure 32: Parasite-derived SERA6 can be purified from hypotonically lysed 
schizont extracts 
In order to analyse SERA6 processing the protein was purified from hypotonically lysed 
parasites. Schizonts were hypotonically lysed and the extracts fractionated by size-
exclusion chromatography. Recovered samples were then analysed by Western blot 
for the presence of SERA6 (A) and SERA5 (B) by using rabbit α-S6C1 or full-length 
SERA5 (mAb 24C6.1F1). The majority of SERA6 was detected in fractions 33 and 34 
whereas the majority of SERA5 appeared in fraction 35. Fractions 33 and 34 were then 
applied in anion-exchange chromatography for further purification.  
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Figure 33: Parasite-derived SERA6 is processed by PfSUB1 at at least two sites 
To investigate whether parasite-derived SERA6 undergoes processing by rPfSUB1, 
parasite-derived SERA6 was incubated at 37°C with and without rPfSUB1, with or 
without rPD and combined with rPfSUB1 and rPD. Samples were taken at 0, 10, and 
120 min and analysed by Western blot using rabbit α-S6C1 antibodies (A). SERA6 is 
cleaved several times, from a ~135 kDa product, via ~125, ~100, and ~75 kDa 
products to even smaller fragments. Minimal processing was observed in samples 
containing rPfSUB1 and the rPD. This was caused by the addition of rPfSUB1 
moments before adding rPD. In a next step it was analysed whether the processing of 
the parasite-derived SERA6 was analogous to processing of SERA6 in the parasite. 
For that the samples from the rPfSUB1 processing assay were comigrated next to 
mature schizont extracts. The cleavage products migrate at the same size as the 
different SERA6 species found in very late schizonts (B, late schiz, lysed in SDS 
sample buffer), suggesting that in vitro cleavage by rPfSUB1 replicates the processing 
observed in the parasite. Additional und unpredicted processing of SERA6 was 
observed. To identify whether the COS-7 cell derived rSERA6 WT processed with 
rPfSUB1 also comigrates with SERA6 fragments from schizont extracts, rSERA6 WT 
was incubated at 37°C with rPfSUB1 and samples were taken at 0, 10, 60 and 180 min 
and analysed by Western blot using rabbit α-S6C1 (C). Samples were analysed by 
comigration with schizont extracts. Four major bands were observed ~135 kDa (C, a), 
~125 kDa (C, b), ~100 kDa (C, c) and ~75 kDa (C, d). These results also indicate that 
the additional processing in parasite-derived SERA6 might be due to other proteases 
that were possibly copurified with SERA6. rPD: recombinant PfSUB1 prodomain 
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Figure 34: Strategy for N-terminal sequencing of SERA6 processing sites  
Schematic of SERA6 showing the wild-type form (rS6-FL) and the mutations introduced 
to generate mutants SERA6mutS1 (rS6-FLmutS1), SERA6mutS2 (rS6-FLmutS2), and 
SERA6mutS1S2 (rS6-FLmutS1S2) for recombinant expression (A). These mutants 
were designed to block PfSUB1 processing. As attempts to purify rSERA6 remained 
unsuccessful a new strategy was developed to obtain pure rSERA6 (B). Various 
recombinant SERA6 mutants were expressed in E. coli as IB, IB were then lysed with 8 
M urea and samples were buffer exchanged to PBS. The samples were then separated 
by SDS-PAGE and the bands corresponding to full-length SERA6 were excised and 
the crushed gel pieces incubated with rPfSUB1. The digestion products were again 
separated by SDS-PAGE, transferred to PVDF membrane, and the cleavage sites 
were identified via N-terminal sequencing. IB: E. coli inclusion bodies 
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Figure 35: Recombinant SERA6 is cleaved in three distinct sites by PfSUB1 in 
vitro 
Recombinant full-length proteins SERA6 (rS6-FL), SERA6mutS1 (rS6-FLmutS1), 
SERA6mutS2 (rS6-FLmutS2), and SERA6mutS1S2 (rS6-FLmutS1S2) were incubated 
with or without rPfSUB1 and products visualised on a Coomassie Blue stained SDS-
PAGE gel (A). Top panel: Full-length SERA6 is processed to a ~75 kDa form (a). 
SERA6mutS1 is processed to a ~110 kDa form (b). SERA6mutS2 is processed to a 
~100 kDa form (c). SERA6mutS1S2 is unexpectedly processed to a ~125 kDa form (d). 
Bands a, b, c and d were N-terminally sequenced and the obtained sequence is 
indicated to the right of the gel. Bottom panel: a ~12 kDa product was generated by 
rPfSUB1 cleavage of recombinant SERA6 and SERA6mutS1 (e) and shown to be the 
C-terminal fragment by N-terminal sequencing. N-terminal sequencing confirmed two 
previously predicted processing sites and identified a third previously unpredicted 
processing site (B). 
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Figure 36: Processing of SERA6 by PfSUB1 in at least one site is indispensable 
in the parasite 
Schematic of transfection strategy for single homologous recombination applied in this 
work (A). The strategy was based on a chimera between genomic sera6 and 
recodonised sera6 which facilitated single-homologous recombination in the targeted 
sera6 locus. The recodonised portion of each construct carried the cleavage site 
mutations. Two primer pairs were applied for identification of positive integrants by 
diagnostic PCR with the primer binding sites labelled in green (A). Primer pair 5′UTRb 
and 9 were used for the confirmation of the presence of genomic DNA. Primer pair 
5′UTRb and 37 were applied to detect any integration (~1.8 kbp) as primer 37 
exclusively binds to the recodonised sera6 sequence (A). 
Results of the diagnostic PCR of SERA6 chimera wild-type control (pHH-SERA6chim) 
and parasite lines showing presence of homologous recombination events are shown 
in B. In a first step SERA6st2 deletion of P4-P1 (pHH-SERA6chim∆S2), SERA6st2 
substitution of P2-P1 with Ala-Ala (pHH-SERA6chim_mutS2) and SERA6st2 
substitution in combination with SERA6stX substitution of P3-P1 with Ala-Ala-Ala (pHH-
SERA6chim_mutS2Sx) were identified as positive for integration by diagnostic PCR (B, 
left hand panel). At the same time the presence of genomic DNA was confirmed (B, left 
hand panel, asterisk). A pHH-AMA1 transfected and cloned line served as negative 
control. A doublet was always observed, similar to SERA5 (Robert Stallmach, 
unpublished). The PCR positive lines were then analysed by Southern blot using the 
DIG method (C). Bands at ~3.3 kbp are expected for if the integration of the SERA6 
chimera was successful. All by PCR identified integration events were confirmed by 
Southern blot (C). The SERA6 chimera transfection plasmid served as control 
(pHHSERA6chimplasmid). The transfected lines were not cloned therefore the plasmid 
and the non-integrated sera6 loci were still detected by Southern blot (C, both ~9.5 
kbp, asterisk). 
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Figure 37: Recombinant PbSERA3 is processed by recombinant PfSUB1 in a 
SERA6 similar manner 
Recombinant PbSERA3 WT and rPbSERA3 C639A were expressed in insect cells. 
Culture supernatants were harvested after three days, pelleted and filtered. 
Supernatants were then purified by anion-exchange chromatography followed by size-
exclusion chromatography. Recovered samples were then analysed by Western blot 
using α-PbS3C1. Both recombinant proteins were eluted in fractions 31 to 33 (A). The 
fractions were then pooled separately for each protein, buffer exchanged into PfSUB1 
activity buffer and subjected to rPfSUB1 processing assays. The rPbSERA3 WT and 
rPbSERA3 C639A were incubated at 37°C with or without rPfSUB1, with or without rPD 
and combined with rPfSUB1 and rPD. Samples were taken at 0 and 120 min and 
analysed by Western blot using α-PbS3C1. Recombinant PbSERA3 was processed by 
rPfSUB1 from ~135 kDa (B, a) over ~100 kDa (B, b) to ~75 kDa (B, c). Additional 
processing was observed for rPbSERA3 WT to ~48 kDa (B, d) and ~42 kDa (B, e). For 
rPbSERA3 C639A only the conversion to the ~48 kDa (B, d) was observed. The 
conversion of both rPbSERA3 to a ~48 kDa fragment was unpredicted as an event 
mediated by rPfSUB1. Recombinant PbSERA3 underwent unexpected processing in 
samples incubated with rPfSUB1 and rPD. Fluorogenic substrate peptide assays 
revealed that the rPD was no longer functional and was replaced with a fresh stock 
rPD. 
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Figure 38: PbSERA3 is processed by PfSUB1 in an unpredicted site 
The appearance of a 48 kDa rPbSERA3 fragment after processing with rPfSUB1 raised 
the question of whether PbSERA3 encodes for an unpredicted PfSUB1 processing site. 
An rPbSERA3 fragment, between the predicted PbSERA3st1 and PbSERA3st2, was 
expressed with an N-terminal 6xHis- and S-tag (rPbS3C1, A). The recombinant protein 
was expressed as IB. The IB were solubilised with 8 M urea and rPbS3C1 was purified 
using Nickel-Histidine chelation. The recombinant protein was then subjected to 
rPfSUB1 processing assays, samples were taken at 0 and 120 min and analysed by 
Western blot using α-PbS3C1. As expected the ~75 kDa fragment was processed to a 
fragment of 48 kDa (B, asterisk). To investigate whether the cleavage occurred on the 
N- or C-terminus the same nitrocellulose membrane was probed with a α-His antibody 
(the rPbS3C1 carried an N-terminal 6xHis-tag). The signal disappeared after 
processing by rPfSUB1 implying that cleavage occurs at the N-terminus. The same 
samples were transferred to PVDF membrane and the processing site was N-terminally 
sequenced. Recombinant PfSUB1 processes rPbSERA3 also at an unfavourable 
AIGQ↓NEEP motif (C). 
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Figure 39: Overview of SERA6 processing by PfSUB1 
SERA6 is processed by PfSUB1 at three sites. The full-length SERA6 was processed 
in site SERA6st3 to a ~125 kDa fragment. This was suggested to be the first step in a 
proteolytic cascade as this fragment disappeared throughout the course of the 
processing assay. SERA6 undergoes further processing by PfSUB1 in SERA6st1 
followed by processing in SERA6st2 releasing fragments of ~100 kDa and ~75 kDa 
respectively. Both of these fragments carry the central papain-like protease domain. 
Additional processing steps have not been analysed in this work. 
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5 PbSERA3 and SERA6 are malarial proteases that require activation by 
PfSUB1 
5.1 Introduction 
As discussed in the Introduction, SERA6 carries a central papain-domain which 
putatively confers a cysteine protease activity. Previous work showing the 
indispensable nature of the sera6 gene in P. falciparum cultures (Miller et al., 2002b) 
raised the possibility that this cysteine protease activity may be required for the role of 
SERA6 and parasite survival. In this part of the work this putative protease activity of 
SERA6 was thoroughly investigated. First, it was attempted to precisely analyse the 
importance of the putative catalytic Cys residue for parasite survival, by attempting to 
modify this residue in the parasite. This approach was intended to address two main 
questions: firstly, whether the putative catalytic Cys is required for the correct function 
of SERA6 and secondly whether this function is required for parasite survival. It was 
next attempted to determine the proteolytic activity of SERA6. In a first step E. coli 
derived recombinant SERA6 was refolded and analysed for protease activity. Secondly 
it was attempted to purify SERA6 from parasite culture supernatants to investigate 
protease activity analysis. This was followed by protease activity studies with the 
parasite-derived SERA6 and E. coli cell lysates containing soluble rS6C1. Finally, the 
putative cysteine protease activity of recombinant PbSERA3, the P. berghei orthologue 
of SERA6, was examined.  
 
5.2 Results 
5.2.1 The putative catalytic Cys of SERA6 is indispensable for parasite survival 
Many previous studies have shown that the replacement of a catalytic residue 
in cysteine proteases can ablate proteolytic activity without affecting the protease fold 
(Baker et al., 1993;Pei et al., 1996). This approach has been used to investigate the 
activity of a variety of enzymes and putative enzymes. In order to establish the 
importance of the putative catalytic Cys644 of SERA6, a substitution of this residue 
with an Ala644 residue in 3D7 P. falciparum parasites was attempted. Predictions were 
that this Cys residue confers a cysteine protease function of SERA6 and a replacement 
would not be tolerated by the parasites. As demonstrated above a chimera construct of 
genomic sera6 and recodonised sera6 can be used to successfully drive single cross-
over homologous recombination into the sera6 locus (see chapter 4). Accordingly a 
similar transfection strategy was applied to integrate the catalytic residue substitution 
into the endogenous sera6 locus in 3D7 parasites. Two constructs were designed, one 
(pHH-SERA6chim) designed to reconstitute the wild-type SERA6 gene product as a 
control for integration, and the other designed to produce the SERA6 C644A 
substitution (pHH-SERA6chimC/A, see Figure 40A, for a construct overview). Parasites 
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were transfected on 11 independent occasions with pHH-SERA6chim and seven 
independent occasions with pHH-SERA6chimC/A and integrated parasite populations 
were selected by cycling on and off drug. A diagnostic PCR was designed with primers 
to bind to recodonised sera6 and which were unlikely to anneal to genomic sera6 
making the identification of integrant lines more specific (for additional information see 
chapter 4). As shown in Figure 40B, integration was detected for the SERA6 WT but 
not SERA6 C644A as a band of the expected size (1.8 kbp). Southern blot analysis 
was then performed in an attempt to confirm the integration of the PCR positive 
parasite lines. As shown in Figure 40C one band at ~3.3 kbp was detected in digests of 
genomic DNA from the SERA6 WT line but not of the SERA6 C644A line, indicating 
integration of SERA6 WT but not SERA6 C644A. SERA6 C644A on the other hand 
only showed a band at ~9.5 kbp (see Figure 40C, asterisk). These parasites appeared 
to have maintained the transfection vector in episomal form and also contain the 
undisrupted sera6 locus. The detection of bands other than the integrated sera6 locus 
was due to the fact that although the transfected lines had undergone drug cycling, 
they had not been cloned. These results suggest that the replacement of Cys644 of 
SERA6 is not tolerated by the parasite. Therefore the findings suggest that this putative 
catalytic residue is required for the persistence of the parasite asexual life-cycle.  
 
5.2.2 Attempted refolding of recombinant SERA6  
Having established that the predicted catalytic Cys644 of SERA6 appeared 
indispensable for parasite survival in vitro it was next attempted to demonstrate the 
protease activity of SERA6 in vitro. As recombinant expression of SERA6 remained 
challenging the screen for protease activity was attempted with a variety of 
approaches. An overview of these approaches can be found in Table 15. Many 
eukaryotic proteases were shown to successfully gain proteolytic activity after they 
were recovered from IB and then correctly refolded (Cabrita et al., 2004). A commonly 
used method for protein refolding is rapid dilution as described for many proteins 
(Buckle et al., 2005;Chow et al., 2006). Therefore it was expected that once rSERA6 
was correctly refolded it would become proteolytically active. Initial attempts to do this 
with SERA6 used rSERA6 which was expressed in E. coli IB. In a first step it was tried 
to recover various rSERA6 fragments from IB followed by several refolding attempts. 
The refolded rSERA6 fragments were then used to screen for protease activity via 
zymography. Zymograms are carried out by separating the putative protease on a 
SDS-polyacrylamide gel copolymerised with the enzyme substrate. Once activated by 
buffer exchanging, to remove the SDS, the protease can cleave the substrate to 
smaller fragments which can readily diffuse out from the gel. After staining the gel with 
Coomassie Blue this results in a band of clearing at the position of protease activity.  
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To attempt to obtain correctly refolded rSERA6, IB containing either rS6-FL, 
rS6C1 or rS6C2 were first washed and then solubilised in 8 M urea. All protein 
refolding attempts were made directly from the solubilised material without any 
preceding purification steps. All three proteins were then rapidly diluted into a large 
variety of refolding buffers (see Table 10). The refolded samples were then analysed 
by separation on CN-PAGE since insoluble protein aggregates would be expected to 
not enter the CN-polyacrylamide gels. This was followed by Western blot analysis 
using a commercial α-His antibody (recognising the N-terminal 6xHis-tag). Figure 41A 
shows that bands appeared for rS6C1 and rS6C2 after the recombinant proteins were 
refolded in the buffers that were used in refolding approaches for the following proteins: 
falcipain 2, SERA5 and also buffer 1 to 3 from the Quick Refolding Kit (Pierce). A band 
for rS6-FL was not as clearly visible but a smear was detected by Western blot. The 
results suggested that at least a small proportion of the three rSERA6 fragments was 
refolded. In an additional approach to assess the state of refolding the same samples 
were analysed by adding DTT or not to the 2x SDS sample buffer. Upon the addition of 
DTT the intramolecular disulphide-bonds of refolded proteins would be disrupted 
causing a size shift on SDS-polyacrylamide gels between samples with and without 
DTT. As seen in Figure 41B, samples that were refolded in falcipain 2 refolding buffer 
did not reveal a size shift upon the addition of DTT. This suggested that neither rS6C1 
nor rS6C2 were correctly refolded. However, the Western blot results indicated 
refolding of at least a small proportion of rS6C1 and rS6C2. Therefore zymography was 
used to screen these samples for protease activity. Both rS6C1 and rS6C2 were 
refolded in the falcipain 2 refolding buffer and the samples were separated on SDS-
polyacrylamide gels copolymerised with gelatin. After the electrophoresis the SDS was 
replaced with TX-100 and each gel was incubated in a buffer designed to allow 
cysteine protease activity (Chow et al., 2006). As a control, 1 µg papain was 
additionally run on each of the gels. No white bands, except in the papain sample, were 
visible in Figure 41C indicating that rS6C1 and rS6C2 did not process any of the 
substrates. The most likely explanation for this observation was that neither the 
refolded rS6C1 nor rS6C2 possess any proteolytic activity in this assay. A second 
explanation could be that the recombinant fragments were correctly refolded but the 
substrates or developing buffers used were unsuitable. Additional substrates (BSA and 
marvel milk powder) and developing buffers (a pH 7.7 buffer or falcipain 2 activity 
buffer) were therefore tried, but also failed to reveal any protease activity (data not 
shown).  
In summary in this section it was attempted to characterise SERA6 cysteine 
protease activity by refolding protein fragments that were recombinantly expressed in 
E. coli IB. Although a variety of methods was applied, protease activity was not 
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observed, which might have been due to several reasons. Firstly the proteins were 
likely to be only partially refolded, hence were not in their native state which is required 
for the catalytic triad residues to be in the correct proximity for efficient proteolytic 
activity. Secondly, in case the proteins had been correctly refolded it was unclear 
whether any of the substrates used in the zymography approaches were suitable 
substrates for SERA6. As it was difficult to assess why the fragments were 
proteolytically inactive it was decided to next screen for SERA6 activity with the 
parasite-derived protein. 
 
5.2.3 Parasite-derived SERA6 shows no detectable protease activity 
After the unsuccessful activity screen of refolded rSERA6, the aim of this 
section was to investigate further into the putative cysteine protease activity of SERA6 
by using parasite-derived SERA6.  
 
5.2.3.1 A fragment of SERA6 isolated from parasite culture supernatants shows 
no detectable protease activity  
It is known that upon the rupture of iRBCs a small 50 kDa SERA5 fragment, 
containing the central papain-like protease domain, can be found in culture supernatant 
(Delplace et al., 1985;Delplace et al., 1987). It had yet to be established whether a 
similar SERA6-derived central domain can also be detected in culture supernatant after 
egress. Therefore it was first decided to attempt to identify and purify a SERA6 central 
domain from parasite culture supernatants after egress which could then be used to 
screen for activity.  
To investigate whether a SERA6-central domain indeed accumulated in the 
culture supernatant of ruptured parasites, culture supernatants were collected and 
fractionated by anion-exchange chromatography as described by (Silmon de Monerri et 
al., 2011). Fractions were analysed by Western blot using rabbit α-S6C1. As shown in 
Figure 42A an approximately 42 kDa protein reactive with the antibody was eluted 
between fractions 26 and 31 (see Figure 42A, left hand panel). These fractions were 
pooled, concentrated 60-fold and further purified by size-exclusion chromatography. 
The reactive protein (henceforth referred to as SERA6-central) was recovered in two 
peak fractions (see Figure 42A, right hand panel). These were pooled and stored froze 
in aliquots.  
The next set of experiments involved screening the SERA6-central for protease 
activity. One of the approaches used was the incubation of the SERA6 central domain 
with iRBC ghosts. Infected RBC ghosts are lysed and resealed RBCs that still harbour 
all the membranes derived from the parasite and the RBC with the integrated and 
peripheral associated membrane proteins. Therefore it was suggested that if the 
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SERA6 central domain possessed proteolytic activity one of the membrane proteins 
found in iRBC ghosts might be processed by the putative cysteine protease.  
In a first step SERA6-central was tested for autocatalytic processing. This was 
attempted by concentrating the SERA6-central 5-fold and incubating it for 4 hours or 
overnight at 37°C with or without the addition of calcium (some cysteine proteases, 
such as the calpains, are known to be calcium dependant Ohno et al., 1984). The 
samples were then analysed by SDS-PAGE and Coomassie Blue staining. As shown in 
Figure 42B, no signs of autocatalytic breakdown were observed in any of the samples. 
In a second attempt to look for protease activity in the SERA6-central preparations, the 
protein was incubated with iRBC ghosts that were obtained by lysing iRBCs in a 
hypotonic buffer. Following incubation of iRBC ghosts in the presence of SERA6-
central at 37°C, samples taken after 0, 1, 2, 4, 5 hours were analysed by SDS-
polyacrylamide gels and silver staining. As seen in Figure 43A no differences were 
observed between the start sample and samples after 5 hours, suggesting no protease 
activity against the ghost proteins or the processed proteins were too low in abundance 
to be visible. 
In a final approach the activity of SERA6-central was analysed with BSA 
substrate zymograms. SERA6-central was separated in polyacrylamide gels containing 
BSA and the gels incubated in four distinct buffers: falcipain 2 activity buffer, papain-
activity buffer, and a pH 8.2 buffer with or without the addition of 5 mM CaCl2. 1 µg 
papain was used as positive control. As seen in Figure 43B no white bands were 
visible for SERA6-central. This indicated that either SERA6-central was inactive or the 
conditions were unsuitable for SERA6-central to process BSA.  
In conclusion, several attempts to detect protease activity in the parasite 
derived SERA6-central preparations were unsuccessful. This could be due to several 
reasons. One possible explanation may be that the SERA6-central domain found in 
culture supernatants does not possess proteolytic activity or the assay conditions were 
unsuitable for SERA6-central to show activity. 
 
5.2.3.2 Parasite-derived full-length SERA6 possesses no detectable protease 
activity 
The next set of experiments focused in assessing parasite-derived full-length 
SERA6 which was purified as described previously (see chapter 4). Previous data had 
confirmed the processing of parasite-derived SERA6 by rPfSUB1 (see chapter 4) and it 
was suggested that this proteolytic maturation frees SERA6 as an active protease. It 
was unknown which of the SERA6 forms might possess enzymatic activity. To not 
simply miss out on that activity by using the “wrong” form it was decided to use 
rPfSUB1-digested parasite-derived SERA6 samples that contain all SERA6 processing 
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fragments for activity screens. In preliminary experiments the processing of SERA6 
was monitored by Western blot to identify the time required to digest the protein to 
completion. Figure 44A shows that 30 min of processing was sufficient to obtain 
preparations containing all SERA6 forms. Consequently samples from that time point 
were then used in activity screens. Processed SERA6 and appropriate controls 
(rPfSUB1 only, parasite-derived SERA6 only, and a buffer only control) were then 
incubated with several fluorogenic peptide substrates and fluorescence measurements 
taken at various time-points. Samples were digested to completion after 72 hours by 
addition of Pronase to reveal maximum fluorescence levels. Figure 44B shows that 
only one substrate, the TACE substrate IV (Abz-LAQAVRSSR-Dpa), showed a clear 
increase in fluorescence emission. The assay was then repeated with two different 
concentrations of the TACE IV substrate peptide. Measurements were taken after 5 
min and overnight incubation at 37°C. This time no clear difference could be observed 
and several repetitions of the experiment delivered inconclusive results (see Figure 
44C). These data suggested that this approach was not suitable for detecting parasite-
derived SERA6 protease activity.  
 
5.2.4 Activity of recombinant and soluble SERA6 requires further investigation 
To continue investigation into SERA6 activity it was decided to screen the 
rS6C1 fragment from the soluble fraction of E. coli for putative proteolytic activity 
against fluorogenic peptide substrates. This was possible as, as described earlier, a 
small proportion of the expressed rS6C1 was expressed in the soluble fraction of 
recombinant E. coli cells. It was predicted that the rS6C1 found in the soluble fraction 
of E. coli cell lysates was correctly folded and therefore active. Since several attempts 
to purify it from the E. coli lysate failed (see chapter 3), it was decided to use the whole 
E. coli cell lysate containing rS6C1 for the activity screens in this section. As a control 
for these assays, a catalytic site mutant, rS6C1 C644A, was designed. If, after the 
incubation with fluorogenic substrate peptides, emission levels increased in the rS6C1 
and not the mutant rS6C1 C644A samples, this should reflect SERA6 activity. 
Both rS6C1 and rS6C1 C644A were recombinantly expressed in E. coli cells 
and a BugBuster Master Mix soluble fraction (crude bacterial lysate) was separated 
from IB by centrifugation. Fluorogenic peptide assays were then conducted with the 
crude bacterial lysate without further purification. Several AMC fluorogenic substrate 
peptides (see Table 11) were incubated with the lysates at 37°C and measurements 
were taken at 0 hours and 4 hours. As controls, rS6C1 and rS6C1 C644A were 
incubated with buffer only, AMC peptide 7 was incubated with buffer only and AMC 
peptide 6 was processed with pronase. As seen in Figure 45 some peptides underwent 
hydrolysis as indicated by an increase in fluorescence. However, this activity was 
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equally found in both the rS6C1 and the rS6C1 C644A digests, indicating that the 
activity was likely due to contaminating bacterial proteases. The results suggested that 
this approach was unsuitable to detect SERA6 protease activity. 
 
5.2.5 PbSERA3: An active cysteine protease that requires PfSUB1 processing 
for activation 
As no protease activity associated with SERA6 could be detected with all the 
above described approaches, the characterisation of a SERA6 orthologue was 
attempted. This was facilitated by the fact that it was previously shown that PbSERA3 
undergoes proteolytic processing by PfSUB1 in a manner similar to that of SERA6. 
Determining protease activity of a SERA6 orthologue appeared the best approach to 
gain insights into in vitro and in vivo substrates and identify the role of SERA6 in the P. 
falciparum life-cycle. The aim of this section was therefore to search for protease 
activity mediated by PbSERA3. 
 
5.2.5.1 PbSERA3 shows autocatalytic protease activity 
As described in chapter 4, rPbSERA3 undergoes processing by rPfSUB1 at 
three sites. However, the rPbSERA3 WT appeared to undergo a final additional 
processing step (conversion from 48 kDa to 42 kDa) which was not observed for the 
rPbSERA3 C639A and therefore unlikely to be caused by rPfSUB1. As rPbSERA3 WT 
was expressed in a soluble form and therefore likely correctly folded it was suspected 
that this step might have been caused by autocatalytic processing of rPbSERA3. To 
investigate whether the conversion from approximately 48 kDa to 42 kDa was indeed 
autocatalytic the recombinant protein was digested with rPfSUB1 with or without the 
addition of E64 (rPbSERA3 WT +/-E64). E64 is an irreversible, potent and highly 
selective cysteine protease inhibitor which acts by covalently binding to the active thiol 
group of cysteine proteases. PfSUB1, a serine protease, cannot be inhibited with E64. 
Therefore E64 was expected to prevent the final processing step if it was autocatalytic. 
Samples taken at intervals during the digestions were analysed by Western blot with α-
PbS3C1. As controls the rPbSERA3 WT was incubated alone or in presence of 
rPfSUB1 and rPD.  
Figure 46A shows that both sets of samples (-/+ E64) showed largely similar 
maturation patterns. However, whereas the recombinant PbSERA3 WT -E64 
underwent the previously observed maturation from the full-length protein through 
several intermediates to a prominent band visible at approximately 42 kDa, the 
recombinant PbSERA3 WT +E64 failed to be completely converted to the 42 kDa 
fragment and both 48 kDa and 42 kDa forms were detected with the same signal 
intensity. These results were consistent with the idea that the final conversion of 
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rPbSERA3 might be due to a cysteine protease which was sensitive to E64. Figure 46A 
also shows that in the absence of rPfSUB1 or in the presence of an rPfSUB1 inhibitor 
no processing was observed at all. This indicated that the E64-sensitive protease 
responsible for the final conversion only became active after the initial proteolytic 
maturation of rPbSERA3 WT by rPfSUB1. This raised the possibility that the protease 
responsible for the final processing step might be rPbSERA3 WT after activation by 
rPfSUB1.  
Although the data so far implied that the last processing step was performed by 
rPbSERA3 only a mutation of the catalytic Cys in rPbSERA3 to abort any cysteine 
protease activity could provide an adequate control. If the final processing step was 
mediated by PbSERA3 itself, a difference would be expected to be detected between 
rPbSERA3 WT and C639A after processing with rPfSUB1. To assess this, a mutant in 
which the catalytic Cys residue of PbSERA3 was replaced with an Ala residue 
(PbSERA3 C639A) was recombinantly expressed and purified in a manner identical to 
the approach used for rPbSERA3 WT. Both proteins were then digested with rPfSUB1 
and digests analysed by Western blot with the α-PbS3C1 antibodies. Figure 46B 
shows that both proteins undergo an identical processing pattern except for the final 
conversion step (lanes 1, 2, 6-8). Here, whereas the rPbSERA3 WT was converted to 
the final form of 42 kDa, the C639A mutant accumulated at 48 kDa. This result shows 
that modification of the putative catalytic Cys in rPbSERA3 C639A prevented the final 
conversion, strongly suggesting that the final processing step was due to an 
autocatalytic activity of rPbSERA3 WT. Importantly the results also implied that the 
rPbSERA3 WT required processing by rPfSUB1 to become proteolytically active.  
Of course it can be argued that processing PbSERA3 by PfSUB1 does not 
reconstitute physiological events as both are derived from two different Plasmodium 
species. However, PbSERA3 is predicted to be processed at the same sites by 
PfSUB1 and PbSUB1 which was confirmed by in vitro processing of peptide substrates 
(Catherine Suarez, unpublished). As recombinant PbSUB1 was unavailable during this 
study, PfSUB1 was used throughout this work. The PbSERA3 activity assay will purely 
be applied to identify putative SERA6 substrates and not to explore the role of 
PbSERA3 in the P. berghei life-cycle, therefore not causing any conflict about the 
authenticity. 
 
5.2.5.2 Autocatalytic processing of rPbSERA3 is E64 sensitive 
E64 inhibits most cysteine proteases at a concentration of 10 µM and parasite 
egress can also be prevented when parasites are cultured in the presence of 10 µM 
E64 (Boyle et al., 2010b). The results from the previous section showed that 20 µM 
E64 only partially prevented the final processing step of rPbSERA3 WT it was therefore 
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decided to investigate whether increasing E64 concentrations might fully inhibit the final 
conversion step. To test this, recombinant PbSERA3 WT was digested with rPfSUB1 in 
the presence of increasing concentrations of E64 and the digests analysed by Western 
Blot as previously. As shown in Figure 46B the signal for the 42 kDa processing 
fragment decreased with increasing E64 concentrations and at 100 µM was very faint 
compared to the signal at 48 kDa (lanes 3-5). In comparison digests of rPbSERA3 
C639A produced only the 48 kDa fragment, with no sign of production of the 42 kDa 
form (lane 6). The rPbSERA3 C639A-derived 48 kDa product comigrated on SDS 
PAGE with the 48 kDa fragment that was detected in rPbSERA3 WT +100 µM E64 
samples, indicating that both bands might resemble the same form of rPbSERA3. This 
provided more evidence that the final conversion is dependent on a cysteine protease 
activity and additionally that this step is mediated by autocatalytic processing of 
rPbSERA3.  
To investigate the effect of other protease inhibitors on the autocatalytic 
processing of rPbSERA3 WT digests were preformed with or without three different 
protease inhibitors. The serine and cysteine protease inhibitors leupeptin and antipain 
were tested first. Samples of digests were analysed by Western blot with the α-
PbS3C1 antibodies. As shown in Figure 47A leupeptin and antipain had no effect on 
the autocatalytic processing since the maturation patterns were the same as the 
sample not containing any protease inhibitors. Next it was attempted to analyse 
whether the processing could be inhibited with recombinant PbICP (rPbICP), a cysteine 
protease inhibitor secreted by P. berghei parasites (Rennenberg et al., 2010). Digests 
performed with or without 1 µM rPbICP (a kind gift from Volker Heussler,) were 
analysed by Western blot as previously. Figure 47B shows that the rPbICP did not 
inhibit the autocatalytic processing of rPbSERA3 WT. However, this result was not 
entirely conclusive since the PbSERA3 antibody cross-reacted with the rPbICP and 
many unspecific bands were detected. This was probably due to the fact that both, the 
rPbSERA3 used to raise the antibodies and the rPbICP used in this experiment, were 
produced in E. coli. 
In summary this section showed that the autocatalytic processing step of 
rPbSERA3 WT was sensitive to 100 µM E64 but not to leupeptin or antipain and 
possibly not PbICP. 
 
5.3 Discussion 
5.3.1 Exploring SERA6 activity in the parasite 
SERA5 has long believed to be indispensable in the parasite asexual life-cycle, 
since several attempts to knockout the gene in vitro have failed (Miller et al., 
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2002b;McCoubrie et al., 2007). Recent approaches have dissected the importance of 
SERA5 in the parasite asexual life-cyle further and have shown that though SERA5 is 
indispensable it is not a proteolytic enzyme as the active site Ser can be replaced with 
Ala in the parasite (Robert Stallmach, unpublished). In this chapter the same approach 
was applied to a study of SERA6 as previous data also suggested the protein to be 
required for parasite survival (Miller et al., 2002b). In transfection experiment aimed at 
attempted replacement of the active site Cys644 with an Ala, 8 out of 11 wild-type 
controls showed integration but none out of seven Cys to Ala replacements revealed 
single homologous recombination events. These results strongly imply that SERA6 is 
an active cysteine protease in the parasite and that this activity is indispensable for 
parasite survival. It remains possible that the Cys644 is required for an essential fold 
conferring correct function of the protein, for example that Cys644 may not be required 
for protease activity but for correct folding of the protein. SERA6 encodes 29 Cys 
residues in total and SERA5 encodes for 28 Cys residues and these Cys residues are 
positionally conserved between SERA5 and SERA6. SERA5 however does not encode 
for a Cys residue at the active site but is still correctly folded, suggesting that it is likely 
not to be required for protein fold but for protease activity. Therefore it appears unlikely 
that the disruption of the SERA6 Cys644 has detrimental effects on the protein fold 
rather than an effect on a protease activity.  
The substitution of an active site residue in order to investigate protease activity 
has been widely used (Clark et al., 1978;Baker et al., 1993;Pei et al., 1996). Despite 
Ala being an adequate choice for an active site substitution as it is a small amino acid 
with only the sulfhydryl group missing in comparison to the Cys residue, it would be 
intriguing to analyse whether the parasite can tolerate a substitution of the catalytic Cys 
residue with a Ser residue. This would be an intriguing approach as the Ser residue 
might confer a serine protease activity on SERA6.  
 
5.3.2 Exploring SERA6 activity in vitro 
At the beginning of this work it was hypothesised that SERA6 may require 
processing by PfSUB1 to be matured to an active protease. It was therefore decided to 
express SERA6 recombinantly in E. coli and then use the recombinant material in 
activity screens, such as zymograms, autocatalytic processing assays and fluorogenic 
substrate peptide assays. Several attempts to express various rSERA6 fragments in E. 
coli based expression systems proved unsuccessful, the insolubility of recombinant E. 
coli derived SERA6 being the first obstacle that had to be overcome in this part of the 
work. Previous work from other groups has shown that cysteine proteases such as 
falcipain 2 were shown to possess proteolytic activity after the proteins were refolded 
from material which was derived from solubilised IB (Shenai et al., 2000). As rS6C1 
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was predicted to carry the protease domain of SERA6 it was attempted to refold this 
recombinant protein following expression in IB. The results from these refolding studies 
were inconclusive. It was difficult to assess the correct refolding stage of rS6C1 since 
activity could not be employed as a refolding measurement tool. Others have shown 
that correct refolding of proteases such as falcipain 2 was revealed because substrates 
(haemoglobin in case of falcipain 2) were known and if the recombinant material 
showed protease activity it was correctly refolded. Although it appeared that some of 
rS6C1 was refolded, protein refolding as a tool to obtain active SERA6 was 
disregarded in subsequent approaches.  
Several attempts to determine SERA6 protease activity by screening bacterial 
cell lysates containing rS6C1, parasite-derived SERA6 or the parasite-derived SERA6-
central domain with various techniques such as fluorogenic substrate peptide assays, 
zymograms, autocatalytic processing assays and activity assays on iRBC samples 
failed to detect any protease activity. In general all activity screens attempted in this 
work were complicated by two major challenges. Firstly, it was unknown whether any of 
the above-mentioned SERA6 fragments possessed protease activity. Secondly, any 
activity of any of the SERA6 fragments could have been masked by not having the 
correct substrate available.  
New tools for the study of SERA6 activity were developed at the end of this 
work and will be applied in future approaches. The rSERA6 WT and rSERA6 C644A 
were successfully produced as soluble proteins by expression COS-7 cells. These two 
recombinant proteins can be used to screen for activity. This is especially important as 
the C644A mutant constitutes a very suitable control. The use of fluorogenic peptide 
substrate libraries for screening for SERA6 activity could provide a wide range of 
putative substrates. Additionally the COS-7 cell-derived rSERA6 can be screened in 
assays with iRBCs or RBC ghosts similar to an approach in which new PfSUB1 
substrates were identified (Silmon de Monerri, 2010;Silmon de Monerri et al., 2011). 
One of the major obstacles in activity screens with parasite-derived SERA6 was 
obtaining the protein in sufficient amounts for screens. Coomassie Blue staining of the 
protein preparations revealed that even after two different large-scale protein 
purification steps SERA6 was not the most abundant protein in those fractions and was 
not even visible on the gel. Therefore for future approaches it will be necessary to 
improve the purification of parasite-derived SERA6. The integration of an epitope-tag 
into the genomic sera6 gene could provide such a tool for specific purification of the 
protein. As an example of this, Stallmach et al. were successful in integrating a TAP-
tag into the genomic sera5 gene (Robert Stallmach, unpublished). The TAP-tag 
contains a tobacco etch virus (TEV) protease cleavage site which was used to release 
”mature” SERA5 from an affinity column after purification from parasite cultures (Rigaut 
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et al., 1999;Puig et al., 2001). A similar approach could be employed for SERA6 as a 
tool to obtain sufficient amounts for protease activity screens, provided that the tag did 
not interfere with this activity. 
 
5.3.3 Cysteine protease activity of a SERA6 orthologue: promising insights 
PbSERA3 was recombinantly expressed with the expectation that an active 
SERA6 orthologue could successfully be employed to identify SERA6 substrates. This 
was a particularly intriguing possibility because the subcellular localisation and 
expression patterns of PbSERA3 are well understood and it has been shown to be 
indispensable for P. berghei parasite survival (Schmidt-Christensen et al., 
2008;Putrianti et al., 2009). Processing assays with the recombinant protein produced 
very promising results as differences were immediately observed in the processing 
profile of protein processed with rPfSUB1 in the presence and absence of E64. The 
difference between these two samples was that final PbSERA3 maturation appeared to 
be almost completely ablated in the presence of E64. This suggested the involvement 
of a cysteine protease in rPbSERA3 processing, but one that became active only after 
initial processing by rPfSUB1. Analysis of the rPbSERA3 C639A mutant then revealed 
that the replacement of Cys with Ala showed an identical phenotype as rPbSERA3 
inhibited with E64. This identified the final processing step as being due to an 
autocatalytic activity of rPbSERA3, showing for the first time that a Cys-type SERA 
possesses cysteine protease activity. Additional attempts to prevent the autocatalytic 
processing of rPbSERA3 WT with leupeptin and antipain did not prevent the final 
conversion. Results from inhibition assays with rPbICP were inconclusive due to cross-
reactivity of the α-PbS3C1 antibody. The structure of PbICP was recently identified 
which indicated that the SERAs are unlikely targets for this cysteine protease inhibitor 
and therefore it would not prevent the final autocatalytic conversion of PbSERA3 WT 
(Hansen et al., 2011). 
In order to investigate into rPbSERA3 activity it was attempted to precisely 
identify the autocatalytic processing site, with the intention of using that information to 
generate a fluorogenic substrate peptide based on this site. Confirming the proteolytic 
activity by cleaving synthetic substrates based on autoprocessing sites has been used 
for several proteases including PfSUB1 (Sajid et al., 2000). A fluorogenic substrate 
based on the autoprocessing site is likely to also be a good substrate in trans. This 
step required N-terminal sequencing of the 42 kDa fragment by Edman degradation. 
For this, a protein concentration of at least 10 pmol had to be obtained (corresponding 
to a readily visible band on a Coomassie Blue stained polyacrylamide gel). However, 
throughout this work rPbSERA3 amounts were never sufficient for this step despite 
thorough investigation to improve the efficiency of insect cell expression system. Future 
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work will include the improvement of purification methods of rPbSERA3 to achieve this 
aim. In the meantime many additional attempts were made to explore the activity of 
rPbSERA3 by employing a variety of protease inhibitors to attempt to block 
autocatalytic processing. Exploration of the activity of rPbSERA3 is at the very 
beginning, and in future work, after gaining enough recombinant protein, it can be 
thoroughly analysed with a variety of different methods including screening of 
fluorogenic substrate peptide libraries, zymograms and incubation with parasite 
material (P. berghei and P. falciparum). Future work with rPbSERA3 could reveal 
substrates that can be applied to screen for SERA6 activity in vitro and in the parasite; 
for example a substrate peptide based on the autoprocessing site of PbSERA3 might 
be also processed by an active SERA6. 
During this work it was also discovered that rPbSERA3 was processed by 
rPfSUB1 at a third, unpredicted site. N-terminal sequencing revealed that this site is an 
unfavoured rPfSUB1 site (Koussis, 2009;Koussis et al., 2009;Silmon de Monerri, 
2010;Silmon de Monerri et al., 2011).  
   
5.3.4 SERA6 cysteine protease activity in the parasite 
P. falciparum SERA6 has yet to be shown to possess cysteine protease activity. 
However, the data presented here shows that the catalytic Cys appears indispensable 
for parasite survival in vitro and a SERA6 orthologue possesses cysteine protease 
activity, strongly suggesting that SERA6 is an active protease which is required for 
parasite survival. Of particular interest is the observation that the protease activity of 
the SERA6 orthologue is E64 sensitive. E64 is an irreversible inhibitor of cysteine 
proteases and has been shown in a number of studies to prevent egress (Salmon et 
al., 2001;Greenbaum et al., 2002;Boyle et al., 2010b). Recent data suggest that 
cysteine proteases are involved in the breakdown of the EPM and not the PVM as 
parasites cultured in the presence of E64 were shown to rupture the PVM but not the 
EPM (Glushakova et al., 2008). Other, conflicting data suggest that E64 has an effect 
on the breakdown of the PVM (Wickham et al., 2003). Albeit contradictory, all the 
studies indicate the importance of cysteine proteases in the breakdown of the 
membranes surrounding the parasites. In this work 100 µM E64 was found to prevent 
autocatalytic processing of rPbSERA3. However, a concentration of only 10 µM E64 is 
sufficient to prevent parasite egress. Homology modelling of the SERA5 papain-like 
domain with the protease domains of falcipain 2 and falcipain 3 (Chrislaine Withers-
Martinez, unpublished) has suggested that the entrance to the S2 pocket in SERA5 is 
restricted by the aromatic ring of the Tyr735 residue. This Tyr residue is conserved in 
SERA6 (Tyr783) and PbSERA3 (Tyr780). E64 requires binding to the S subsites to 
then covalently bind to the active site Cys (Varughese et al., 1989). As the aromatic 
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ring of the Tyr residue in the predicted S2 pocket restricts the access of E64, the 
inhibitor is unlikely to interact with the catalytic Cys of PbSERA3. Therefore E64 is a 
rather low potent inhibitor of PbSERA3. As a result it would be predicted that high 
concentrations of E64 might be required to if at all inhibit rPbSERA3. This is consistent 
with the results in this section as concentrations ≥100 µM E64 were required to prevent 
autocatalytic processing of PbSERA3. This suggests on the other hand that SERA6 
may not be the cysteine protease that is inhibited by E64 to prevent egress in parasite 
cultures, where concentrations of as little as 10 µM can block egress. However, in 
agreement with recent data that E64 inhibits breakdown of the EPM but not PVM it 
could be speculated that SERA6 is involved in a cascade leading to PVM rupture. 
Further exploration of this hypothesis requires the identification of SERA6 activity and 
its substrates in the parasite. 
Egress of P. falciparum parasites is poorly understood and it is difficult to even 
speculate about putative SERA6 substrates. In recent years new insights into egress 
have been gained with the identification of proteases involved in this step. PfSUB1 is 
the best understood proteolytic player in egress but it performs a dual function as it 
also primes the merozoite surface for invasion (Yeoh et al., 2007;Koussis et al., 
2009;Silmon de Monerri et al., 2011). In this work SERA6 was shown to be processed 
by PfSUB1, releasing a central fragment carrying the putative protease domain. After 
being processed by PfSUB1 SERA6, perhaps now an active protease, may move on to 
play its part in a cascade leading to egress. Additionally it is has to mentioned that the 
lack of homologous recombination events in in vitro P. falciparum cultures not always 
confirms an essential biological role of the respective gene product in the human host 
or mosquito vector. In order to address this future work should include transfection 
complementation approaches. In these experiments dual transfections will be 
conducted with the homologues recombination integration construct carrying the for the 
parasite putative deleterious gene modifications (for example deletion of sera6st2 or 
Cys644Ala). At the same time an episomal construct carrying the wild type sera6 to 
“rescue” or complement the introduced mutation would be transfected. If the results 
observed during this study are due to the mutation of endogenous sera6 it can be 
expected that the complementation approach would ensure parasite survival whereas 
parasites with no complementary plasmid would not survive. 
Future work could also include the modification of PkSERA4 in the P. knowlesi 
parasite. This might involve disrupting the entire gene, replacing the predicted SUB1 
cleavage sites and replacing the active site Cys. If these modifications have similar 
effects to the modifications described for sera6 this could provide another set of 
evidence for the importance of SERA6 and its orthologues. 
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Table 15: Summary of all attempted SERA6 activity screens 
SERA6 (origin) Method of activity screen Activity 
E. coli refolded 
rS6-FL, rS6C1, rS6C2 
Fluorogenic peptide substrate 
assays 
Autocatalytic processing 
Zymograms 
Fluorogenic peptide assays 
positive due to contaminating 
proteases 
E. coli soluble fraction 
rS6-FL, rS6C1, rS6C2 
Fluorogenic peptide substrate 
assays 
Autocatalytic processing 
Zymograms 
No 
E. coli soluble fraction 
rS6C1 WT 
Fluorogenic peptide substrate 
assays 
Autocatalytic processing 
No 
Parasite-derived semi-pure full-
length SERA6 
Fluorogenic peptide substrate 
assays 
Autocatalytic processing 
No 
Parasite-derived SERA6-central 
Fluorogenic peptide substrate 
assays 
Autocatalytic processing 
Processing iRBC ghosts 
Zymograms 
No 
COS-7 cell derived rSERA6 WT  Autocatalytic processing No 
   
PbSERA3 (origin) Method of activity screen Activity 
Tn5 insect cells 
rPbSERA3 WT 
Autocatalytic processing Yes 
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Figure 40: The predicted catalytic Cys of SERA6 is indispensable for parasite 
survival 
Schematic of transfection strategy for single homologous recombination applied in this 
work (A). The strategy was based on a chimera between genomic sera6 and 
recodonised sera6 which facilitated single-homologous recombination in the targeted 
sera6 locus. 3D7 parasites were transfected with two different constructs, pHH-
SERA6chim and pHH-SERA6chimC/A to either reconstitute the wild-type SERA6 
coding sequence or to replace the active site Cys644 with an Ala residue. Introduced 
mutations were located within the recodonised region of the transfection constructs. 
Transfected parasite lines were selected for integration by drug selection and genomic 
DNA was extracted after four drug cycles. Diagnostic PCR was applied to screen for 
integration. Positions of the primer pairs applied in the screens are indicated in green 
(A). The presence of genomic DNA was confirmed by using primer pair 5′ UTRb and 9 
(B, right hand panel, asterisk). In a second PCR, with primer pair 5′ UTRb and 37, a 
band of the expected size (~1.8 kbp) was detected for pHH-SERA6chim but not for 
pHH-SERA6chimC/A indicating integration for the wild-type control but not the C644A 
mutant (B, left hand panel). A doublet was visible in all diagnostic PCRs of all 
transfected lines possibly due to the binding properties of the primer pair used. The 
uncloned PCR positive parasite lines were then analysed by Southern blot using the 
DIG method (C). A band at ~3.3 kbp was visible for parasites transfected with pHH-
SERA6chim but not those transfected with pHH-SERA6chimC/A (C, red box). DNA of 
the transfection plasmid itself served as control in the PCR reactions (pHH-
SERA6chimplasmid). Because the transfected lines were not clonal, both the input 
plasmid and the wild-type sera6 locus were still detected by Southern blot (C, both ~9.5 
kbp, asterisk). These results suggest that the sera6 locus is accessible to homologous 
recombination but that substitution of the active site Cys residue may not be tolerated 
by the parasite. 
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Figure 41: Refolded recombinant SERA6 showed no protease activity 
Three different SERA6 fragments, rS6-FL, rS6C1 and rS6C2 were recombinantly 
expressed in E. coli IB. The IB were washed in 2 M urea buffer containing TX-100 
before they were finally solubilised in 8 M urea. The preparations were then rapidly 
diluted 20 fold into a variety of refolding buffers and incubated for 4 days at 4°C. All 
samples were then analysed by CN-PAGE followed by Western blot. Western blots 
were probed with antibodies against the N-terminal 6xHis-tag. Samples refolded in 
buffer 1, 2, 3 (Quick Refolding Kit, Pierce), SERA5 refolding buffer and falcipain 2 
refolding buffer were the only samples that showed bands on the CN-polyacrylamide 
gels, suggesting that these recombinant proteins were at least partially refolded (A). To 
next assess the level of refolding rS6-FL, rS6C1 and rS6C2 refolded in the falcipain 2 
buffer, were concentrated, separated on SDS-polyacrylamide gels with or without DTT 
and stained with Coomassie Blue. The addition of DTT was expected to cause a size 
shift if the protein had formed intramolecular disulphide bonds during refolding. No 
clear size shift was observed (B). However, differences in protein amounts that entered 
the gel were visible for samples with or without DTT, suggesting refolding of a small 
proportion of recombinant protein (B). Samples of rS6C1 and rS6C2 refolded in 
falcipain 2 buffer were purified by size-exclusion chromatography and subjected to 
zymograms on gelatin gels, using papain activity buffer as developing buffer. No bands 
of clearing were detected, indicating an absence of activity in this assay. Activity was 
only observed for the papain control (C). IB: E. coli inclusion bodies; CN-PAGE: Clear 
Native PAGE 
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Figure 42: A protein corresponding to the SERA6 central domain is found in 
parasite culture supernatants after egress 
Supernatants were collected after the egress of highly synchronous schizonts and 
fractionated by anion-exchange chromatography followed by size-exclusion 
chromatography. After each fractionation step collected samples were analysed by 
Western blot using the α-S6C1 antibody. After anion exchange chromatography a 
small fragment that reacted with the central SERA6 antibody was found in fractions 26 
to 31 (A, left hand panel). These fractions were pooled and further purified by size-
exclusion chromatography with a HiLoad 26/60 Superdex 200 prep-grade column. The 
antibody-reactive protein was now detected in fractions 41 to 44 (A, right hand panel). 
The peak fractions 42 and 43 were pooled, concentrated and stored frozen in aliquots. 
Samples were incubated at 37°C for 4 hours or overnight with and without Ca2+ and 
DTT, to assess for autocatalytic processing, and then analysed by SDS-PAGE and 
stained with Coomassie Blue staining (B). No differences between the start samples 
and the incubated samples were observed. The start samples were diluted 5 fold with 
SDS-sample buffer whereas the other samples were diluted 2 fold therefore the start 
sample appeared weaker after staining with Coomassie Blue. h: hours; o/n: overnight 
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Figure 43: Screen of SERA6-central detects no protease activity 
The purified SERA6-central domain was screened for protease activity using two 
approaches. First it was incubated with iRBC ghosts with or without the addition of 
Ca2+. The mix was incubated for 5 hours and samples were taken every hour, 
separated by SDS-PAGE and fractionated proteins visualised by silver stain. In order to 
check for any processing, samples were compared to the start sample (A). No 
differences were detected between the start sample and samples after 5 hours. Next 
SERA6-central was separated on polyacrylamide gels containing BSA as substrate to 
test for protease activity by zymograms. The zymograms were developed in four 
different buffers: falcipain 2 activity buffer, papain activity buffer, pH 8.2 activity buffer 
and pH 8.2 activity buffer with 5 mM CaCl2. Papain was applied as positive control. As 
no bands of clearing were observed it was concluded that the SERA6-central domain 
was inactive or at least not processing the BSA substrate in any of the 4 different 
developing conditions (B). Papain was applied as a positive control. iRBC: infected red 
blood cells; h: hours 
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Figure 44: Parasite-derived SERA6 shows no activity in fluorogenic peptide 
substrate assays 
Late stage schizonts were hypotonically lysed and full-length parasite SERA6 was 
purified by size-exclusion and anion-exchange chromatography. It was unknown which 
of the SERA6 fragments possessed protease activity therefore samples containing all 
SERA6 fragments were used in fluorogenic peptide substrate assays. Parasite-derived 
SERA6 was processed with rPfSUB1 and samples were analysed by Western blot 
using rabbit α-S6C1. SERA6 processing fragments appeared after 10 and 30 min (A). 
It was decided to use the 30 min sample for all subsequent activity screens (A, black 
box). A variety of fluorogenic peptide substrates was screened, with three controls 
included in the assays: buffer only, unprocessed SERA6 only and rPfSUB1 only (to test 
for any background processing). Samples were incubated for 5 min, 3 hours or 72 
hours. After the final measurement pronase was added to cleave substrates to 
completion, resulting in maximum emission levels of each peptide. The TACE IV 
substrate (Abz-LAQAVRSSSR-Dpa) was the only peptide to show any increase in 
fluorescence after the incubation with processed parasite-derived SERA6 and was 
therefore the only one displayed below (B). The same peptide was then tested in 
triplicate at a concentration of 10 µM and 20 µM with several controls (SERA6 only, 
rPfSUB1 only and SERA6/rPfSUB1/rPD). This time the samples were incubated for 5 
min or overnight and additional controls included SERA6 only, rPfSUB1 only and 
SERA6 processed with rPfSUB1 in the presence of the rPD. No difference in 
fluorescence levels was observed between the controls and the processed SERA6 
samples. Hence it was suggested that the activity observed during the first assay was 
due to contaminating proteases. rPD: rPfSUB1 prodomain; o/n: overnight 
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Figure 45: E. coli lysates containing rS6C1 show no protease activity 
To screen for protease activity E. coli expressing rS6C1 or rS6C1 C644A were 
collected and lysed with BugBuster Master Mix. The cell lysate was separated from IB 
by centrifugation. 15 AMC fluorogenic substrate peptides (numbers according to 
peptides displayed in Table 11 were resuspended in HEPES buffer and incubated with 
the E. coli cell lysate containing rS6C1 or rS6C1 C644A. The samples were incubated 
at 37°C and measurements were taken after 0 and 4 hours. Controls for the assay: 
rS6C1 and rS6C1 C644A with buffer only and 50 µg pronase with AMC peptide 6 after 
4 hours. In order to detect activity of soluble rS6C1 differences in emission levels for 
each peptide after processing with either rS6C1 or rS6C1 C644A were required. None 
of the AMC peptides showed a clear difference between the wild-type and mutant 
rS6C1. h: hours; IB: E. coli inclusion bodies 
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Figure 46: Autocatalytic processing reveals PbSERA3 cysteine protease activity 
Recombinant PbSERA3 WT was expressed and purified from insect cell supernatants 
and digested with rPfSUB1 with or without 20 µM E64. Controls included rPbSERA3 
only and rPbSERA3 with rPfSUB1 and rPD. Samples were taken after 10, 60, 180 min 
and analysed by Western blot with α-PbS3C1 antibodies. In samples without E64 
rPbSERA3 underwent almost complete processing and the majority accumulated at 42 
kDa. In samples containing E64 the final conversion to the 42 kDa fragment appeared 
much slower and was never as prominent as in the rPbSERA3 without E64 sample. 
This suggests a role for a cysteine protease in the final conversion step. Both controls 
confirmed that the initial processing is mediated by rPfSUB1 as rPbSERA3 WT alone 
was stable as was rPbSERA3 with rPfSUB1 and rPD (A). Next it was investigated 
whether increased E64 concentrations could completely block the conversion to a 42 
kDa fragment and more importantly whether the last processing step was due to 
autocatalytic processing of rPbSERA3 WT. To do this rPbSERA3 C639A was 
expressed and purified from insect cells precisely as described for the rPbSERA3 WT. 
Recombinant PbSERA3 WT was digested with rPfSUB1 in the presence of 10, 20 and 
100 µM E64 and compared to rPbSERA3 C639A which was also processed with 
rPfSUB1. The conversion from 48 kDa to 42 kDa was almost completely inhibited by 
100 µM E64 (B). The rPbSERA3 C639A mutant accumulated at the same 48 kDa form 
as the rPbSERA3 C639A. Both results implied that the final conversion to 42 kDa is 
due to autocatalytic processing of rPbSERA3 WT. rPD: rPfSUB1 prodomain; numbers 
below B refer to lanes 
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Figure 47: Autocatalytic processing of PbSERA3 is insensitive to leupeptin, 
antipain, or PbICP 
To test whether the autocatalytic processing can not only be prevented in the presence 
of E64, rPbSERA3 WT was digested with rPfSUB1 in the presence of the reversible 
cysteine and serine protease inhibitors leupeptin and antipain at a concentration of 20 
µg/ml. After the incubation at 37°C samples were taken after 0 and 120 min and 
analysed by Western blot with α-PbS3C1 antibodies. Controls included rPbSERA3 WT 
and rPbSERA3 C639A only and in presence of both rPfSUB1 and rPD. Leupeptin and 
antipain had no effect on the autocatalytic processing of rPbSERA3 as samples 
containing the inhibitors showed identical processing patterns as samples without 
protease inhibitors (A). Next it was tested whether rPbICP, a potent cysteine protease 
inhibitor expressed by P. berghei, blocked the autocatalytic processing of rPbSERA3 
WT. Controls included rPbSERA3 WT processed with rPfSUB1 in presence of 100 µM 
E64 and rPbSERA3 C639A processed with rPfSUB1. Samples were taken after 0 and 
120 min and analysed by Western blot. Despite strong cross-reactivity between rPbICP 
and the α-PbS3C1 antibody the accumulation of the bottom 42 kDa band was still 
detectable (B, asterisk). Due to cross-reactivity of the antibodies it remained 
inconclusive whether the 42 kDa band in fact represented the rPbSERA3 final fragment 
showing that PbICP had no effect on the autocatalytic processing. rPD: rPfSUB1 
prodomain; PI: protease inhibitor; leu: leupeptin; ant: antipain 
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6 Conclusions and future perspectives: SERA6 and its role in the malaria life-
cycle 
At the beginning of this work SERA6 was predicted to be localised to the PV of late 
stage schizonts and some data was available showing that SERA6 encodes for 
processing sites that are cleavable by PfSUB1 in vitro. Most importantly previous work 
from other groups had suggested that SERA6 was important for blood stage parasites. 
Therefore this study attempted to explore (A) the localisation of SERA6 (B) the 
processing of SERA6 by PfSUB1 and finally (C) the protease activity of SERA6. Five 
main conclusions can now be drawn from the work in this study. 
 
1. SERA6 is located to the PV of in vitro P. falciparum blood stage schizonts 
2. SERA6 is processed by PfSUB1 late in the asexual life-cycle in vitro 
3. Part of the PfSUB1 processing of SERA6 appears to be important for the 
parasite in vitro 
4. The catalytic Cys of SERA6 may be required for parasite survival in vitro 
5. PbSERA3, a SERA6 orthologue, becomes an active cysteine protease upon 
processing by PfSUB1 
 
It can therefore be hypothesised that SERA6 is an essential cysteine protease that 
becomes active upon proteolytic maturation by PfSUB1 late in the intra-erythrocytic 
stages of P. falciparum in vitro cultures. The question remains however, what is the 
exact role of SERA6 in the parasite life-cycle. Based on results from this study this last 
section will explore the possibility of SERA6 being involved in a proteolytic cascade 
leading to egress.  
Many cysteine proteases are known to become active enzymes upon 
proteolytic maturation (Voet et al., 2004). Once activated through processing by 
PfSUB1, SERA6 might cleave its substrates in the PV or the host cell cytosol. During 
localisation experiments in this work it was noted that a small proportion of SERA6 is 
membrane associated. It is unknown whether this membrane is derived from the PVM 
or EPM. Does this membrane association imply that upon activation SERA6 cleaves 
integral or peripheral associated membrane proteins triggering the breakdown of the 
PVM and the EPM? PV or PVM proteins interacting with SERA6 could include EXP1 
and the early transcribed membrane proteins (ETRAMPs), which are integral proteins 
of the PVM. EXP1 and ETRAMPs are thought to form pores in the PVM which might be 
important in maintaining the structural integrity of this membrane (Spielmann et al., 
2006). Upon proteolytic processing perhaps by SERA6, EXP1 and some or all 
members of the ETRAMP family could undergo structural changes causing the 
breakdown of the PVM.  
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This breakdown might also be triggered by another interaction pathway. SERA6 
might also process a member of the Plasmodium perforin-like protein family. Perforin-
like proteins are soluble proteins that can form a membrane pore complex upon 
physiological changes such as proteolytic maturation (Uellner et al., 1997;Kafsack et 
al., 2010). Evidence for a role for the perforin-like proteins in the breakdown of 
membranes surrounding the parasite and a role in egress has been given recently 
(Ecker et al., 2007;Kafsack et al., 2008;Kafsack et al., 2010). Therefore processing of a 
perforin-like protein by SERA6 might cause structural changes to the protein that 
enable it to play its role in egress by inducing pores in the PVM or EPM.  
The involvement of SERA6 in the breakdown of the PVM is also supported by 
observations made in IFAs. These results showed a strong SERA6 signal in late stage 
schizonts with tightly packed merozoites. These tightly packed merozoites arguably 
indicate a still intact PVM. In IFAs of schizonts with widely distributed merozoites but 
intact EPM no SERA6 signal was observed. These schizonts possibly displayed a 
ruptured PVM, suggesting that the rupture of the PVM coincides with the loss of 
SERA6. These observations possibly suggest a SERA6 role in the breakdown of the 
PVM.  
SERA6 might have several roles throughout egress, which may not only include 
the breakdown of the PVM but also the EPM. The RBC cytoskeleton proteins α-
spectrin, ankyrin, band 4.9 and actin are thought to undergo proteolytic processing 
around egress (Millholland et al., 2011). Therefore upon rupture of the PVM, active 
SERA6 may translocate into the RBC cytosol where it may process proteins of the 
RBC cytoskeleton. This is supported by the experimental evidence that E64 prevents 
the rupture of the EPM but not the PVM (Wickham et al., 2003). Hence the breakdown 
of the EPM appears cysteine protease dependent and the protease involved might be 
SERA6 if SERA6 can be inhibited with E64. Other proteases, such as falcipain 2, 
plasmepsin II or the host cell calpain, may be involved in rupture of the EPM (Le 
Bonniec et al., 1999;Dua et al., 2001;Hanspal et al., 2002;Chandramohanadas et al., 
2009;Silmon de Monerri, 2010;Millholland et al., 2011).  
SERA5 has previously been considered to possess weak proteolytic activity but 
recent data suggest that SERA5 is essential but not an essential enzyme (Robert 
Stallmach, unpublished). Due to the results shown in this work, it can be proposed that 
SERA5 and SERA6 have distinct roles in the parasite. In order to analyse the protease 
activity of SERA6 future work will require the screen for PbSERA3 substrates which will 
eventually lead to the identification of putative SERA6 substrates. Any putative 
substrates could then be used to identify the activity of SERA6 in vitro and in the 
parasite.  
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In summary results from this work showed that SERA6 is located to the PV 
where it undergoes proteolytic maturation by PfSUB1, possibly releasing SERA6 as an 
active cysteine protease which is essential for parasite survival. Proteases have been 
implicated in many diseases and serve as excellent drug targets and play key roles in 
the treatment of for example HIV/AIDS and cancer (Podgorski et al., 2003;Drag et al., 
2010). SERA6 is unique to Plasmodium and no homologues can be found in the 
human host which makes it an excellent target for the development of new 
antimalarials (Venter et al., 2001;Arisue et al., 2011).  
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